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Abstract 
Cyclodextrins (CDs) are cyclic oligosaccharides, mainly consisting of 6, 7 or 8 
α-D-glucopyranose units (α-CD, β-CD and γ-CD) linked by α-(1,4) bonds. These 
water-soluble, biocompatible oligosccharides do no elicit immune responses and have 
low toxicity in animals and humans. The objective of this thesis was to develop novel 
CD-based cationic polymers and supramolecular architectures for efficient gene 
delivery. In this study, a series of novel cationic star polymers consisting of α-CD 
core and oligoethylenimine (OEI) arms and cationic supramolecular polyrotaxanes 
composed of multiple OEI-grafted CDs threaded on various copolymer chains have 
been synthesized. Results indicated that these cationic polymers not only could 
efficiently compact plasmid DNA into small nanoparticles, but also showed excellent 
gene transfection efficiency and low in vitro cytotoxicity in various cell lines. Hence, 
they are promising non-viral gene delivery vectors and can be widely used in future 
gene therapy applications. 
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Cyclodextrins (CDs) are cyclic oligosaccharides, consisting mainly of 6, 7 or 8 α-
D-glucopyranose units (α-CD, β-CD and γ-CD) linked by α-(1,4) bonds. These water-
soluble, biocompatible oligosccharides do not elicit immune responses and have low 
toxicity in animals and humans. Over the last few decades, they have been industrially 
used in many applications such as pharmaceuticals, fragrance, foods and so on. The 
appearance of CDs is like a doughnut and their inner cavity is hydrophobic. Thus, 
various guest molecules can be fitted into this hydrophobic cavity of CDs to form 
non-covalent inclusion complexes (ICs). The ability of CDs to form ICs has been 
exploited in CD drug formulations. The objective of this thesis was to develop novel 
cationic star polymers consisting of α-CD core and oligoethylenimine (OEI) arms and 
soluble, cationic supramolecular polyrotaxanes composed of multiple OEI-grafted 
CDs threaded on various copolymer chains for efficient gene delivery. 
Cationic star polymers can be synthesized by grafting multiple OEI arms of 
different lengths and structure (ethylenediamine, pentaethylenehexamine, linear PEI 
with an average molecular weight of 423, and branched PEI with an average 
molecular weight of 600) to the activated hydroxyl groups of an α-CD ring. In 
addition, to prepare novel soluble, cationic supramolecular polyrotaxanes, a series of 
novel polyrotaxanes were synthesized in high yield with copolymers (PPG-PEG-PPG 
triblock copolymers, PEG-PPG-PEG triblock copolymers or PPG-ran-PEG 
copolymers) and CDs (α-CDs or β-CDs) based on the block-selected inclusion 
complexation between the copolymers and CDs, followed by conjugation of 2,4,6-
trinitrobenzene sulfonate (TNBS) to both ends of copolymer chains as blocking 
stoppers. And then, various OEI chains with different chain length and structure 
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(ethylenediamine, pentaethylenehexamine, linear PEI with an average molecular 
weight of 423, and branched PEI with an average molecular weight of 600) were 
grafted onto the above polyrotaxanes to form cationic supramolecular polyrotaxanes 
with multiple OEI-grafted CDs, leading to the increase of the solubility of the 
polyrotaxanes. The resulting cationic, soluble star polymers and supramolecular 
polyrotaxanes were isolated and purified by size exclusion chromatography and their 
purity was determined by Gel Permeation Chromatography. Their compositions were 
further characterized by NMR.  
Results indicated that all the cationic polymers could efficiently compact plasmid 
DNA into small nanoparticles, which was confirmed by agarose gel electrophoresis, 
particle size analysis, and zeta potential measurements, as well as atomic force 
microscopy imaging. They also showed excellent gene transfection efficiency that 
was comparable to or even higher than that of branched polyethylenimine (PEI) with 
molecular weight of 25 K, one of the most effective polymeric gene-delivery carriers 
studied to date. Moreover, they displayed much lower in vitro cytotoxicity than that of 
branched PEI (25 K) in various cell lines.  
Hence, these novel soluble, cationic star polymers and supramolecular 
polyrotaxanes can be promising non-viral gene delivery vectors with high gene 
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1.1 Research background 
1.2 Objectives and value of study 
1.3 Scope of the study 
1.4 References 
 
1.1 Research background 
Diseases are always one of the most serious threats against the existence of human 
beings. For centuries, different therapies have been developed to cure various diseases. 
Recently, gene therapy has been of growing interest in the therapy of some diseases, 
especially for most hereditary diseases.1-12 Gene therapy is a novel approach to treat, 
cure, or ultimately prevent disease by changing the expression of a person's genes. In 
other words, it can supply a gene that will lead to biosynthesis of the appropriate 
functional protein to remedy the defect(s) of the specific gene.2 However, the lack of 
efficient, safe and selective carriers for DNA to the nucleus of the target cells is a 
major limiting factor for the clinical application of gene therapy. 
Over the last few decades, cationic polymers are receiving growing attention as 
gene-delivery carriers. Compared with other gene delivery systems (viral vectors and 
cationic lipids), cationic polymers for gene delivery are generally economical and 
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stable, and they can be produced in a large scale and show low host immunogenicity. 
By now a great number of polycations have been reported to be able to deliver gene, 
including homopolymers or derivatives of polyethylenimine (PEI),13 poly(L-lysine),14 
polyamidoamine dendrimers,15 Poly(β-amino ester),16 polyphosphoester,17,18 and 
chitosan,19,20 etc. 
Cyclodextrins (CDs), which are cyclic, water-soluble, and biocompatible oligo- 
sccharides, have low toxicity in animals and humans and do not elicit immune 
responses. They are quite notable due to their unique structures and properties. CDs 
mainly consist of 6, 7 or 8 α-D-glucopyranose units (α-CD, β-CD and γ-CD) linked 
by α-(1,4) bonds (Figure 1.1).21,22 From X-ray structures it appears that the secondary 
hydroxyl groups (C2 and C3) in CDs are located on the wider edge of the ring and the 
primary hydroxyl (C6) on the other edge and that the apolar C3 and C5 hydrogens and 
ether-like oxygens are at the inside of the torus-like molecules. This special structure 
brings CDs many distinct properties: CDs can dissolve in water because the outside of 
CDs is hydrophilic, and they can also provide a hydrophobic matrix because the 
inside cavity of CDs is apolar.23 As a result of this cavity, CDs are able to form 
inclusion complexes with a wide range of guest molecules. Hence, chemical 
modifications or conjugations and inclusion abilities are easily acquired due to the 
above chemical structures of CDs. Over the last few decades CDs and their 
derivatives have been industrially used in many applications such as pharmaceuticals, 
fragrance, foods and so on.21,24 
In 1999, Davis’s group published the first report of using conjugates of CDs in the 
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delivery of nucleic acid.25 Since then, a variety of CD-containing polymers have been 
developed for gene delivery. In these polymers, CDs either are modified to contain 
amines and serves as part of the backbone of linear polymers,25-27 or are pendent on a 
polycation (such as PEI) skeleton.28 In addition to offering satisfactory efficiency in 
mediating gene transfection, these CD-modified polycations usually display lower 
toxicities when compared with their pristine counterparts. 
However, the application of CDs in gene delivery system has not been developed 
sufficiently till now; very little is known about the modification of CDs with 
oligoethylenimine (OEI) chains and CD-containing supramolecular polyrotaxanes 
based on inclusion complexation, which are developed and used as gene-delivery 
carriers. 
 
Figure 1.1 Schematic representations of β-CD. The open and closed arrows point to 
primary and secondary hydroxyl groups, respectively. The CD architecture is a cup 
that is 0.79±0.01 nm from top to bottom (primary OH face to secondary OH face), 
and is slightly larger on the face containing secondary hydroxyl groups. The cavity 
(0.47-0.53, 0.60-0.65 and 0.75-0.83 nm for α-, β- and γ-CD, respectively) and 
exterior diameters of the CDs (1.46±0.04, 1.54±0.04 and 1.75±0.04 nm for α-, β- and 
γ-CD, respectively, for the faces containing secondary hydroxyl groups) expand as the 
number of glucopyranoside units increase. 21,22 
 
1.2 Objectives and value of study 
The research reported here was carried out on the cationic star polymer consisting 
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of α-CD core and OEI arms, the supramolecular structures formed by various 
copolymers and multiple OEI-grafted CDs, and their applications in gene delivery 
systems. The specific objectives of this study were: 
z To synthesize a series of cationic star polymers by conjugating multiple OEI arms 
of different lengths and structure ((ethylenediamine, pentaethylenehexamine, 
linear PEI with an average molecular weight of 423, and branched PEI with an 
average molecular weight of 600) to an α-CD core, which were isolated and 
purified using size exclusion chromatography (SEC), and characterize the star 
polymers using Gel Permeation Chromatography (GPC), 13C and 1H NMR, and 
elemental analysis; 
z To prepare novel polyrotaxanes in high yield with various copolymers 
(PPG-PEG-PPG triblock copolymers, PEG-PPG-PEG triblock copolymers or 
PPG-ran-PEG copolymers) and different CDs (α-CD or β-CD) based on the 
block-selected inclusion complexation between the copolymers and CDs, 
followed by conjugation of 2,4,6-trinitrobenzene sulfonate (TNBS) to both ends 
of copolymer chains as blocking stoppers, and characterize them with 1H and 13C 
NMR; 
z To conjugate various OEI chains with different chain length and structure 
(ethylenediamine, pentaethylenehexamine, linear PEI with an average molecular 
weight of 423, and branched PEI with an average molecular weight of 600) to the 
CD rings of the above polyrotaxanes, which were isolated and purified by SEC, 
and characterize the resulting cationic supramolecular polyrotaxanes using GPC, 
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13C and 1H NMR, and elemental analysis; 
z To condense plasmid DNA (pDNA) into small nanoparticles with the above 
cationic polymers and confirm the condensation ability of the cationic polymers 
by agarose gel electrophoresis, particle size analysis, and zeta potential 
measurements, as well as atomic force microscopy (AFM) imaging. 
z To determine the gene transfection efficiency and in vitro cytotoxocity of the 
complexes formed by the above cationic polymers and pDNA in a variety of cell 
lines. 
This research should provide a series of new carriers for gene delivery systems and 
extend the applications of cationic supramolecular polyrotaxanes based on CDs to the 
field of gene therapy. Furthermore, this study could be helpful in clarifying how 
cationic polymers transfer DNA to the target nuclei. 
 
1.3 Scope of study 
This thesis covers the study on the novel cationic star polymers consisting of α-CD 
core and OEI arms and cationic polyrotaxanes formed by various copolymers and 
different CDs and their application as carriers in gene therapy. Other supramolecular 
structures such as rotaxanes, catenanes and polycatenanes and their applications are 
not considered. 
For the various parts of the study, the key is the preparation of novel functional 
materials for gene transferring. In the following chapters, the preparation processes of 
these materials are described and their gene-delivery capabilities are determined. 
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2.1 Introduction to gene therapy and gene delivery vectors 
Genes, which are carried on chromosomes inside cells, are the basic physical and 
functional units of heredity in every living organism. Humans have between 30,000 
and 40,000 genes. They determine obvious traits such as hair and eye color, as well as 
more subtle characteristics, such as the ability of blood to carry oxygen. Even some 
complex characteristics, such as physical strength, are considered the result of 
interactions of a number of different genes along with environmental influences. 
Strictly speaking, a gene is defined as the segment of deoxyribonucleic acid (DNA) 
sequence corresponding to a single protein. (or to catalytic or structural RNA 
molecule for those genes that produce ribonucleic acid (RNA) but not protein).1 In 
other words, most genes can carry the instructions that allow cells to produce specific 
proteins, which are biological macromolecules comprising linear chains of amino 
acids that affect most of the chemical reactions carried out by the cells. Meanwhile, 
other genes can produce RNA molecules, which play key roles in protein biosynthesis 
and gene regulation. 
When genes are altered or damaged (known as defective genes) and the encoded 
proteins are unable to carry out their normal functions, genetic disorders can result. In 
fact, each of us carry about half a dozen defective genes. Furthermore, most of us 
remain blissfully unaware that about one in ten persons in the world has, or will 
develop at some later stage, an inherited genetic disorder, and approximately 2,800 
specific conditions are known to be caused by defects (mutations) in just one of the 
patient's genes.2 
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Recently, growing interests have focused on gene therapy with the increasing 
knowledge of genes.3-15 Gene therapy is a novel approach to treat, cure, or ultimately 
prevent disease by inserting genes into an individual cell and tissues and changing the 
expression of the individual’s genes. In detail, the inserted genes will lead to 
biosynthesis of the appropriate functional protein to remedy the defect(s) of the 
specific gene. In addition, these genes can encode the protein that is not missing or 
dysfunctional in the patients to provide different therapeutic benefits. For example, 
the toxic proteins encoded by specific gene can be introduced into the tumor cell. 
These proteins can render the malignant cell more sensitive to the cytotoxic therapy 
than normal ones or protect the normal cells against drug toxicity.4  
In the past decades researchers have developed several methods to replace or repair 
the targeted defective genes: (a) A normal gene may be inserted into a nonspecific 
location within the genome to replace a nonfunctional gene. This approach is most 
common. (b) An abnormal gene could be swapped for a normal gene through 
homologous recombination. (c) The abnormal gene could be repaired through 
selective reverse mutation, which returns the gene to its normal function. (d) The 
regulation (the degree to which a gene is turned on or off) of a particular gene could 
be altered.6  
In general, a gene cannot be directly inserted into a person’s cell, and one of the 
most important factors for successful gene therapy is a carrier molecule, called a 
vector, which delivers the therapeutic genes into the patient’s target cells. Currently 
two types of gene delivery vectors have been developed: viral and non-viral.  
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Viruses are naturally evolved to infect cells and transfer their genetic materials into 
host cells. In fact, they have a tropism toward certain cell types because they bear 
molecules on their surface that can interact with membrane receptors and then enter 
the cells by endocytosis. By their mechanism of infection these viral vectors can 
easily be released in the cytoplasm by destabilizing or fusing its external coat with the 
membrane of the endosome. Once entered into the nucleus, the transgene held by the 
virus can be expressed temporally (episomal state of DNA) or in a stable way 
(integration into the cell genome).16 At present the viral vectors developed include 
retroviruses such as murine leukaemia viruses (MuLV) and lentiviruses, and DNA 
viruses such as adenoviruses, adeno-associated viruses, Herpes simplex viruses and 
lentiviruses, which are more efficient than non-viral vectors. 16-22 However, there are 
several problems in use: toxicity and immunogenicity, restricted targeting of specific 
cell types, transient duration of gene expression, low capacity for foreign genes, 
difficulties in generation of sufficiently high viral titres, and high cost. 23-24 For these 
reasons, many researchers have increasingly focused on non-viral vectors as an 
alternative to viral vectors.  
Non-viral vectors mainly include cationic lipids (liposomes) and cationic polymers. 
Figure 2.1 shows the general procedure for most non-viral gene delivery systems: 
DNA condensation and complexation, endocytosis, and nuclear targeting/entry.25 
Concretely, firstly negatively charged DNA molecules are condensed and/or 
complexed with cationic transfection reagents before delivery. Then, these complexes 
are taken up by cells, usually through endocytosis. Endocytosis is a multistep process 
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involving binding, internationalization, formation of endosomes, fusion with 
lysosomes, and lysis. The extremely low pH and enzymes within endosomes and 
lysosomes usually bring about degradation of entrapped DNA and associated 
complexes. Finally, DNA that has survived both endocytotic processing and 
cytoplasmic nucleases must then dissociate from the condensed complexes either 
before or after entering the nucleus. Once inside the nucleus, the transfection 
efficiency of delivered DNA is mostly dependent on the composition of the gene 
expression system.25-27 In this process there exist three major  barriers to gene 
delivery: low uptake by target cells, inadequate release of DNA molecules with 
stability after endocytosis and poor nuclear targeting.25,28 
 
Figure 2.1 Schematic drawing of DNA delivery pathways with three major barriers: 
low uptake across the plasma membrane, inadequate release of DNA molecules with 
limited stability, and lack of nuclear targeting. (A) DNA−complex formation. (B) 
Uptake. (C) Endocytosis (endosome). (D) Escape from endosome. (E) Degradation 
(edosome). (F) Intracellular release. (G) Degradation (cytosol). (H) Nuclear targeting. 
(I) Nuclear entry and expression.25 
Cationic lipids are amphiphilic molecules composed of three basic constituents: one 
or two fatty acid side chains (aryl or alkyl) as hydrophobic moiety, a linker and a 
hydrophilic amino group as polar headgroup. In aqueous media, the cationic 
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headgroup promotes interaction with DNA, whereas the hydrophobic moiety 
assembles into a bilayer vesicular-like structure (liposomes) in the presence of a 
helper lipid.29,30 Freeze-fracture electron micrographs and X-ray diffraction studies 
show that DNA is sandwiched between many liposomal particles.31,32 Recently, many 
species of cationic lipids have been developed: dioctadecylamidoglicylspermin 
(DOGS), N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTM- 
A), 3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium 
trifluoroacetate (DOSPA), 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), di- 
methyldioctadecylammonium bromide (DDAB), dioleoyl phosphatidylethanolamine 
(DOPE), etc.33-47 But there are several problems have not been solved yet: after 
intravenous injection, some of the cationic lipids can activate the complement so that 
they are rapidly cleared by liver and spleen; 48-50 certain proteins such as protein 
kinase C may also be affected detrimentally by cationic amphiphilies;51 toxic effect in 
vitro and in vivo, including changes of cells, such as cell shrinking, reduced number of 
mitoses and vacuolization of the cytoplasm.52,53 In addition, non-viral vectors are 
generally less efficient in delivering DNA and initiating gene expression as compared 
to their viral counterparts, particularly when used in vivo to date.15,38  
Cationic polymers are another type of non-viral gene vectors and they have also 
received increasing attention in the past decade.54-67 Cationic polymers can also be 
classified into two groups: nautral polymers, such as proteins and peptides, e.g. 
poly(L-lysine) and poly(L-glutamic acid); and synthetic polymers, such as derivatives 
or homopolymers of polyethylenimine, polyphosphoester, polyamidoamine and 
 13




Polyethylenimine (PEI) is a polymer that has been known for a long time and which 
has been widely used in processes such as paper production (Polymin®) and 
wastewater (Epomin®), as well as shampoo manufacturing.68 This polymer is 
available in two main forms: linear and branched (Figure 2.2). The branched form is 
produced by acid-catalyzed polymerization of aziridine monomers, resulting in 
random branched polymers. Linear forms of PEI are attainable by a similar process, 



















Figure 2.2 Chemical structures of branched and linear PEIs. 
In 1995, PEI was first introduced by Behr as gene-delivery carrier,71 and then it has 
become one of the gold standards of non-viral gene delivery. Although PEI is 
available in a broad range of molecular weights (from <1 K to1600 K), often highly 
branched PEIs with molecular weight in the range from 25 K to 800 K and linear PEI 
22 K are most frequently used in gene delivery.72-74 These PEI/DNA complexes yield 
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high levels of transgene expression in many cell lines and primary cells under in 
vitro75,76 and in vivo71,77-81 conditions. 
The relatively high gene transfection efficiency of PEI is believed to be due in large 
part to efficient escape from the endocytic pathway through the proton-sponge 
mechanism. As mentioned above, the endocytic pathway is one of three major barriers 
to gene delivery, since it leads to the intracellular degradation of DNA. PEI has a high 
density of amino groups due to every third atom on the PEI backbone being a nitrogen 
atom. In linear PEI, all of these nitrogen atoms can be protonated, whereas in 
branched PEI, only two-thirds of them (primary and secondary amino groups) can be 
charged.59 At physiological pH only 15-20% of the above chargeable nitrogen atoms 
are protonated 82 This unique property makes PEI an extraordinary strong proton 
sponge. In the presence of PEI in endosome, it has been proposed that endolysosomes 
are acidified by the action of an ATPase enzyme that actively transports protons from 
the cytosol into the vesicle. Then, PEI undergoes large changes in protonation during 
endocytic trafficking. However, the proton-sponge PEI prevents acidification of 
endocytic vesicles, causing the ATPase to transport more protons to reach the desired 
pH. The accumulation of protons in the vesicle must be balanced by an influx of 
counter ions (chloride ions). The increased ion concentration ultimately causes 
osmotic swelling and rupture of the endosome membrane, which releases the 
PEI/DNA complexes into the cytosol (Figure 2.3). In brief, PEI enhances intracellular 
trafficking by buffering the endosomal compartments, thus protecting the DNA from 
lysosomal degradation by endosomal DNA release via lysosomal disruption.7,54,83-85  
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Figure 2.3 Schematic of the proton-sponge mechanism. Protonation of the proton- 
sponge polymer (green) causes increased influx of protons (and counter-ions) into 
endocytic vesicles. Increasing osmotic pressure causes the vesicle to swell and 
rupture.54 
High cationic charge density of PEI also contributes to the formation of stable and 
highly condensed particles (spherical, globular or rod-like structures) by interacting 
with DNA.86 This process is supposed to rely predominantly on electrostatic 
interactions.87,88 It is found that the particle size is related to the efficiency of 
endocytosis and the velocity of cytoplasmatic movement.68,89 The complexation of 
DNA with PEI protects DNA from enzymatic degradation by charge neutralization in 
subcellular compartments, and promotes DNA movement in cytosol and finally, the 
nuclear localization for transgene expression.82,90 The binding of PEI to DNA is 
thought to be mainly driven by entropic forces arising from the release of counter ions. 
The high charge density of PEI enables more counter ions to be released upon binding 
with DNA, thus forming more stable complexes.88 In addition, the structure of PEI 
has a great influence on the formation and the particle size of PEI/DNA complexes. 
For either branched or linear PEI, it has been found that the molecular weight of PEI 
affects both condensation behavior and complex size: generally, the complex size 
decreases with the increase of the molecular weight of PEI in the range of 2-25 K.91-94 
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Also, complex formation is dependent on the degree of polymer branching. Primary 
amino groups are known to condense DNA better than other amino groups due to their 
higher protonation at a given pH.95 The binding capability of PEI could be correlated 
to the number of primary amino groups and the complex stability increases with 
primary amino groups content, thus leading to a higher transfection efficiency.58,62 
Beside particle size, the surface charge of PEI/DNA complexes is also an important 
parameter determining transfection efficiency, as well as other interactions of the 
complexes. An excess of polycation, as usually used for efficient condensation and 
tight compaction of DNA, leads to a net positive surface charge of the PEI/DNA 
complex. The positive surface charge can be measured as a high positive zeta 
potential, and it has already been found that this positive surface charge usually serves 
to bind to cells via electrostatic interactions with the negatively charged cell 
membrane during the cellular uptake process, followed by pinocytosis or endocytosis. 
This process is also referred to as non-specific adsorptive endocytosis.96,97 For the 
complexes of PEI/DNA, at the N/P ratios (the ratio of amino group in polymer to 
phosphate group in plasmid DNA is defined as N/P ratio) usually used for complete 
complexation, they have a zeta potential in the range of 30-35 mV.98,99 Moreover, 
there seem to be no major differences in zeta potential between DNA complexes 
using different PEIs.100  
However, the huge amount of surface positive charge also results in a rather high 
toxicity of PEI, which is one of the major limiting factors especially for its in vivo use. 
Indeed, positively charged complexes can induce erythrocyte aggregation98,101 and 
 17
trigger the activation of the complement system and removal by the reticulo- 
endothelial system.48 They also have intracellular toxicity ⎯ PEI has recently been 
identified as an apoptotic agent.102,103 Although the mechanism has not been fully 
delineated, it has been found that the cytotoxicity is affected by polymer architecture 
with increased toxicity observed with an increase in molecular weight and increased 
branching of the macromolecule. 68,72,104 Also, The cationic surface charge of the 
complexes results in numerous unspecific interactions with negatively-charged 
cellular blood component, vessel endothelia and plasma proteins (such as albumin, 
fibronectin, immunoglobulines, complement factors or fibrinogen).98 These 
interactions lead to very short plasma half-lives.105  
Some researchers ascribe the toxicity of the complexes to excess free PEI in the 
complexes, but purification of the complexes not only is shown to decrease the 
cytotoxicity as a result of the removal of excess PEI, but also leads to a decrease in 
transfection efficiency. In other words, the free PEI substantially contributes to 
efficient transfection and mediates toxic effects in a dose-dependent manner at the 
same time. This effect is attributed to the ability of the free polymer to propagate 
endosomal release, an assumption supported by the fact that the transfection 
efficiency is re-established after the addition of free PEI. 106 In addition, an excess of 
polycation is essential to generate a hydrophilic cationic corona around the complex 
for sufficient solubilization. Although PEI and DNA alone show excellent aqueous 
solubilities, their complexes become insoluble at a neutral charge.107 
Hence, the structure of PEI has been extensively modified and many novel PEI 
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derivatives and conjugates have been synthesized as efficient gene-delivery carriers. 
The aim of these modifications is to reduce cytotoxicity, improve the transfection 
efficiency, or increase the solubility, biodegradability or chemical homogeneity of 
PEI.  
One of the first and most extensively investigated attempts to modify PEI is the 
covalent coupling of poly(ethylene glycol) (PEG) chains to the polymer, resulting in 
block or graft copolymers. Figure 2.4 shows the preparation strategies for the 
PEGylation of ligand-containing PEI/DNA complexes. To provide such complexes 
with virus-like transport domain, cell-binding ligands such as transferrin (Tf) or 
epidermal growth factor (EGF) are covalently linked to the particles, and 
receptor-specific interaction and endocytosis into target cells is demonstrated (Figure 
2.4a).108-110 As shown in Figure 2.4b, the PEGylation has been achieved either by 
condensing DNA with PEG-PEI copolymers (pre-PEGylation) or coupling a PEG 
layer onto the surface of preformed complexes (post-PEGylation). 108,111,112 In contrast 
to pre-PEGylatin methods, post-PEGylation suffers from a rather time consuming 
sequence of conjugation steps that must be performed on PEI/DNA complexes.113 In 
general, the modification of the complexes with PEG results in shielding of the 
positive surface charges and create a steric barrier against self-aggregation and 
unfavorable interactions with plasma proteins, and with cellular components in the 
bloodstream. That is, the shielding of PEG may reduce the undesired and unspecific 
interactions between the complexes and blood components or non-target cells due to 
cationic surface charges.108,114 Also, modification with PEG improves colloidal 
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properties of the complexes of PEG-modified polycatons and DNA, such as a neutral 
zeta potential, low cytotoxicity, and little or no tendency for aggregation in vitro.115 
However, attachment of PEG and other steric stabilizers to polycations may interfere 
with cellular processing, resulting in reduced transfection efficiency in vivo, 
especially at lower doses.116-118  
Besides PEG, many polymers have also been used for the surface shielding of 
PEI/DNA complexes. For example, Pluronic copolymers, which possess the 
PEO-PPO-PEO structure, are surface-active and capable of self-assembly into 
micelles in aqueous solutions. It have been found that the Pluronic-PEI 
copolymer/DNA complexes are sufficiently stable in solution despite complete 
neutralization, and exhibit elevated levels of transgene expression.119  
In addition, various other derivatives and conjugates of PEI with polyacrylic acid 
(PAA),120 dextran121 or dextran sulfate,122 poly(N-2-hydroxypropyl)methacrylamide) 
derived copolymers (PHPMA),123,124 as well as plasma proteins like transferrin125,126 
or human serum albumin127 etc, have been synthesized in recent years. The aim is 
either to improve one particular aspect of PEI-mediated transfection (increase 
solubility of the complexes, enhance endosomolytic activity, improve nuclear 
transport, and so on) or gain a better insight into the mechanism of transfection (and 







Figure 2.4 (a) Schematic presentation of ligand-containing and shielded PEI/DNA 
complexes for gene transfer. (b) Preparation strategies for the PEGylation of 
ligand-containing PEI/DNA complexes. Strategy A: a ligand is covalently conjugated 
to PEI. Condensation of DNA with this conjugate leads to ligand-containing DNA 
complexes (step 1) which are subsequently modified with a PEG derivative reacting 
with free amino groups of the polycation (step 2). Strategy B: DNA is condensed with 
PEI (step 1) and the resulting complexes are modified by a heterobifunctional PEG 
derivative which first reacts with amino groups of the polycation (step 2). 
Subsequently, ligands are incorporated into the complexes by covalent conjugation 
with the distal end of the polycation (step 3). Strategy C: in a one-step process, DNA 




Poly(L-lysine) (PLL) is one of the first cationic polymers employed for gene 
transfer. In 1987, Wu et al. conjugated PLL with asialoorosomucoid, a ligand for the 
asialoglycoprotein receptor, for hepatocellular gene targeting.129 PLL is a linear 
polypeptide with the amino acid lysine as the repeat unit (Figure 2.5); thus, it 
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possesses a biodegradable nature. This property is very useful for in vivo applications. 
However, the polymer exhibits modest to high toxicity. The PLL/DNA complexes are 
not only prone to aggregation under physiological conditions,7 but are also rapidly 
bound to plasma proteins and cleared from the circulation.130,131 To overcome these 









Figure 2.5 Chemical structure of Poly(L-lysine) 
Targeting ligands, such as transferrin receptor,134 epidermal growth factor 
receptor,135 CD3-T cell receptor,136 folate receptor137 and so on, are also linked to the 
polymer chain (even in early studies) resulting in enhanced transfections.129,138 
Nevertheless, the naturally occurring receptor ligands are either proteins or complex 
carbohydrates, which are extremely difficult to obtain consistently in high purity 
(>98%). These receptor ligands are usually covalently crosslinked to poly(L-lysine), 
thereby creating novel antigenic epitopes.139    
Although some PLL/DNA complexes have small particle size and are taken up into 
cells as efficiently as PEI/DNA complexes, their transfection efficiencies remain 
several orders of magnitude lower.57 A potential reason for this is the lack of amino 
groups with a pKa between 5 and 7, thus allowing no endosomolysis and low levels of 
transgene expression.140 In other words, different from PEI, at physiological pH the 
 22
N-atoms of PLL are nearly fully protonated, resulting in poor escape from the 
endocytic pathways. The inclusion of targeting moieties or co-application of 
endosomolytic agent like chloroquine141 or fusogenic peptides142 may improve 
reporter gene expression. Another approach can create the desirable proton sponge 
effect similar to that of PEI/DNA complexes by introducing histidine or other 
imidazole-containing structures to PLL backbone, thus possessing a buffering 
capacity in the endolysosomal pH range.143 Histidylated PLL shows better 
transfection efficiency than PLL/chloroquine mixture.144  
Overall, it seems unlikely that poly(L-lysine)-based complexes with DNA will find 
clinical applications because of their relative low transfection efficacy. Hence, 
poly(L-lysine) has been relegated to a role in mechanistic studies or as a point of 
comparison to more promising polymers in recent years. 
 
2.4 Polyaminoamine dendrimer 
Dendrimers are spheroidal and cascade polymers consisting of a central core 
molecule which acts as the root from which a number of highly branched, tree-like 
arms originate in an ordered and symmetric fashion. The degree of branching is 
expressed in the generation of the dendrimer. Currently the synthesis methods of 
dendrimers include divergent strategy (starting from a central core) and convergent 
strategy (starting with what will become the periphery of the molecule building 
inwards).  
The polyaminoamine (PAMAM) dendrimers are polymers containing both tertiary 
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amines at the branch points as well as primary amines at the termini (Figure 2.6). 
They are normally based on an ethylenediamine or ammonia core with four and three 
branch points, respectively. They are synthesized by the divergent method, involving 
an exhaustive Michael addition of ethylenediamine with methyl acrylate, followed by 
addition of the resulting ester core to an excess of ethylenediamine. 145 This synthesis 
gives a high yield of first-generation PAMAM dendrimers, with higher generations 
arising from repetition of the previous two steps (e.g. G3, G4…). Generation up to 10 
can be formed before further assembly is limited by the “de Gennes dense packing” 
phenomenon.146 The dendrimers so prepared have a consistent size, structure, and 
charge characteristic of their generation, i.e. these polymers are well-defined and 
chemically very homogeneous. In fact, their monodispersity is remarkable, with 
polydispersity values (MW/Mn) in the range from 1.000002 to 1.005.147  
Due to the high cationic charge density of primary amine groups on the surface of 
the polymer, PAMAM dendrimers have been proposed as DNA delivery agents. 
Haensler and Szoka were first to report the use of PAMAM dendrimers for gene 
delivery. They found that the sixth-generation dendrimer was better than higher and 
lower generations by about 10-fold.148 In fact, PAMAM dendrimers of generation G3 
to G10 are all found to form stable complexes with DNA. However, their ability to 
transfect different cell lines varies, and polymer structure does not directly correlate 
with the transfection efficiency.145     
Because of the dendrimer structure, PAMAM dendrimers show high densities of 
amino groups in the periphery of the molecules. Hence, the complexation process 
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between dendrimers and DNA does not seem to differ fundamentally from other 
cationic polymers with high charge density: the terminal primary amino groups of 
dendrimers interact with the phosphate groups of DNA to form complexes, which 
protect DNA from degradation.62,149 The interaction between dendrimer and DNA is 
based on electrostatic interaction150 and lacks any sequence specificity.62 Also, similar 
to PEI, not all the amino groups of PAMAM dendrimers are protonated at 
physiological pH, and the lower pKa of the dendrimers cause them to act as proton 
sponges, enabling more efficient endosomal escape.83 Furthermore, the addition of 
cationic excipients such as diethylaminoethyl-dextran (DEAE-dextran) can enhance 





































Figure 2.6 Chemical structure of a Polyaminoamine dendrimer 
(generation 1 and core is ethylenediamine) 
The high surface positive charges are also related to the dendrimer toxicity. Studies 
on a solution of rat blood cells shows that a generation dependence of PAMAM 
dendrimers is observed in haemolysis and changes of erythrocyte morphology.152 
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Moreover, the degree of substitution and the type of amine functionality is important, 
with primary amines being more toxic than secondary or tertiary amines.153 The 
cytotoxicity of the polymers is also found to be generation-dependent, with higher 
generation dendrimers being the most toxic.153-155 Shielding of surface groups has also 
been used successfully to reduce toxicity, e.g. through covalent attachment of PEG or 
fatty acids. The modification of terminal groups has been suggested to be more 
efficient for higher generations dendrimers, as the relatively higher density of 
non-toxic surface groups may also be more effective in preventing access to 
potentially toxic core. 152   
In addition, partially degraded PAMAM dendrimers (i.e. a high molecular weight 
dendrimer missing some branches designated “fractured dendrimer”) seem to be more 
effective than that of intact dendrimers. Heat treatment of the polymer in some 
solvents (for example, water or ethanol) causes solvolysis of some amide bonds, 
resulting in a heterodisperse population of fractured dendrimers that increase 
transfection efficacy up to 50-fold.156,157 The mechanism of the enhancement seems to 
be twofold. First, the fractured dendrimers have greater flexibility, allowing a more 
beneficial interaction with the plasmid DNA.156 Second, fractured PAMAM 
dendrimer/DNA complexes seem to have enhanced solution stability in comparison to 
intact PAMAM dendrimer/DNA complexes, which tend to aggregate.62 
 
2.5 Poly[(2-dimethylamino)ethyl methacrylate] 
Poly[(2-dimethylamino)ethyl methacrylate] (PDMAEMA) is a synthetic polymer 
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containing side chains with tertiary amino groups (Figure 2.7). It is water-soluble and 
can form compact complexes with DNA by electrostatic interaction.158 The particle 
size and zeta potential of the PDMAEMA/DNA complexes are dependent on the ratio 
of the polymer to DNA. Also, as a result it has been found that the complexes with a 
slightly positive zeta potential (25-30 mV) and a size around 200 nm possess the 
highest transfection potential.159,160 Compared with DEAE-dextran and poly(L-lysine), 
the transfection efficiency of these complexes is two-fold higher than DEAE- 
dextran/DNA complexes and eight times than PLL/DNA complexes in the medium in 
the presence of chloroquine. The cytotoxicity of PDMAEMA is lower than that of 
PLL, but higher than that of DEAE-dextran.160 Interestingly, the transfection 
efficiency of the complexes is not affected by the presence of serum proteins, even 






Figure 2.7 Chemical structure of Poly[(2-dimethylamino)ethyl methacrylate]  
Earlier workers proposed that PDMAEMA, which like PEI was only partially 
protonated at physiological pH, facilitated cell transfection by being endocytosed, 
complexed with DNA, and subsequently acting as a “proton sponge” to burst 
endosomes/lysosomes and release DNA to the cytosol. It also seemed feasible that the 
cytotoxicity of PDMAEMA might result from lysosomal bursting, which can induce 
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cell death.160,161 However, the experiment results from Dubruel’s and Jones’s groups 
are different from the above hypothesis.162-164 Dubruel et al. synthesized a series of 
polymethacrylates and found that the buffering properties of the synthetic polymers 
are not necessarily the decisive element in the transfection process: the polymers 
containing imidazole groups or acid functions show buffering properties in the pH 
range of the endosomes (pH 5.5-7.4), in analogy with the “PEI proton sponge”, but 
they have a lower transfection capacity, probably due to a restricted cell uptake.162,163 
Jones and co-workers also found that, although PDMAEMA affected the morphology 
of late endosomes/lysosomes, it did not physically disrupt them to release their 
contents to the cytosol. Hence, a more detailed study on the membrane interaction 




Polyphosphazenes are biodegradable cationic polymers, which have been used as 
synthetic gene-delivery carriers in the past few decades. These biodegradable 
polymers show lower cytotoxicity and comparable in vitro transfection activities as 
compared to the non-degradable counterparts. Furthermore, the degradation properties 
of these polymeric vectors can be employed as a valuable tool to regulate the 
unpacking and release of the DNA inside the cells. 
Polyphosphazenes (Figure 2.8) bearing cationic moieties are synthesized from 
poly(dichloro)phosphazene, which in turn is obtained by thermal polymerization of 
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hexachlorocyclotriphosphazene in 1,2,4-trichlorobenezene. Next, either 2-dimethyl- 
aminoethanol (DMAE) or 2-dimethylaminoethylamine (DMAEA) side groups are 















Figure 2.8 Chemical structures of (a) poly(DMAE)-phosphazene, 
and (b) poly(DMAEA)-phosphazene. 
These polymers are positively charged at physiological pH due to the tertiary 
amines on the side groups, thus they are able to condense DNA to form positively 
charged particles. In COS7 cells, the transfection efficiencies of both polypho- 
sphazenes are comparable to PDMAEMA, but their cytotoxicity is lower than that of 
PDMAEMA. More interestingly, the transfection efficiency of poly(DMAE)- 
phosphazene is three-fold higher in the absence of serum than in the presence of 
serum, probably due to the unfavorable interactions between polymer/DNA 
complexes and serum proteins. In contrast, poly(DMAEA)-phosphazene shows a 
three-fold lower transfection efficiency in the absence of serum. In addition, it is 
observed that the polymers can degrade in time under physiological conditions due to 
hydrolysis of the biodegradable polyphosphazene backbone.165 The results of in vivo 
tumor transfection test of poly(DMAEA)-phosphazene show that the gene expression 
is primarily confined to tumor tissue, which is remarkable since few cationic 
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polymers have this property without shielding.166  
 
2.7 Poly(β-amino ester) 
Linear poly(β-amino ester)s (PAEs), another class of safe, hydrolytically 
biodegradable polymers for gene delivery, have both tertiary amines and esters in 
their backbones. The traditional development process of new biomedical polymers 
includes that polymers are designed one at a time and then individually tested for their 
properties. Different from this iterative process, linear PAEs can be synthesized by a 
combinational synthetic strategy, via the conjugation addition of primary amines or 
bis(secondary amine)s to diacrylates (Figure 2.9). The wide variety of commercially 
available diamines and diacrylates facilitates parallel synthesis of structurally diverse 
libraries of polymeric biomaterials. Furthermore, these new synthetic vector families 
































Figure 2.9 Synthesis of linear poly(β-amino ester)s (PAEs) by the conjugate addition 
of primary or bis(secondary amines) to diacrylates.168 
Langer and co-workers have already synthesized several libraries, thousands of 
PAEs with the semi-automated, solution-phase parallel synthesis.167-172 The 
high-throughput synthesis and screening of these materials not only result in several 
hundred of polymers that transfect as well as or better than the current gold standard 
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⎯ PEI, but also obtain large amounts of structure-function information and identify 
several structures common in effective polymers. They have also found that polymer 
molecular weight, polymer chain end-group and polymer/DNA ratio have a 
significant impact on gene transfer. Through the control and optimization of these 
parameters, the polymers can successfully mediate gene transfer at levels that 
surpasses both PEI and Lipofectamine 2000 in vitro.171-173    
However, in general, linear cationic polyester polymers are reported to degrade 
very fast in aqueous solution and to release DNA from polymer/DNA complexes 
within a few hours. This means that the application of linear polyester polymers could 
be limited for long duration because of its fast degradation rate. Hence, several 
hyperbranched174-176 or crosslinked177-179 poly(β-amino ester)s with slow degradation 
have been developed as gene-delivery carriers recently.  
 
2.8 Polyphosphates and polyphosphoramidates 
Both polyphosphates (PPEs) and polyphosphoramidates (PPAs) are water-soluble 
and cationic polyphosphoesters. These polymers with repeating phosphoester bonds in 
the backbone are structurally versatile, and biodegradable through hydrolysis and 
possibly enzymatic digestion at the phosphoester linkages under physiological 
conditions.180  
Polyphosphates (PPEs) bear a phosphoester backbone and the positive charges are 
introduced by linking residues containing amino groups to the phosphoryl side chain 
via phosphorus ester bonds (Figure 2.10). The PPEs are appealing for gene delivery 
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applications because of their potential biocompatibility and similarity to bio- 
macromolecules such as nucleic acids. In 2001, poly(2-aminoethyl propylene 
phosphate) (PPE-EA) with a β-aminoethoxy side chain was designed and synthesized 
in high molecular weight and investigated as gene-delivery carrier.181 PPE-EA is 
designed to have nontoxic building blocks and it can be hydrolyzed to generate 
α-propylene glycol, phosphate and ethanolamine in physiological condition. Hence, 
the polymer has significantly low cytotoxicity at a concentration up to 0.1 mg/mL 
compared to PEI and PLL. PPE-EA mediates a higher level of gene expression, for 
example, in HEK293 and at the optimal charge ratio PPE-EA transfects cells much 
more efficiently than PLL. Nevertheless, the transfection efficiency greatly depends 








PPE-EA:      R=H,       m=2
PPE-HA:      R=H,       m=6
PPE-MEA:   R=CH3,   m=2
(CH2)mN+H2RCl-
 
Figure 2.10 Chemical structures of some polyphosphates (PPEs) 
A unique feature of PPEs is the capability of controlled release of plasmid from 
PPE/DNA complexes, achieved as a result of PPE’s degradation. It has been found 
the side chain structure is a crucial factor determining the mechanism and kinetics of 
hydrolytic degradation of PPEs.182 Previous work by Penczek demonstrated that the 
degradation of polyphosphoester with a methoxy or ethoxy side chain was 
considerably slower.183 However, when the ethoxy side groups are replaced with 
ethoxyl amino groups, PPE-EA can degrade to oligomers and fail to condense pDNA 
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due to the decrease of the net positive charges. Different from PPE-EA, nevertheless, 
PPE-HA with longer alkylamino groups, degrades much more slowly in PBS. The 
relatively rapid degradation of PPEs with cationic side groups suggests a self-catalytic 
degradation mechanism involving nucleophilic attack of the phosphate bonds by the 
pendent amino groups. This mechanism also leads to a cleavage of the side chain, 
yielding negatively charged phosphate ions instead.180 This result has already been 
observed during the degradation of PPE-MEA.182 Degradation of these PPEs 
involving the cleavage of the backbone along with the side groups, generating less 
positively charged products, contributes to the controlled release of pDNA. Moreover, 
the higher hydrophobicity imparted by the longer alkyl side chain could hinder the 
nuclephilic attack by hydroxyl ion, resulting in slow degradation kinetics. 182 Hence, 
the degradation mechanism, particularly the side chain cleavage, seems to be the 
dominant factor affecting the DNA release rate of PPE/DNA complexes. This 
controlled release property can be adjusted by varying N/P ratio as well as the 
molecular design of the carrier, which in turn can also influence the transfection in 
vivo and in vitro.182,184,185   
Polyphosphoramidates (PPAs) are series of polymers with a phosphoester 
backbone containing different charge groups in the side chain connected to the 
backbone through a phosphoramide bond (Figure 2.11). These PPA carriers with 
lower cytotoxicity compared with PEI and PLL show charge-dependent transfection 
abilities and DNA binding capacities. 186-188 PPA-SP, PPA bearing spermidine side 
chain, was firstly prepared as a non-viral vector for gene delivery in 2002. It has been 
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found that gene expression mediated by PPA-SP is greatly enhanced when 
endolysosomalytic reagent such as chloroquine is used in conjunction. Under the 
optimized condition, PPA-SP/DNA complexes yield a luciferase expression level 




















Figure 2.11 Chemical structures of some polyphosphoramidates (PPAs) 
In fact, the pendent charge groups of PPAs have a great influence on the 
transfection efficiency: PPAs with primary amino group (PPA-SP and PPA-EA) are 
the most efficient in transfecting several cell lines,186,187 while other PPAs with 
secondary, tertiary and quaternary amino groups only achieve moderate or low levels 
of gene expression.187 Futherthemore, it is worth noting that introducing multiple 
polymeric carriers with different charged groups (e.g. PPA-SP/PPA-DMA mixture, 
with primary amino groups and tertiary amino groups) into the same complexes can 
enhance the transfection efficiency compared with complexes comprising single PPA 
carrier alone. The mechanism of the higher transfection efficiency mediated by this 
mixture is unclear till now and it appears to be unrelated to the particle size, zeta 




Chitosan, obtained by the partial alkaline deacetylation of chitin, the second most 
abundant natural polymer, is a non-toxic, biocompatible and biodegradable amino 
polysaccharide. It is composed of two subunits, D-glucosamine and N-acetyl-D- 
glucosamine, which are linked by a (1→4) glycosidic linkage (Figure 2.12). Chitosan 
is widely used as food additive and pharmaceutical excipient.189 In 1995, preparation 
of self-assembling polymeric and oligomeric chitosan/DNA complexes was first 
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Figure 2.12 Chemical structure of chitosans: (A) glucosamine subunits, and (B) 
N-acetyl glucosamine subunits. 
The chitosan backbone of glucosamine subunits shows a high density of amino 
groups, and requires pH values below 6 to be soluble. In detail, chitosans with high 
molecular weight (more than 100 K) are dissolved only in dilute acid solution, and the 
polymers with low molecular weight (such as 22 K) are highly soluble in 
physiological buffer solution.191 Chitosan can effectively bind DNA and protect it 
from nuclease enzymatic degradation via electrostatic interactions of positively 
charged amino groups of chitosan with the negatively charged phosphate groups of 
DNA.192 The stability of chitosan/pDNA complexes have been shown to depend on 
the molecular weight of chitosan, the ratio of pDNA to chitosan and the preparation 
medium.193  
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Transfection efficiency mediated by chitosans with molecular weight more than 
100 K is less than that of chitosans with molecular weight of 15 K and 52 K.194 
Optimum molecular weight of chitosans is dependent on the cell lines. Chitosans with 
molecular weight in the range between 10-50 K are excellent as gene transfer 
reagents.194 For example, Chitosan with molecular weight 22 K demonstrated higher 
transfection efficiency than PLL, while its cytotoxicity was lower than PLL.191  
Erbacher et al. investigated chitosan and lactosylated chitosan vectors for their 
transfection efficiencies in vitro. In their studies, the complexes of chitosan with DNA 
are found to transfect effectively HeLa cells, independent of the presence of 10% 
serum. Also, the transfection of the complexes is not enhanced by using 
endosomolytic agents such as chloroquine to facilitate escape of DNA from the 
lysosomal compartment. More interestingly, the gene expression is observed to 
gradually increase over time (from 24-96 h). At 96 h, chitosan is found to be 10-times 
more efficient than PEI mediated transfection.195 Roy and co-workers described an 
immunoprophylactic strategy using oral allergen-gene immunization to moderate 
peanut antigen-induced murine anaphylactic responses. Oral administration of DNA 
nanoparticles synthesized by complexing pDNA with chitosan results in transduced 
gene expression in the intestinal epithelium, thus indicating the probable use of 
chitosan/DNA nanoparticles in murine anaphylactic responses. 196  
To increase transfection efficiency, trimethylated chitosan oligomers (TMO) was 
prepared through quaternization of oligomeric chitosan as demonstrated by Thanou et 
al.197 These cationic polymers have been characterized and tested for their efficiency 
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on transfecting COS1 cells and Caco2 cells. When chitosan and quaternized chitosan 
oligomers are mixed with DNA, they spontaneously form complexes. All synthesized 
derivatives show excellent solubility in water at different pH values. Furthermore, the 
complexes have been tested for specific targeting to Hep-G2 cells and for expression 
of the β-gal reporter gene. The complexes efficiently transfect the Hep-G2 cells, 
possibly by internalization via the galactose receptor presenting on the cellular surface 
of Hep-G2 cells, as proposed by Murata.198 Actually, the transferrin receptor is one of 
the first to be exploited for receptor-mediated gene delivery. The number of 
transferrin molecules attached to each nanoparticle surface varies according to the 
molecular weight of the polymer.199 Compared to non-modified chitosan, the method 
results in a fourfold enhanced transfection efficiency, depending on the cell line. 
Conjugation of C-terminal globular domain of the fiber protein (KNOB) to 
chitosan-DNA nanoparticles also results in a 130-fold increase in the transfection 
efficiency in HeLa cells and several fold in HEK293 cells.199  
In addition, Lee and Kim et al synthesized hydrophobically modified chitosan with 
deoxycholic acid and demonstrated efficient transfection of chitosan/DNA complexes 
into COS7 cell lines. The deoxycholic acid-modified chitosan can self-associate to 
form micelles of a mean diameter of 160 nm. The transfection efficiency of the 
complexes is enhanced compared to that achieved by pristine DNA, but lower than 
that achieved by Lipofectamine.200,201 Park and co-worker used galactosylated 
chitosan-graft-PEG (GCP) as a DNA vector, and the transfection efficiency using 
GCP/DNA complexes was very low, mainly because of interaction with plasma 
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leading to dissociation of GCP/DNA complexes.202 N-dodecylated chitosan (CS-12) 
was also synthesized and incorporated with DNA to form a self-assembly complex by 
Yau et al.194 The incorporation of CS-12 can enhance the thermal stability of DNA, 
but no analysis of transfection efficiency in vitro and in vivo has been published by 
the author at the moment.  
 
2.10 Cyclodextrin-containing cationic polymers 
Cyclodextrins (CDs) are torus shaped cyclic D-gluco-oligosaccharides produced 
from starch by enzymatic degradation. Although CDs containing between 6 to 12 
D(+)-glucopyranose units attached by α-(1,4) glucosidic bonds have been isolated, 
only those containing 6 (α-CD), 7 (β-CD) or 8 (γ-CD) residues in a oligomer structure 
are currently used (Figure 2.13). CDs have an amphiphilic structure, which consists of 
a hydrophobic inner cavity and hydrophilic exterior and is capable of interacting with 
a large variety of guest molecules to form non-covalent inclusion complexes. 
Moreover, these water-soluble, biocompatible oligosaccharides do not elicit immune 
responses and have low toxicity in animals and humans. Hence, they are industrially 
used in many applications such as pharmaceuticals, fragrance, foods and so on.203,204  
A new class of linear, CD-based polymers was introduced by Davis and co-workers 
in 1999 for gene delivery applications.205 Since then, numerous CD-containing 
polymers have been used as delivery vehicles for nucleic acid. The linear cationic 
β-CD-based polymers are synthesized by condensation of difunctionalized CDs 
monomers and difunctionalized co-monomers, thus their polymer structure can be 
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methodically controlled. The interaction between the polymers and DNA can form 
compact complexes with diameter about 100 nm. The transfection efficiency of the 
β-CD-based polymers is comparable to that of PEI and lipofectmine, at the same time 
they show low in vivo and in vitro toxicity.205-207 The effect of CD size (β- or γ-CD), 
charge center (amidine or quaternary ammoniums), and charge density on 
gene-delivery efficiency and polymer toxicity have also been investigated. As a result, 
it is found that large size of CD, long distance of cationic center to CD and high 
content of CDs in the polymer are favorable to increase transfection efficiency and 
reduce cytotoxicity. The quaternary ammonium analogues exhibit lower gene 


































































































α-CD β-CD γ-CD  
Figure 2.13 Chemical structure of cyclodextrins (CDs): α-CD, β-CD, and γ-CD. 
Uekama and colleagues synthesized a series of PAMAM dendrimer-CD and 
PAMAM-modified dendrimer-CD conjugates by grafting CD (α-, β- and γ-CD) to 
generations of PAMAM dendrimers (G2, G3, and G4) or PAMAM-modified 
dendrimers (G2) to guide rational design of CD-containing non-viral gene 
carriers.211-214 Linear and branched PEIs grafted with β-CD were also synthesized and 
efficiently delivered nucleic acids to cultured cells with low toxicity than the 
unmodified pristine PEIs.215,216   
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A key feature of the complexes of CD-containing polymer with DNA is that the 
particles can be readily surface-modified by the formation of inclusion complex 
(Figure 2.14). In a series of publications Davis and co-workers have demonstrated 
PEGylation of the complexes by modification with adamantane-PEG conjugates (the 
adamantane and CD form inclusion complex with high association constant).217-219 
This self-assembly approach to the complexes modification has also been used to 
functionalize the complexes with targeting ligands such as galatose, transferring and 
insulin for cell-specific uptake.216,220,221   
 
Figure 2.14 (A). Schematic of inclusion compound formation. (B). Schematic for 
post-DNA-complexation PEGylation by inclusion compound formation by PEG-AD 
and ligand-PEG-AD. PEG is conjugated to adamantane. Adamantane forms an 
inclusion complex with β-cyclodextrin on the complex surface and brings with it PEG 
or PEG-L to decorate the complex and provide steric stabilization and targeting.220 
In addition, Tang et al. used CDs and CD derivatives to crosslink low molecular 
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branched PEI to form high molecular weight cationic polymers, which displayed 
lower cytotoxicity and high gene transfection in cultured cells.222,223 Recently, soluble 
supramolecular inclusion complexes formed by threading α- or γ-CD over linear 
cationic homopolymer or copolymer have been synthesized and examined as gene 
carries. The inclusion complexes show high transfection efficiency and significantly 
lower cytotoxicity.224,225 Ooya et al. also introduced aminoethyl- carbamoyl (ACE) 
groups to the polyrotaxanes consisting of α-CD and poly(ethylene glycol), and they 
found that the introduction of ACE groups enhanced the opportunity of complexion 
with DNA.226 Later, they reported the use of dimethylaminoethyl- modified α-CDs 
threaded onto a PEO chain and capped by cleavable end groups. The cleavage of the 
end groups cause the dethreading of α-CDs and rapid release of DNA in cells, but the 
tertiary amines conjugated to the α-CDs may not be efficient in DNA complexation 
and gene delivery.227  
 
2.11 References 
1. Alberts B.; Johnson A.; Lewis J.; Raff M.; Roberts K.; Walter P. Molecular 
biology of the cell (4th edition), Garland Science, New York, 2002, 9. 
2. Gene therapy - an overview: http://www.accessexcellence.org/RC/AB/BA/Gene_ 
Therapy_Overview.html.  
3. Anderson, W. F. Science, 1992, 256, 808.  
4. Culver, K. W.; Vickers, T. M.; Lamsam, J. L.; Walling, H. W.; Seregina, T.; Brit. 
Med. Bull., 1995, 51, 192.  
 41
5. Verma, I. M.; Somia, N. Nature, 1997, 389, 239.  
6. Gene Therapy: http://www.ornl.gov/sci/techresources/Human_Genome/medicine/ 
genetherapy.shtml. 
7. Han, S.; Mahato, R. I.; Sung, Y. K.; Kim, S. W. Mol. Ther., 2000, 2, 302. 
8. Gorman, C. Time, 1998, March 16, 37. 
9. Evans, C. H.; Gouze, E.; Gouze, J. N.; Robbins, P. D.; Ghivizzani, S. C. Adv. 
Drug Deliver. Rev., 2006, 58, 243. 
10. Stribley, J. M.; Rehman, K. S.; Niu, H.; Christman, G. M. Fertil. Steril., 2002, 77, 
645. 
11. Davidson, B. L.; Breakfield, X. O. Nat. Rev. Neurosci., 2003, 4, 353.  
12. Kmiec, E. B. Sci. Am., 1999, 87, 240. 
13. Tarner, I. H.; Muller-Ladner, U.; Fathman, C. G. Trends Biotechnol., 2004, 22, 
304. 
14. Emery, D. W. Clin. Appl. Immun. Rev., 2004, 4, 411. 
15. Piskin, E.; Dincer, S.; Turk, M. J. Biomater. Sci. Polymer Edn, 2004, 15, 1181. 
16. McTaggart, S.; Al-Rubeai, M. Biotechnol. Adv., 2002, 20, 1. 
17. Zhang X.; Godbey, W. T. Adv. Drug Deliver. Rev., 2006, 58, 515. 
18. Robbins, P. D.; Tahara, H.; Ghivizani, S. C. Trends Biotechnol., 1998, 16, 35. 
19. Ramano, G. Drug News & Perspect., 2005, 18, 311. 
20. Friedmann, T. Sci. Am., 1997, 276, 80. 
21. Walther, W.; Stein, U. Drugs, 2000, 60, 249. 
22. Hendrie, P. C.; Russell, D. W. Mol. Ther., 2005, 12, 9. 
 42
23. Crystal, R. G. Science, 1995, 270, 404. 
24. Tripathy, S. K.; Black, H. B.; Goldwasser, E.; Leiden, J. M. Nat. Med., 1996, 2, 
545. 
25. Luo, D.; Saltzman, W. M. Nat. Biotechnol., 2000, 18, 33. 
26. Khalil, I. A.; Kogure, K.; Akita, H.; Harashima, H. Pharmacol. Rev., 2006, 58, 
32. 
27. Lechardeur, D.; Verkman, A. S.; Lukacs, G. L. Adv. Drug Deliver. Rev., 2005, 57, 
755. 
28. Wiethoff, C. M.; Middaugh, C. R. J. Pharm. Sci., 2003, 92, 203. 
29. El-Aneed, A. J. Control. Rel., 2004, 94, 1. 
30. De Laporte, L.; Rea, J. C.; Shea, L. D. Biomaterials, 2006, 27, 947. 
31. Radler, J. O.; Koltover, I.; Salditt, T.; Safinya, C. R. Science, 1997, 275, 810. 
32. Sternberg, B.; Sorgi, F. L.; Huang, L. FEBS Lett., 1994, 356, 361. 
33. Mahato, R. I. Adv. Drug Deliver. Rev., 2005, 57, 699. 
34. Zhang, S.; Xu, Y.; Wang, B.; Qiao, W.; Liu, D.; Li, Z. J. Control. Rel., 2004, 100, 
165. 
35. de Lima, M. C. P.; Simoes, S.; Pires, P.; Faneca, H.; Duzgunes, N. Adv. Drug 
Deliver. Rev., 2001, 47, 277. 
36. Tranchant, I.; Thompson, B.; Nicolazzi, C.; Mignet, N.; Scherman, D. J. Gene 
Med., 2004, 6, S24. 
37. Nicolazzi, C.; Garinot, M.; Mignet, N.; Scherman, D.; Bessodes, M. Curr. Med. 
Chem., 2003, 10, 1263. 
 43
38. Miller, A. D. Curr. Med. Chem., 2003, 10, 1195. 
39. Kumar, V. V.; Singh, R. S.; Chaudhuri, A. Curr. Med. Chem., 2003, 10, 1297. 
40. Dass, C. R.; Choong, P. F. M. J. Control. Rel., 2006, 113, 155. 
41. Hashida, M.; Kawakami, S.; Yamashita, F. Chem. Pharm. Bull., 2005, 53, 870. 
42. Hofland, H. E. J.; Shephard, L.; Sullivan, S. M. Proc. Natl. Acad. Sci. USA, 1996, 
93, 7305. 
43. Bartsch, M.; Weeke-klimp, A. H.; Meijer, D. K. F.; Scherphof, G. L.; Kamps, J. A. 
A. M. J. Lipos. Res., 2005, 15, 59. 
44. Audouy, S. A. L.; de Leij, L. F. M. H.; Hoekstra, D.; Molema, G. Pharmaceut. 
Res., 2002, 19, 1599. 
45. Hirko, A.; Tang, F. X.; Hughes, J. A. Curr. Med. Chem., 2003, 10, 1185. 
46. Ilies, M. A.; Seitz, W. A.; Balaban, A. T. Curr. Pharm. Design, 2002, 8, 2441. 
47. Ewert, K.; Slack, N. L.; Ahmad, A.; Evans, H. M.; Lin, A. J.; Samuel, C. E.; 
Safinya, C. R. Curr. Med. Chem., 2004, 11, 133. 
48. Plank, C.; Mechtler, K.; Szoka, F. C.; Wagner, E. Hum. Gene Ther., 1996, 7, 
1437. 
49. Pouton, C. W.; Seymour, L. W. Adv. Drug Deliver. Rev., 1998, 34, 3. 
50. Bally, M. B.; Harvie, P.; Wong, F. M. P.; Kong, S.; Wasan, E. K.; Reimer, D. L. 
Adv. Drug Deliver. Rev., 1999, 38, 291. 
51. Aberle, A. M.; Tablin, F.; Walker, N. J.; Gruenert, D. C.; Nantz, M. H. 
Biochemistry, 1998, 37, 6533.. 
52. Lappalainen, K.; Jaaskelainen, I.; Syrjanen, K.; Urtti, A.; Syrjanen, S. 
 44
Pharmaceut. Res. 1994, 11, 1127. 
53. Fillion, M. C.; Phillips, N. C. Int. J. Pharm., 1998, 162, 159. 
54. Pack, D. W.; Hoffman, A. S.; Pun, S.; Stayton, P. S. Nat. Rev., 2005, 4, 581. 
55. Fewell, J. G.; Matar, M.; Slobodkin, G.; Han, S. O.; Rice, J.; Hovanes, B.; Lewis, 
D. H.; Anwer, K. J. Control. Rel., 2005, 109, 288. 
56. Hunter, A. C. Adv. Drug Deliver. Rev., 2006, 58, 1523. 
57. Merdan, T.; Kopecek, J.; Kissel, T. Adv. Drug Deliver. Rev., 2002, 54, 715. 
58. Reschel, T.; Konak, C.; Oupicky, D.; Seymour, L. W.; Ulbrich, K. J. Control. Rel., 
2002, 81, 201. 
59. Garnett, M. Crit. Rev. Ther. Drug, 1999, 16, 147. 
60. De Smedt, S. C.; Demeester, J.; Hennink, W. E. Pharmaceut. Res., 2000, 17, 113 
61. Leong, K. W.; Mao, H. Q.; Truong-Le, V. L.; Roy, K.; Walsh, S. M.; August, J. T. 
J. Control. Rel., 1998, 53, 183. 
62. Tang, M. X.; Szoka, F. C. Gene Ther., 1997, 4, 823. 
63. Anwer, K.; Rhee, B. G.; Mendiratta, S. K. Crit. Rev. Ther. Drug, 2003, 20, 249. 
64. Park, T. G.; Jeong, J. H.; Kim, S. W. Adv. Drug Deliver. Rev., 2006, 58, 467. 
65. Putnam, D. Nat. Mat., 2006, 5, 439. 
66. Eliyahu, H.; Barenholz, Y.; Domb, A. J. Molecules, 2005, 10, 34. 
67. Leong, K. W. MRS Bull., 2005, 30, 640. 
68. Neu, M.; Fischer, D.; Kissel, T. J. Gene Med., 2005, 7, 992. 
69. Godbey, W. T.; Wu, K. K.; Mikos, A. G. J. Control. Rel., 1999, 60, 149. 
70. Kroschwitz J. I. Encyclopedia of polymer science and engineering (2nd edition), 
 45
Wiley, New York, 1985, 680. 
71. Boussif, O.; Lezoualc’h, F.; Zanta, M. A.; Mergny, M. D.; Scherman, D.; 
Demeneix, B.; Behr, J. P. Proc. Natl. Acad. Sci. USA, 1995, 92, 7297. 
72. Fischer, D.; Bieber, T.; Li, Y.; Elsasser, H. P.; Kissel, T. A. Pharmaceut. Res., 
1999, 16, 1273. 
73. Marschall, P.; Malik, N.; Larin, Z. Gene Ther., 1999, 6, 1634. 
74. Campeau, P.; Chapdelaine, P.; Seigneurin-Venin, S.; Massie, B.; Tremblay, J. P. 
Gene Ther., 2001, 8, 1387. 
75. Boussif, O.; Zanta, M. A.; Behr, J. P. Gene Ther., 1996, 3, 1074. 
76. Erbacher, P.; Remy, J. S.; Behr, J. P. Gene Ther., 1999, 6, 138. 
77. Abdallah, B.; Hassan, A.; Benoist, C.; Goula, D.; Behr, J. P. Hum. Gene Ther., 
1997, 7, 1947. 
78. Boletta, A.; Benigni, A.; Lutz, J.; Remuzzi, G.; Soria, M. S.; Monaco, L. Hum. 
Gene Ther., 1997, 8, 1243. 
79. Lecocq, M.; Wattiaux-De Coninck, S.; Laurent, N.; Wattiaux, R.; Jadot, M. 
Biochem. Biophys. Res. Commun., 2000, 278, 414. 
80. Goula, D.; Remy, J. S.; Erbacher, P.; Wasowicz, M.; Levi, G.; Abdallah, B.; 
Demeneix, B. A. Gene Ther., 1998, 5, 712. 
81. Ferrari, S.; Moro, E.; Pettenazzo, A.; Behr, J. P.; Zachello, F.; Scarpa, M. Gene 
Ther., 1997, 4, 1100. 
82. Suh, J.; Paik, H. J.; Hwang, B. K. Bioorg. Chem., 1994, 22, 318. 
83. Sonawane, N. D.; Szoka, R. C.; Verkman, A. S. J. Biol. Chem., 2003, 278, 44826. 
 46
84. Ferrari, S.; Pettenazzo, A.; Garbati, N.; Zacchello, F.; Behr, J. P.; Scarpa, M. 
Biochim. Biophys. Acta, 1999, 1447, 219. 
85. Godbey, W. T.; Barry, M. A.; Saggau, P.; Wu, K. K.; Mikos, A. G. J. Biomed. 
Mater. Res., 2000, 51, 321.  
86. Dunlap, D. D.; Maggi, A.; Soria, M. R.; Monaco, L. Nucleic Acids Res., 1997, 25, 
3095. 
87. Bloomfield, V. A. Curr. Opin. Struct. Biol., 1996, 6, 334. 
88. Bronich, T.; Kabanov, A.; Marky, L. J. Phys. Chem. B, 2001, 105, 6041. 
89. Park, K.; Kwon, I.; Yui, N.; Jeong, S.; Park, K. Biomaterials and drug delivery 
towards new millennium, 2000, 249. 
90. Godbey, W. T.; Wu, K. K.; Mikos, A. G. Proc. Natl. Acad. Sci. USA, 1999, 96, 
5177. 
91. Kunath, K.; von Harpe, A.; Fisher, D.; Peterson, H.; Bickel, U.; Voigt, K.; Kissel, 
T. J. Control. Rel., 2003, 89, 113. 
92. Brissault, B.; Kichler, A.; Guis, C.; Leborgne, C.; Danos, O.; Cheradame, H. 
Bioconjugate Chem., 2003, 14, 581. 
93. Petersen, H.; Kunath, K.; Martin, A. L.; Stolnik, S.; Roberts, C. J.; Davies, M. C.; 
Kissel, T. Biomacromolecules, 2002, 3, 926. 
94. Gosselin, M. A.; Gou, W.; Lee, R. J. Bioconjugate Chem., 2001, 12, 989. 
95. Wolfert, M. A.; Dash, P. R.; Nazarova, O.; Oupicky, D.; Seymour, L. W.; Smart, 
S.; Strohalm, J.; Ulbrich, K. Bioconjugate Chem., 1999, 10, 993. 
96. Duncan, R.; Pratten, M. K.; Lloyd, J. B. Biochem. Biophys. Acta, 1979, 587, 463. 
 47
97. Leonetti, J. P.; degols, G.; Lebleu, B. Bioconjugate Chem., 1990, 1, 149. 
98. Ogris, R.; Brunner, S.; Schuller, S.; Kircheis, R.; Wagner, E. Gene Ther., 1999, 6, 
595. 
99. Kircheis, R.; Schuller, S.; Brunner, S.; Ogris, M.; Heider, K. H.; Zauner, W.; 
Wagner, E. J. Gene Med., 1999, 1, 111. 
100.Kircheis, R.; Wightman, L.; Schreiber, A.; Robitza, B.; Rossler, V.; Kursa, M.; 
Wagner, E. Gene Ther., 2001, 8, 28. 
101.Eliyahu, H.; Servel, N.; Domb, A. J.; Barenholz, Y. Gene Ther., 2002, 9, 850. 
102.Moghimi, S. M.; Symonds, P.; Murray, J. C.; Hunter, A. C.; Debska, G.; 
Szewczyk, A. Mol. Ther., 2005, 11, 990. 
103.Moghimi, S. M.; Hunter, A. C.; Murray, J. C. FASEB J., 2005, 19, 311. 
104.Fischer, D.; von Harpe, A.; Kunath, K.; Petersen, H.; Li, Y. X.; Kissel, T. 
Bioconjugate Chem., 2002, 13, 1124. 
105.Oupicky, D.; Dash, P. R.; Seymour, L. W. Ulbrich, K. Bioconjugate Chem., 1999, 
10, 764. 
106.Boeckle, S.; von Gersdorff, K.; van der Piepen, S.; Culmsee, C.; Wagner, E.; 
Ogris, M. J. Gene Med., 2004, 6, 1102. 
107.Vinogradov, S. V.; Bronich, T. K.; Kabanov, A. V. Bioconjugate Chem., 1998, 9, 
805. 
108.Ogris, M.; Walker, G.; Blessing, T.; Kircheis, R.; Wolschek, M.; Wagner, E. J. 
Control. Rel., 2003, 91, 173. 
109.Kircheis, R.; Kichler, A.; Wallner, G.; Kursa, M.; Ogris, M.; Felzmann, T.; 
 48
Buchberger, M.; Wagner, E. Gene Ther., 1997, 4, 409. 
110.Blessing, T.; Kursa, M.; Holzhauser, R.; Kircheis, R.; Wagner, E. Bioconjugate 
Chem., 2001, 12, 529. 
111.Kursa, M.; Walker, G. F.; Roessler, V.; Ogris, M.; Roedl, W.; Kircheis, R.; Wagner, 
E. Bioconjugate Chem., 2003, 14, 222. 
112.Kichler, A.; Chillon, M.; Leborgne, C.; Danos, O.; Frisch, B. J. Control. Rel., 
2002, 81, 379. 
113.Lungwitz, U.; Breunig, M.; Blunk, T.; Gopferich, A. Eur. J. Pharm. Biopharm., 
2005, 60, 247. 
114.Bromberg, L.; Alakhov, V. Y.; Hatton, T. A. Curr. Opin. Colloid In., 2006, 11, 
217. 
115.Tan, J. F.; Ravi, P.; Too, H. P.; Hatton, T. A.; Tam, K. C. Biomacromolecules, 
2005, 6, 498. 
116.Merdan, T.; Kunath, K.; Petersen, H.; Bakowsky, U.; Voigt, K. H.; Kopecek, J.; 
Kissel, T. Bioconjugate Chem., 2005, 16, 785. 
117.Mishra, S.; Webster, P.; Davis, M. E. Eur. J. Cell Biol., 2004, 83, 97. 
118.Sung, S. J.; Min, S. H.; Cho, K. Y.; Lee, S.; Min, Y. J.; Yeom, Y. I.; Park, J. K. 
Biol. Pharm. Bull., 2003, 26, 492. 
119.Gebhart, C. L.; Sriadibhatla, S.; Vinogradov, S.; Lemieux, P.; Alakhov, V.; 
Kabanov, A. V. Bioconjugate Chem., 2002, 13, 937. 
120.Trubetskoy, V. S.; Wong, S. C.; Subbotin, V.; Budker, V. G.; Loomis, A.; 
Hagstrom, J. E.; Wolff, J. A. Gene Ther., 2003, 10, 261. 
 49
121.Tseng, W. C.; Jong, C. M. Biomacromolecules, 2003, 4, 1277. 
122.Tiyaboonchai, W.; Woiszwillo, J.; Middaugh, C. R. Eur. J. Pharm. Sci., 2003, 19, 
191. 
123.Oupicky, D.; Ogris, M.; Howard, K. A.; Dash, P. R.; Ulbrich, K.; Seymour, L. W. 
Mol. Ther., 2002, 5, 463. 
124.Carlisle, R. C.; Etrych, T.; Briggs, S. S.; Preece, J. A.; Ulbrich, K.; Seymour, L. W. 
J. Gene Med., 2004, 6, 337. 
125.Kircheis, R.; Schuller, S.; Brunner, S.; Ogris, M.; Heider, K. H.; Zauner, W.; 
Wagner, E. J. Gene Med., 1999, 1, 111. 
126.Kircheis, R.; Wightman, L.; Schreiber, A.; Robitza, B.; Rossler, V.; Kursa, M.; 
Wagner, E. Gene Ther., 2001, 8, 28. 
127.Rhaese, S.; von Briesen, H.; Rubsamen-Waigmann, H.; Kreuter, J.; Langer, K. J. 
Control. Rel., 2003, 92, 199. 
128.Kichler, A. J. Gene Med., 2004, 6, S3. 
129.Wu, G. Y.; Wu, C. H. J. Biol. Chem., 1987, 262, 4429. 
130.Ward, C. M.; Read, M. L.; Seymour, L. W. Blood, 2001, 97, 2221. 
131.Dash, P. R.; Read, M. L.; Barrett, L. B.; Wolfert, M. A.; Seymour, L. W. Gene 
Ther., 1999, 6, 643. 
132.Lee, M.; Kim, S. W. Pharmaceut. Res., 2005, 22, 1. 
133.Maruyama, A.; Watanabe, H.; Ferdous, A.; Katoh, M.; Ishihara, T.; Akaike, T. 
Bioconjugate Chem., 1998, 9, 292. 
134.Wagner, E.; Zenke, M.; Cotten, M.; Beug, H.; Birnstiel, M. L. Proc. Natl. Acad. 
 50
Sci. USA, 1990, 87, 3410. 
135.Chen, J.; Gamou, S.; Takayanagi, A.; Shimizu, N. FEBS Lett., 1994, 338, 167. 
136.Buschle, M.; Cotton, M.; Kirlappos, H.; Mechtler, K.; Schaffner, G.; Zauner, W.; 
Birnstiel, M. L.; Wagner, E. Hum. Gene Ther., 1995, 6, 753. 
137.Gottschalk, S.; Cristiano, R. J.; Smith, L. C.; Woo, S. L. Gene Ther., 1994, 1, 185. 
138.Suh, W.; Chung, J. K.; Park, S. H.; Kim, S. W. J. Control. Rel., 2001, 72, 171. 
139.Stankovics, J.; Crane, A. M.; Andrews, E.; Wu, C. H.; Wu, G. Y.; Ledley, F. D. 
Hum. Gene Ther., 1994, 5, 1095. 
140.Merdan, T.; Kunath, K.; Fischer, D.; Kopecek, J.; Kissel, T. Pharmaceut. Res., 
2002, 19, 140. 
141.Pouton, C. W.; Lucas, P.; Thomas, B. J.; Uduehi, A. N.; Milroy, D. A.; Moss, S. H. 
J. Control. Rel., 1998, 53, 289. 
142.Wagner, E.; Plank, C.; Zatloukal, K.; Cotten, M.; Birnstiel, M. L. Proc. Natl. 
Acad. Sci. USA, 1992, 89, 7934. 
143.Pichon, C.; Goncalves, C.; Midoux, P. Adv. Drug Deliver. Rev., 2001, 53, 75. 
144.Midoux, P.; Monsigny, M. Bioconjugate Chem., 1999, 10, 406. 
145.Braun, C. S.; Vetro, J. A.; Tomalia, D. A.; Koe, G. S.; Koe, J. G.; Middaugh, C. R. 
J. Pharm. Sci., 2005, 94, 423. 
146.Ruiz, J.; Lafuente, G.; Marcen, S.; Ornelas, C.; Lazare, S.; Cloutet, E.; Blais, J. C.; 
Astruc, D. J. Am. Chem. Soc., 2003, 125, 7250. 
147.Brothers II, H. M.; Piehler, L. T.; Tomalia, D. A. J. Chromatogr. A, 1998, 814, 
233. 
 51
148.Haensler, J.; Szoka, F. C. Bioconjugate Chem., 1993, 4, 372. 
149.Bielinska, A. U.; Kukowska-Latallo, J. F.; Baker, J. R. Biochim. Biophys. Acta, 
1997, 1353, 180. 
150.Chen, W.; Turro, N. J.; Tomalia, D. A. Langmuir, 2000, 16, 15. 
151.Kukowska-Latallo, J. F.; Bielinska, A. U.; Johnson, J.; Spindler, R.; Tomalia, D. 
A.; Baker, J. R. Proc. Natl. Acad. Sci. USA, 1996, 93, 4897. 
152.Malik, N.; Wiwattanapatapee, R.; Klopsch, R.; Lorenz, K.; Frey, H.; Weener, J. 
W.; Meijer, E. W.; Paulus, W.; Duncan, R. J. Control. Rel., 2000, 65, 133. 
153.Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T. Biomaterials, 2003, 
24, 1121. 
154.Jevprasesphant, R.; Penny, J.; Jalal, R.; Attwood, D.; McKeown, N. B.; 
D’Emanuele, A. Int. J. Pharm., 2003, 252, 263. 
155.Duncan, R.; Izzo, L. Adv. Drug Deliver. Rev., 2005, 57, 2215. 
156.Tang, M. X.; Redemann, C. T.; Szoka, F. C. Bioconjugate Chem., 1996, 7, 703. 
157.Hudde, T.; Rayner, S. A.; Comer, R. M.; Weber, M.; Isaacs, J. D.; Waldmann, H.; 
Larkin, D. P. F.; George, A. J. T. Gene Ther., 1999, 6, 939. 
158.van de Wetering, P.; Cherng, J. Y.; Talsma, H.; Crommelin, D. A.; Hennink, W. E. 
J. Control. Rel., 1998, 53, 145. 
159.Cherng, J. Y.; van de Wetering, P.; Talsma, H.; Crommelin, D. J. A.; Hennink, W. 
E. Pharmaceut. Res., 1996, 13, 1038. 
160.van de Wetering, P.; Cherng, J. Y.; Talsma, H.; Hennink, W. E. J. Control. Rel., 
1997, 49, 59. 
 52
161.van de Wetering, P.; Moret, E. E.; Schuurmans-Nieuwenbroek, N. M. E.; van 
Steenbergen, M. J.; Hennink, W. E. Bioconjugate Chem., 1999, 10, 589. 
162.Dubruel, P.; Christiaens, B.; Vanloo, B.; Bracke, K.; Rosseneu, M.; 
Vandekerckhove, J.; Schacht, E. Eur. J. Pharm. Sci., 2003, 18, 211. 
163.Dubruel, P.; Christiaens, B.; Rosseneu, M.; Vandekerckhove, J.; Grooten, J.; 
Goossens, V.; Schacht, E. Biomacromolecules, 2004, 5, 379. 
164.Jones, R. A.; Poniris, M. H.; Wilson, M. R. J. Control. Rel., 2004, 96, 379. 
165.Luten, J.; van Steenis, J. H.; van Someren, R.; Kemmink, J.; Schuurmans 
–Nieuwenbroek, N. M. E.; Koning, G. A.; Crommelin, D. J. A.; van Nostrum, C. 
F.; Hennink, W. E. J. Control. Rel., 2003, 89, 483. 
166.de Wolf, H. K.; Luten, J.; Snel, C. J.; Oussoren, C.; Hennink, W. E.; Storm, G. J. 
Control. Rel., 2005, 109,275. 
167.Lynn, D. M.; Anderson, D. G.; Putnam, D.; Langer, R. J. Am. Chem. Soc., 2001, 
123, 8155. 
168.Anderson, D.; Lynn, D. M.; Langer, R. Angew. Chem. Int. Ed., 2003, 42, 3153. 
169.Akinc, A.; Lynn, D. M.; Anderson, D. G.; Langer, R. J. Am. Chem. Soc., 2003, 
125, 5316. 
170.Zugates, G. T.; Anderson, D. G.; Little, S. R.; Lawhorn, I. E. B.; Langer, R. J. Am. 
Chem. Soc., 2006, 128, 12726. 
171.Akinc, A.; Anderson, D. G.; Lynn, D. M.; Langer, R. Bioconjugate Chem., 2003, 
14, 979. 
172.Green, J. J.; Shi, J.; Chiu, E.; Leshchiner, E. S.; Langer, R.; Anderson, D. G. 
 53
Bioconjugate Chem., 2006, 17, 1162. 
173.Anderson, D. G.; Akinc, A.; Hossain, N.; Langer, R. Mol. Ther., 2005, 11, 426. 
174.Zhong, Z.; Song, Y.; Engbersen, J. F. J.; Lok, M. C.; Hennink, W. E.; Feijen, J. J. 
Control. Rel., 2005, 109, 317. 
175.Wu, D. C.; Liu, Y.; Jiang, X.; Chen, L.; He, C. B.; Goh, S. H.; Leong, K. W. 
Biomacromolecules, 2005, 6, 3166. 
176.Wu, D. C.; Liu, Y.; Jiang, X.; He, C. B.; Goh, S. H.; Leong, K. W. 
Biomacromolecules, 2006, 7, 1879. 
177.Kim, T.; Seo, H. J.; Choi, J. S.; Yoon, J. K.; Baek, J. U.; Kim, K.; Park, J. S. 
Bioconjugate Chem., 2005, 16, 1140. 
178.Lim, Y.; Kim, S.; Suh, H.; Park, J. Bioconjugate Chem., 2002, 13, 952. 
179.Kim, H. J.; Kwon, M. S.; Choi, J. S.; Yang, S. M.; Yoon, J. K.; Kim, K.; Park, J. S. 
Biomaterials, 2006, 27, 2292. 
180.Zhao, Z.; Wang, J.; Mao, H-Q.; Leong, K. M. Adv. Drug Deliver. Rev., 2003, 55, 
483 
181.Wang, J.; Mao, H-Q.; Leong, K. W. J. Am. Chem. Soc., 2001, 123, 9480. 
182.Wang, J.; Huang, S-W.; Zhang, P-C.; Mao, H-Q.; Leong, K. W. Int. J. Pharm., 
2003, 265, 75. 
183.Baran, J.; Penczek, S. Macromolecules, 1995, 28, 5167. 
184.Wang, J.; Zhang, P-C.; Mao, H-Q.; Leong, K. W. Gene Ther., 2002, 9, 1254. 
185.Li, Y.; Wang, J.; Lee, C. G. L.; Wang, C. Y.; Gao, S. J.; Tang, G. P.; Ma, Y. X.; Yu, 
H.; Mao, H-Q.; Leong, K. W.; Wang, S. Gene Ther., 2004, 11, 109. 
 54
186.Wang, J.; Zhang, P-C.; Lu, H-F.; Ma, N.; Wang, S.; Mao, H-Q.; Leong, K. W. J. 
Control. Rel., 2002, 83,157. 
187.Wang, J.; Gao, S-J.; Wang, S,; Mao, H-Q.; Leong, K. W. Gene Ther., 2004, 11, 
1001. 
188.Zhang, P-C.; Wang, J.; Leong, K. W.; Mao, H-Q. Biomacromolecules, 2005, 6, 
54. 
189.Illum, L. J. Pharm. Pharmacol., 1998, 15, 1326. 
190.Mumper, R. J.; Wang, J.; Claspell, J. M.; Rolland, A. P. Proc. Intern. Symp. 
Contol. Rel. Bioact. Mater., 1995, 22, 178. 
191.Lee, M.; Nah, J. W.; Kwon, Y.; Koh, J. J.; Ko, K. S.; Kim, S. W. Pharmaceut. 
Res., 2001, 18, 427. 
192.Hejazi, R.; Amiji, M. J. Control. Rel., 2003, 89, 151. 
193.MacLaughlin, F. C.; Mumper, R. J.; Wang, J. J.; Tagliaferri, J. M.; Gill, I.; 
Hinchcliffe, M.; Rolland, A. P. J. Control. Rel., 1998, 56, 259. 
194.Liu, W. G.; Yao, K. D. J. Control. Rel., 2002, 83, 1. 
195.Erbacher, P.; Zou, S.; Bettinger, T.; Steffan, A. M.; Remy, J. S. Pharmaceut. Res., 
1998, 15, 1332. 
196.Roy, K.; Mao, H.-Q.; Huang, S. K.; Leong, K. W. Nat. Med., 1999, 5, 387. 
197.Thanou, M.; Florea, B. I.; Geldof, M.; Junginger, H. E.; Borchard, G. 
Biomaterials, 2002, 23, 153. 
198.Murata, J. I.; Ohya, Y.; Ouchi, T. Carbohydr. Polym., 1997, 32, 105. 
199.Sato, T.; Ishii, T.; Okahata, Y. Biomaterials, 2001, 22, 2075. 
 55
200.Lee, K. Y.; Kwon, I. C.; Kim, Y. H.; Jo, W. H.; Jeong, S. Y. J. Control. Rel., 1998, 
51, 213. 
201.Kim, Y. H.; Gihm, S. H.; Park, C. R. Bioconjugate Chem., 2001, 12, 932. 
202.Park, I. K.; Kim, T. H.; Park, Y. H.; Shin, B. A.; Choi, E. S.; Chowdhury, E. H.; 
Akaike, T.; Cho, C. S. J. Control. Rel., 2001, 76, 349. 
203.Davis, M. E.; Brewster, M. E. Nat. Rev. Drug Discov., 2004, 3, 1023. 
204.Challa, R.; Ahuja, A.; Ali, J.; Khar, R. K. AAPS PharmSci., 2005, 6, E329. 
205.Gonzalez, H.; Hwang, S.; Davis, M. E. Bioconjugate Chem., 1999, 10, 1068. 
206.Hwang, S. J.; Bellocq, N. C.; Davis, M. E. Bioconjugate Chem., 2001, 12, 280. 
207.Cheng, J.; Khin, K. T.; Jensen, G. S.; Liu, A. J.; Davis, M. E. Bioconjugate Chem., 
2003, 14, 1007. 
208.Reineke, T. M.; Davis, M. E. Bioconjugate Chem., 2003, 14, 247. 
209.Reineke, T. M.; Davis, M. E. Bioconjugate Chem., 2003, 14, 255. 
210.Popielarski, S. R.; Mishra, S.; Davis, M. E. Bioconjugate Chem., 2003, 14, 672. 
211.Kihara, F.; Arima, H.; Tsutsumi, T.; Hirayama, F.; Uekama, K. Bioconjugate 
Chem., 2003, 14, 342. 
212.Arima, H.; Chihara, Y.; Arizono, M.; Yamashita, S.; Wada, K.; Hirayama, F.; 
Uekama, K. J. Control. Rel., 2006, 116, 64. 
213.Wada, K.; Arima, H.; TsuTsumi, T.; Chihara, Y.; Hattori, K.; Hirayama, F.; 
Uekama, K. J. Control. Rel., 2005, 104, 3. 
214.Wada, K.; Arima, H.; TsuTsumi, T.; Hirayama, F.; Uekama, K. Biol. Pharm. Bull., 
2005, 28, 500. 
 56
215.Pun, S. H.; Bellocq, N. C.; Liu, A. J.; Jensen, G.; Machemer, T.; Quijano, E.; 
Schluep, T.; Wen, S. F.; Engler, H.; Heidel, J.; Davis, M. E. Bioconjugate Chem., 
2004, 15, 831. 
216.Forrest, M. L.; Gabrielson, N.; Pack, D. W. Biotechnol. Bioeng., 2005, 89, 416. 
217.Davis, M. E.; Bellocq, N. C. J. Incl. Phenom. Macro., 2003, 44, 17. 
218.Binkowski, C.; Lequart, V.; Hapiot, F.; Tilloy, S.; Cecchelli, R.; Monflier, E.; 
Martin, P. Carbohyd. Res., 2005, 340, 1461. 
219.Mishra, S.; Webster, P.; Davis, M. E. Eur. J. Cell Biol., 2004, 83, 97. 
220.Pun, S. H.; Davis, M. E. Bioconjugate Chem., 2002, 13, 630. 
221.Bellocq, N. C.; Pun, S. H.; Jensen, G. S.; Davis, M. E. Bioconjugate Chem., 2003, 
14, 1122. 
222.Tang, G. P.; Guo, H. Y.; Alexis, F.; Wang, X.; Zeng, S.; Lim, T. M.; Ding, J.; Yang, 
Y. Y.; Wang, S. J. Gene Med., 2006, 8, 736. 
223.Huang, H. L.; Tang, G. P.; Wang, Q. Q.; Li, D.; Shen, F. P.; Zhou, J.; Yu, H. Chem. 
Commun., 2006, 2382. 
224.Yamashita, A.; Choi, H. S.; Ooya, T.; Yui, N.; Akita, H.; Kogure, K.; Harashima, 
H. ChemBioChem., 2006, 7, 297. 
225.Shuai, X.; Merdan, T.; Unger, F.; Kissel, T. Bioconjugate Chem., 2005, 16, 322. 
226.Ooya, T.; Yamashita, A.; Kurisawa, M.; Sugaya, Y.; Maruyama, A.; Yui, N. Sci. 
Technol. Adv. Mater., 2004, 5, 363. 
227.Ooya, T.; Choi, H. S.; Yamashita, A.; Yui, N.; Sugaya, Y.; Kano, A.; Maruyama, 






CATIONIC STAR POLYMERS CONSISTING OF α-CYCLODEXTRIN  




3.2 Experimental section 
3.2.1 Materials 
3.2.2 Synthesis of cationic α-CD-OEI star polymers 
3.2.3 Measurements 
3.3 Results and discussion 
3.3.1 Synthesis and characterization of cationic α-CD-OEI star polymers 
3.3.2 Formation of cationic star polymers/DNA complexes 
3.3.3 Cytotoxicity of cationic star polymers 









Cationic polymers are the major type of non-viral gene delivery vectors 
investigated in the past decade.1-6 A large number of polycations have been reported to 
be able to effect gene transfection, including homopolymers or copolymers of 
polyethylenimine (PEI),7 poly(L-lysine),4 polyamidoamine,8 poly(L-glutamic acid),9 
polyphosphoester,10,11 and chitosan.12,13 Among these polymers, PEI homopolymers 
with molecular weights (MW) higher than 25 K are currently the most popular 
polymers used as gene carriers. They are considered the gold standard for polymeric 
non-viral gene delivery due to their high transfection efficiency, but the rather high 
toxicity of these PEI homopolymers strictly limits their application in gene therapy. 
Meanwhile, it is generally believed that PEI homopolymers with a MW less than 1.8 
K shows low gene delivery ability but is less toxic.14 
Cyclodextrins (CDs) are a series of cyclic oligosaccharides composed of 6, 7, or 8 
D(+)-glucose units linked by α-1,4-linkages and named α-, β-, or γ-CD, respectively. 
They are biocompatible, and do not elicit immune responses and have low toxicities 
in animal and human bodies.15 Since 1999, a class of linear and CD-based polymers 
were introduced by Davis and co-workers for the delivery of nucleic acids.16-20 Most 
of these polymers contained amines and CDs in the polymer backbone. Uekama’s 
group also conjugated CDs (α-, β- or γ-CD) to polyamidoamine dendrimers to 
enhance gene transfection.21,22 Further, Davis’ and Pack’s groups modified PEI with 
β-CD, grafting multiple β-CD molecules to linear or branched PEI (MW 25 K).20,23 
These CD-grafted PEIs delivered nucleic acids efficiently to cultured cells with lower 
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toxicity than the pristine PEI (MW 25 K). Recently, Tang et al. also used CDs to 
crosslink low molecular weight branched PEI (MW 600) to form high molecular 
weight cationic polymers (average MW 61 K), which displayed lower cytotoxicity 
and high gene transfection in cultured cells.24 Most recently, we reported the synthesis 
of novel cationic supramolecules composed of multiple oligoethylenimine-grafted 
β-CD that are threaded and blocked on a polymer chain as a new class of polymeric 
gene delivery vectors.25 In contrast to the conventional cationic polymers containing a 
long sequence of covalently bonded repeating units, the novel supramolecular gene 
carriers were designed based on a new mechanism, where many cationic cyclic units 
were threaded upon a polymer chain to form an integrated supramolecular entity to 
function as a macromolecular gene vector, which showed excellent DNA binding 
ability, low cytotoxicity, and high gene transfection efficiency. 
In this study, we synthesized a series of new cationic star polymers where many 
oligoethylenimine (OEI) arms of different lengths are attached to an α-CD core. We 
found that not only do these new α-CD-OEI star polymers show much lower 
cytotoxicity, but the gene transfection efficiency is similar to that of branched PEI 
(MW 25 K). We also investigated the effect of the length of the OEI arms of the star 
polymers, and found that the transfection efficiency of the α-CD-OEI star polymers 
improved with the increase of the chain length of the OEI arms. 
 
3.2 Experimental section 
3.2.1 Materials 
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Pentaethylenehexamine was obtained from Fluka. α-cyclodextrin was purchased 
from Tokyo Kasei incorporation. Ethylenediamine, linear PEI with molecular weight 
of 423 (OEI-9), branched PEI of molecular weight of 600 (OEI-14) and branched PEI 
(MW 25 K) were purchased by Aldrich. D2O used as solvent in the NMR 
measurements was also obtained from Aldrich. Qiagen kit and Luciferase kit were 
purchased from Qiagen and Promega, respectively. 3-(4,5-Dimethylthiazol-2-yl)-2,5- 
diphenyl tetrazolium bromide (MTT), penicillin, and streptomycin were obtained 
from Sigma. 
 
3.2.2 Synthesis of cationic α-CD-OEI star polymers 
The details of the procedure for the preparation of star polymer 2 are given below 
as a typical example. α-CD (0.414 g, 0.4 mmol, 94% purity) was dried at 120 °C in 
vacuum overnight. When the flask cooled, 40 mL dry DMSO was injected under 
nitrogen. After all α-CD was dissolved, the DMSO solution of α-CD was added 
dropwise during a period of 6 h under nitrogen to 40 mL of anhydrous DMSO 
solution in which 1,1’-carbonyldiimidazole (CDI) (5.84 g, 36 mmol) was dissolved, 
and the mixture was stirred overnight under nitrogen at room temperature. Then, a 
mixture of 400 mL THF and 1700 mL Et2O was poured in the resulting solution to 
precipitate the product. The precipitate was centrifuged and washed with THF 3 times. 
The resulting sticky solid was dissolved in 40 mL DMSO and this solution was slowly 
added dorpwise during a 3 h period into 12.55 mL (43.2 mmol) of 
pentaethylenehexamine which was separately dissolved in 40 mL of DMSO with 
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stirring at room temperature, and stirred overnight. 900 mL THF was poured into the 
reaction mixture to precipitate the product. The precipitate was centrifuged and 
washed 3 times with THF, and the resulting crude product was purified by size 
exclusion chromatography (SEC) on a Sephadex G-50 column using DI water as 
eluent. Finally, 0.1891 g white solid 2 was obtained.  
In the preparation of star polymer 4, dichloromethane (DCM) was used to 
precipitate the product instead of THF. Then, the reaction mixture was filtered and the 
solid was washed 3 times with DCM. Finally, the resulting crude product was purified 
by size exclusion chromatography (SEC) on a Sephadex G-50 column using DI water 
as eluent. 
The yields and analytical data for all four products are given below. 
α-CD-OEI star polymer 1. Yield, 21%. 1H NMR (400 MHz, D2O, 22 °C): δ5.14 (s, 
broad, 6H, H(1) of CD), 3.47-4.62 (m, broad, 36H, H(3), H(6), H(5), H(2) and H(4) of 
CD), 2.98-3.47 (t, broad, 12H, CONCH2 of ethylenediamine), 2.86 (s, broad, 12H, 
NCH2 of ethylenediamine). Anal. Calcd for C53H95N12O36•6H2O: C, 40.59; H, 6.81; N, 
10.27. Found: C, 40.35; H, 6.30; N, 10.07. 
α-CD-OEI star polymer 2. Yield, 17%. 1H NMR (400 MHz, D2O, 22 °C): δ4.98 (d, 
broad, 6H, H(1)H of CD), 3.40-4.64 (m, broad, 36H, H(3), H(6), H(5), H(2) and H(4) 
of CD), 2.92-3.40 (t, broad, 14H, CONCH2 of pentaethylenehexamine), 2.65 (m, 
123H, NCH2 of pentaethylenehexamine). Anal. Calcd for C111H237N41O37•4H2O: C, 
47.50; H, 8.81; N, 20.41. Found: C, 47.66; H, 8.96; N, 20.71. 
α-CD-OEI star polymer 3. Yield, 29%. 1H NMR (400 MHz, D2O, 22 °C): δ5.12 (d, 
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broad, 6H, H(1)H of CD), 3.38-4.65 (m, broad, 36H, H(3), H(6), H(5), H(2) and H(4) 
of CD), 2.90-3.38 (m, broad, 7H, CONCH2 of OEI-9), 2.67 (m, 122H, NCH2 of 
OEI-9). Anal. Calcd for C104H226N39O33•5H2O: C, 48.05; H, 9.11; N, 21.13. Found: C, 
47.63; H, 8.53; N, 21.07. 
α-CD-OEI star polymer 4. Yield, 19%. 1H NMR (400 MHz, D2O, 22 °C): δ5.11 (s, 
broad, 6H, H(1)H of CD), 3.46-4.60 (m, broad, 36H, H(3), H(6), H(5), H(2) and H(4) 
of CD), 3.00-3.46 (m, broad, 10H, CONCH2 of OEI-14), 2.67 (m, 264H, NCH2 of 
OEI-14). Anal. Calcd for C179H409N74O35•24H2O: C, 43.97; H, 9.53; N, 19.44. Found: 
C, 42.63; H, 8.65; N, 20.79. 
 
3.2.3 Measurements 
Gel permeation chromatography (GPC) Gel permeation chromatography (GPC) 
analysis was carried out with a Shimadzu SCL-10A and LC-10AT system equipped 
with a Sephadex G-75 column (size: 2.5 × 32 cm), a Shimadzu RID-10A refractive 
index detector. 1× PBS buffer solution was used as the eluent. Fractions were 
collected per 1 mL and were further detected with a HORIBA SEPA-300 high speed 
accurate polarimeter at wavelength 589 nm with cell length 10 cm and response 2 s. 
1H NMR spectra The 1H NMR spectra were recorded on a Bruker AV-400 NMR 
spectrometer at 400 MHz at room temperature. The 1H NMR measurements were 
carried out with an acquisition time of 3.2 s, a pulse repetition time of 2.0 s, a 30° 
pulse width, 5208-Hz spectral width, and 32 K data points. Chemical shifts were 
referred to the solvent peaks (δ = 4.70 ppm for D2O).  
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13C NMR spectra The 13C NMR spectra were recorded on a Bruker AV-400 NMR 
spectrometer at 100 MHz at room temperature. The 13C NMR measurements were 
carried out using composite pulse decoupling with an acquisition time of 0.82 s, a 
pulse repetition time of 5.0 s, a 30° pulse width, 20,080-Hz spectral width, and 32 K 
data points.  
Plasmid The plasmid used was pRL-CMV (Promega, USA), encoding Renilla 
luciferase, which was originally cloned from the marine organism Renilla reniformis. 
All plasmid DNAs were amplified in E. coli and purified according to the supplier’s 
protocol (Qiagen, Hilden, Germany). The quantity and quality of the purified plasmid 
DNA was assessed by optical density at 260 and 280 nm and by electrophoresis in 1% 
agarose gel. The purified plasmid DNA was resuspended in TE buffer (10 mM Tris-Cl, 
pH 7.5, 1 mM EDTA) and kept in aliquots at a concentration of 0.5 mg/mL.  
Cells and Media All cell lines were purchased from ATCC (Rockville, MD). COS7 
and HEK293 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mg penicillin, 
100 μg/mL streptomycin at 37 °C and 5% CO2. Opti-MEM reduced serum medium, 
DMEM medium was purchased from Gibco BRL (Gaithersburg, MD).  
Gel Retardation Experiments Each star polymer was examined for its ability to 
bind pRL-CMV through gel electrophoresis experiments. All the star polymer stock 
solutions were prepared at a nitrogen concentration of 1 mM in distilled water and the 
pH was adjusted to 7.4. Solutions were sterile filtered (0.2 µm) and stored at 4 ºC. 
pRL-CMV (0.2 μg; 2 μl of a 0.1 μg/μl in TE buffer) was mixed with an equal volume 
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of polymer at nitrogen/phosphate (N/P) ratios between 0 and 10. Each mixture was 
vortexed and incubated for approximately 30 min at room temperature and then 
analyzed on 1% agarose gel containing 0.5 µg/mL ethidium bromide (EtBr). Gel 
electrophoresis was carried out in TAE running buffer (40 mM Tris-acetate, 1 mM 
EDTA) with a current of 80V for 40 min in a Sub-Cell system (Bio-Rad Laboratories, 
CA). DNA bands were visualized and photographed by a UV transilluminator and 
BioDoc-It imaging system. Both of them were purchased from UVP Inc, USA. 
Cell viability assay Two cell lines (HEK293 and COS7) were cultured in DMEM 
medium supplemented with 10% FBS at 37 °C, 5% CO2, and 95% relative humidity. 
For cell viability assay, the cells (15,000 cells/well for HEK293, and 10,000 cells/well 
for COS7) were seeded into 96-well microtiter plates (Nunc, Wiesbaden, Germany). 
After 24 h, culture media were replaced with serum-supplemented culture media 
containing serial dilutions of polymer and the cells were incubated for 24 h. 10 μl 
sterile filtered MTT (5 mg/mL) stock solution in PBS was added to each well, 
reaching a final concentration of 0.5 mg MTT/mL. After 5 h, unreacted dye was 
removed by aspiration. The formazan crystals were dissolved in 100 μl/well DMSO 
and measured spectrophotometrically in a microplate reader (Spectra Plus, TECAN) 
at a wavelength of 570 nm. Six wells were treated together as a group. The relative 
cell growth (%) related to control cells cultured in media without polymer was 
calculated by [A]test/[A]control×100%. 
In Vitro transfection and luciferase assay Transfection studies were performed 
with HEK293 and COS7 cells using the plasmid pRL-CMV as reporter gene. In brief, 
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24-well plates were seeded with cells at a density of 5×104/well 24 h before 
transfection. The star polymer/DNA complexes at various N/P ratios were prepared 
by adding the star polymer into DNA solutions dropwise, followed by vortexing and 
incubation for 30 min at room temperature before transfection. At the time of 
transfection, the medium in each well was replaced with reduced-serum medium or 
normal medium. The complexes were added into the transfection medium and 
incubated with cells for 4 h under standard incubator conditions. After 4 h, the 
medium was replaced with 500 µl of fresh medium supplemented with 10% FBS, and 
the cells were further incubated for an additional 20 h under the same conditions, 
resulting in a total transfection time of 24 h. Cells were washed with PBS twice, lysed 
in 100 µl of cell culture lysis reagent (Promega, Cergy Pontoise, France). Luciferase 
gene expression was quantified using a commercial kit (Promega, Cergy Pontoise, 
France) and a luminometer (Berthold Lumat LB 9507, Germany). Protein 
concentration in the sample was analyzed using a bicinchoninic acid assay (Biorad, 
CA, USA). Absorption was measured on a microplate reader (Spectra Plus, TECAN) 
at 570 nm and compared to a standard curve calibrated with BSA samples of known 
concentration. Results are expressed as relative light units (RLUs) per milligram of 
cell protein lysate (RLU/mg protein).  
Dynamic light scattering and zeta-potential measurements Measurements of 
particle size and zeta potential of the complexes were performed using a Zetasizer 
Nano ZS (Malvern Instruments, Southborough, MA, USA). Complex solutions (100 
µl) containing 3 µg of pDNA (pRL-CMV) were prepared at various N/P ratios 
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ranging from 2-30. The mixture was vortexed for 20 s, incubated for 30 min at room 
temperature and diluted in 1 mL of the distilled water before being analyzed on a 
Zetasizer. The size measurement was performed at 25 °C at a 90° scattering angle. 
The mean hydrodynamic diameter was determined by cumulative analysis. The zeta 




onfocal microscopy For confocal microscopy, the plasmid pEGFP-N1 (Clontech 
Laboratories Inc., USA), encoding a red-shifted variant of wild-type green 
fluorescence protein (GFP), was used to examine the GFP expression in HEK293 
cells. HEK293 cells were seeded onto lab-Tek 4-chambered coverglass (Nalge-Nane 
international, USA) at density of 5×104 cells/well in 500 µl of complete DMEM. 
After 24 hours, transfection was undertaken with 2 µg EGFP plasmid. Each chamber 
was transfected in 0.3 mL reduced serum Opti-MEM media. 20 μl of the star 
polymer/DNA suspension was added per well. After 4 h, the transfection media was 
removed and the cells washed. After 20 h of further incubation in serum-containing 
media, the wells was washed with phosphate-buffered saline (PBS) and imaged under 
a laser scanning confocal microscope (LSM 410, Carl Zeiss, USA). GFP fluorescence 
was excited at 488 nm and emission was collected using a 515 nm filter. 
tomic force microscopy (AFM) A Digital Instruments D3000 Atomic Force 
Microscopy in a tapping mode was employed to image the nanoparticle samples. 
Briefly, silicon disks were soaked in 50% acetone for a minimum of 2 h and rinsed 
with distilled water. When the silicon disks were completely dry, 20 µl of star 
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polymer/DNA complexes containing 1 µg of pRL-CMV at N/P ratios 0, 2 and 10 
were placed on the silicon surface for 2 min after which the complexes was carefully 
removed with a piece of tissue paper. All the AFM images were obtained with a scan 
rate of 0.5 or 1 Hz over a selected area of 10×10 µm or 5×5 µm. Image analysis was 
performed using Nanoscope software after removing the background slope by flatting 
images. 
 
3.3 Results and discussion 
3.3.1 Synthesis and characterization of cationic α-CD-OEI star polymers 
Each α-CD ring contains six glucose units, therefore having many hydroxyl groups, 
which can be activated and grafted with multiple oligoethylenimine (OEI) arms of 
different lengths to form a cationic star polymer. As shown in Scheme 3.1, the 
hydroxyl groups of α-CD were activated with 1,1’-carbonyl diimidazole (CDI), 
followed by reaction with large excess of OEI to give the α-CD-OEI star polymers. 
OEIs with different chain lengths, ethylenediamine (n = 1), pentaethylenehexamine (n 
= 5), OEI-9 (n = 9), and OEI-14 (n = 14), were grafted to α-CD to give α-CD-OEI 
star polymers 1, 2, 3 and 4, respectively. To ensure that there was no intra- or 
intermolecular crosslinking, the molar ratio of CDI or OEI to α-CD was more than 
100 in the above grafting reactions. 
Figure 3.1 shows the size exclusion chromatograms of α-CD-OEI star polymers 1 – 
4 in comparison with free α-CD. α-CD has relative small molecular size, which was 
eluted out at the low molecular weight region of the column. The four α-CD-OEI star 
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polymers were eluted out at higher molecular weight region of the column, and 
showed an increase in molecular weight with increasing the OEI arm length, i.e., the 
molecular weight followed the order of α-CD < 1 < 2 < 3 < 4. Each star polymer 
showed a unimodal peak and this peak was eluted out at the same position in both RI 
and OR diagrams. The results indicate that the α-CD-OEI star polymers were pure 
and there were no intra- or intermolecular crosslinking byproducts. 
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Figure 3.1 Size exclusion chromatograms of α-CD (a), and α-CD-OEI star polymers 
1 (b), 2 (c), 3 (d), and 4 (e), detected with refractive index (RI) and optical rotation 
(OR), respectively. 
Figure 3.2 shows the 13C NMR spectra of α-CD-OEI star polymer 2 in comparison 
with its precursors free α-CD and pentaethylenehexamine. In Figure 3.2c, all peaks 
attributed to the α-CD core and the grafting pentaethylenehexamine arms were 
observed. The peak at δ 158.4 ppm corresponds to the carbon of the urethane groups 
that link the pentaethylenehexamine chains to the α-CD core. Compared with free 
α-CD, the peak of C-6 of the α-CD core of star polymer 2 shifted from 60.9 to 64.3 
ppm, which may be because of the grafting of the pentaethylenehexamine arms. In 
fact, of the three types of hydroxyl groups of α-CD, those at the 6-position (primary 
hydroxyl groups) are the most nucleophilic and more subject to the modification 
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Figure 3.2 13C NMR spectra of α-CD (a), pentaethylenehexamine (b), 
and α-CD-OEI star polymer 2 (c) in D2O. 
Figure 3.3 shows the 1H NMR spectra of α-CD-OEI star polymers 1 – 4 in 
comparison with α-CD. In the spectra of Figure 3.3b - 3e, the signals for both α-CD 
core and grafting OEI arms were observed, while the peaks were much broadened due 
to the restriction of the molecular motion by the grafting of OEI to α-CD core. From 
the 1H NMR spectra, the average number of OEI chains grafted onto each α-CD (x) 
was estimated. About 5.8 molecules of ethylenediamine were grafted onto the α-CD 
core in 1, and about 6.8 molecules of pentaethylenehexamine were grafted onto the 
α-CD core in 2; nearly every glucose unit of the α-CD core was grafted with one 
ethylenediamine or pentaethylenehexamine. In the meantime, about 3.4 molecules of 
OEI-9 were grafted on the α-CD core in 3, and about 5.0 molecules of OEI-14 were 
grafted on the α-CD core in 4. It is likely that the longer OEI chains resulted in more 
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difficult grafting because of the spatial hindrance. However, the branched structure of 
OEI-14 increased the number of OEI arms grafted on the α-CD core in star 










































Figure 3.3 1H NMR spectra of α-CD (a) and α-CD-OEI star polymers 1 (b), 2 (c), 3 
(d), and 4 (e) in D2O.  
 
3.3.2 Formation of cationic α-CD-OEI star polymer/DNA complexes 
The ability of the cationic α-CD-OEI star polymers to condense plasmid DNA 
(pDNA) into particulate structures was confirmed by agarose gel electrophoresis, 
particle size and zeta potential measurements, as well as AFM imaging.  
The formation of α-CD-OEI star polymer/DNA complexes was examined by their 
electrophoretic mobility on an agarose gel at various ratios of amino-group (in 
α-CD-OEI star polymer) to phosphate group (in pDNA), defined as N/P ratio. Figure 
3.4 shows the gel retardation results of cationic α-CD-OEI star polymer/DNA 
 73
complexes with increasing N/P ratios in comparison with branched PEI (25 K). 
α-CD-OEI star polymers 1, 2, and 3 showed decreasing pDNA condensation 
capability; they complexed with pDNA efficiently at N/P ratios of 1.5, 2.5, and 4, 
respectively, due to the decreasing primary amino density with increasing the OEI 
length. However, α-CD-OEI star polymer 4, where the arms were branched OEI-14, 
could inhibit the migration of pDNA at N/P ratios of 2, showing similar DNA 
condensation capability to branched PEI (25 K). Therefore, α-CD-OEI star polymers 
1 and 4 have stronger DNA condensation capability due to the relatively higher 
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Figure 3.4 Electrophoretic mobility of plasmid DNA in the complexes between 
α-CD-OEI star polymers and plasmid DNA in comparison with PEI/DNA complex at 
various N/P ratios. 
Figure 3.5 shows the particle size and zeta potential of α-CD-OEI star 
 74
polymer/DNA complexes in comparison with PEI (25 K)/DNA complex at various 
N/P ratios. As shown in Figure 3.5a, all four α-CD-OEI star polymers could 
efficiently compact pDNA into small nanoparticles. Generally, the particle size 
decreased with an increase in N/P ratio until the N/P ratio was between 6 and 8. The 
particle size remained in the 100 – 200 nm range after the N/P ratio reached 8. All 
α-CD-OEI star polymers and PEI (25 K) formed nanoparticles with pDNA with 
comparable sizes at high N/P ratios. The surface net charge of the complexes of 
pDNA with α-CD-OEI star polymers increased from negative to positive as the N/P 




















































Figure 3.5 Particle size (a) and zeta potential (b) of the complexes between 
α-CD-OEI star polymers and plasmid DNA in comparison with PEI/DNA complex at 
various N/P ratios. 
Figure 3.6 shows representative tapping mode AFM images of naked DNA and the 
complexes between α-CD-OEI star polymer 4 and pDNA at N/P of 2 and 10. The 
AFM image of naked plasmid DNA revealed a supercoiled structure of pDNA. At N/P 
ratio 2, supercoiled plasmid DNA could still be identified under AFM while some of 
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the pDNA was condensed to nanoparticles by α-CD-OEI star polymer. Compared 
with the partial condensation at N/P ratio of 2, the pDNA could be tightly packed and 
totally formed nanoparticles at N/P ratio of 10. The results indicate that the 
complexation of pDNA by α-CD-OEI star polymer led to the formation of compact 
nanoparticles. 
500 nm 500 nm 500 nm
 
Figure 3.6 Atomic force microscopy (AFM) images of the supercoiled plasmid DNA 
(a), and the complexes between α-CD-OEI star polymer 4 and DNA at N/P ratios of 2 
(b) and 10 (c). 
 
3.3.3 Cytotoxicity of cationic α-CD-OEI star polymers 
Cytotoxicity of polymeric gene vectors may be an important factor that affects the 
transfection efficiency. Figure 3.7 shows the results of in vitro cytotoxicity of 
α-CD-OEI star polymers analyzed by the MTT method in two cell lines (HEK293 and 
COS7). As shown in Figure 3.7, all the products showed a dose-dependent effect on 
cytotoxicity. The LD50 values, which represent concentration of the polymers 
resulting in 50% inhibition of cell growth, were calculated. The LD50 value of PEI in 
COS7 was 12 µg/mL, while the LD50 values of α-CD-OEI star polymers 1, 2, 3 and 4 
were 451, 519, 560, and 88 µg/mL, respectively. A similar trend was also observed in 
HEK293 cells. Hence, all the four α-CD-OEI star polymers exhibited much lower 
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toxicity in both cell lines than that of PEI (25 K). It may be attributed to the reduction 
of the density of amino groups and the introduction of α-CD in the star polymers. It is 
thought that the high amino density and high molecular weight are the reasons of the 
high cytotoxicity of PEI (25 K). It is noted that α-CD-OEI star polymer 4 showed 
higher cytotoxicity than that of the other three star polymers. This is probably due to 
the higher amino density and the branch nature of OEI-14, which is more similar to 

























































Figure 3.7 Cell viability assay in HEK293 (a) and COS7 (b) cell lines. The cells were 
treated with various concentrations of α-CD-OEI star polymers 1, 2, 3 and 4, and PEI 
(25 K) for 24 hours in a serum-containing medium. Cell viability was determined by 
the MTT assay and expressed as a percentage of control, that is, the untreated cell 
cultures.  
 
3.3.4 Transfection efficiency of cationic α-CD-OEI star polymers 
In vitro transfection efficiency of α-CD-OEI star polymer/DNA complexes was 
assessed using luciferase as a marker gene in HEK293 and COS7 cells. Figure 3.8 
shows the gene transfection efficiency of α-CD-OEI star polymers for DNA delivery 
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in the absence and presence of serum compared with those of branched PEI (25 K) 
and naked pDNA (ND). The transfection results in both cells lines demonstrated that, 
among the α-CD-OEI star polymers examined, the transfection efficiency generally 
increased following the order 1 < 2 < 3 < 4, with more pronounced enhancements 
from star polymers 3 to 4. This indicates that, for the linear OEI arms, the transfection 
efficiency was dependent upon the chain length of the OEI grafted onto α-CD core. In 
the case of α-CD-OEI star polymer 4, the primary amino groups of the branched OEI 
increased its binding ability and complex stability, thus led to much higher 































































































































Figure 3.8 In vitro gene transfection efficiency of the complexes of cationic 
α-CD-OEI star polymer/DNA in comparison with that of PEI (25 K) or naked DNA 
(ND), in HEK293 (a and b) and COS7  (c and d) cells in the absence and presence of 
serum. Data represent mean ± standard deviation (n=3). 
In both cell lines in the absence of serum, with the increase in N/P ratio from 10 to 
30, the transfection efficiency mediated by PEI (25 K) decreased dramatically, most 
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likely due to its high cytotoxicity, while that mediated by α-CD-OEI star polymers 
increased slightly or remained no significant changes (Figure 3.8, a and c). The 
transfection efficiency of complexes formed by star polymer 4 was even higher than 
that of branched PEI (25 K) at most N/P ratios. Particularly, the transfection efficiency 
mediated by star polymer 4 was 50 times higher than that of PEI (25 K) at N/P ratio of 
30 in HEK293 cells, and star polymers 2 and 3 also showed higher transfection 
efficiency than PEI (25 K) under the same conditions (Figure 3.8, a). 
The gene transfection efficiency showed more cell type dependency under serum 
conditions. The transfection efficiency mediated by α-CD-OEI star polymer 4 was 
comparable to that of PEI (25 K) in HEK293 cells, while generally lower than that of 
PEI (25K) in COS7 cells (Figure 3.8, b and d). 
Confirmation of the gene delivery capability of α-CD-OEI star polymer 4 was also 
obtained by fluorescence microscopy (Figure 3.9). Plasmid pEGFP-N1 encoding 
green fluorescence protein (GFP) was used to examine the GFP expression in 
HEK293 cells. GFP expression could not be detected when the transfection was 
mediated by naked DNA, which was used as a negative control (data not shown). 
Strong fluorescence signal could be observed when transfections were mediated by 
either α-CD-OEI star polymer 4 or PEI at N/P ratio of 10. However, when the 
transfection was mediated by PEI (25 K), the GFP expression in HEK293 cells was 





Figure 3.9 The confocal microscopy images of transfected HEK 293 cells. The 
transfections were mediated by (a) α-CD-OEI star polymer 4 and (b) PEI (25 K) at 
N/P ratio of 10 in the absence of serum using green fluorescence protein gene as a 
reporter gene. The same field of cells was observed by Nomarski optics (right panel) 
or by fluorescence microscope (left panel) to visualize GFP expression. 
 
3.4 Conclusion 
A series of novel cationic α-CD-OEI star polymers have been synthesized by 
conjugating multiple oligoethylenimine (OEI) arms onto an α-CD core as non-viral 
gene delivery vectors. The star polymers were fully characterized in terms of their 
molecular structures by using SEC, 13C and 1H NMR, and elemental analysis. The 13C 
NMR spectra provided a strong evidence to show that the conjugation of OEI arms 
mainly occurred at the primary hydroxyl groups of α-CD. α-CD-OEI star polymers 1, 
2, and 3 contained linear OEI arms with chain lengths ranging from 1 – 9 
ethylenimine units, while α-CD-OEI star polymers 4 contained arms of branched OEI 
of 14 ethylenimine units.  
All the four α-CD-OEI star polymers could inhibit the migration of pDNA on 
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agarose gel through formation of complexes with pDNA, and the complexes formed 
nanoparticles with sizes ranging from 100 – 200 nm at N/P ratios of 8 or higher. The 
star polymers displayed much lower in vitro cytotoxicity than that of branched PEI 
(25 K).  
The α-CD-OEI star polymers showed excellent gene transfection efficiency in 
HEK293 and COS7 cells. Generally, the transfection efficiency increased with an 
increase in the OEI arm length. Star polymer 4, with the longest and branched OEI 
arms, showed the highest transfection efficiency among the four star polymers, which 
was comparable to or even higher than that of branched PEI (25 K). The novel 
α-CD-OEI star polymers with different OEI arms can be promising new non-viral 
gene delivery vectors with low cytotoxicity and high gene transfection efficiency for 
future gene therapy applications. 
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Supramolecular architectures composed of chain-interlocked macrocycles such as 
rotaxanes and catenanes have attracted tremendous interest because of their unique 
structures as well as the potential as building blocks for a variety of functional nano-
materials.1-8 Since the first syntheses of polyrotaxanes with multiple α-cyclodextrin 
(α-CD) rings threaded over a polymer chain,9,10 increasing attention has been focused 
on the studies of the supramolecular structures10-19 and their properties for 
electronics20-22 and biomaterials applications.23-27  
Cationic polymers have been the most promising non-viral gene delivery vectors 
investigated in the past decade.28-33 A great number of polycations have been reported 
to effect gene transfection, including homopolymers or derivatives of 
polyethylenimine (PEI),34 poly(L-lysine),31 polyamidoamine,35 poly(L-glutamic 
acid),36 polyphosphoester,37,38 and chitosan.39,40 In contrast to the conventional 
polycations with long sequences of covalently bonded repeating units, we recently 
have designed novel cationic supramolecules with multiple oligoethylenimine-grafted 
CDs that are threaded and blocked on a polymer chain.41 Herein, we demonstrate that 
the cationic supramolecular gene delivery vectors show good DNA binding ability, 
low cytotoxicity, and high gene transfection efficacy that is similar to that of PEI (25 
K), one of the most effective gene delivery polymers studied to date.33  
 
4.2 Experimental section 
4.2.1 Materials 
Pluronic L64 PEO-PPO-PEO triblock copolymer 1 was supplied by BASF, 
Germany. The copolymer has a chain composition of EO13PO30EO13, a number-
average molecular weight of 2900, and an EO content of 40 wt %. The molecular 
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characteristics were confirmed using GPC and 1H NMR spectroscopy, which were 
found to be within the specification of the supplier. 2,4,6-Trinitrobenzene sulfonic 
acid solution and pentaethylenehexamine were purchased form Fluka. 2,4,6-
Trinitrobenzene sulfonic acid solution was neutralized with NaOH solution before 
use. Tris(2-aminoethyl)amine, ethylenediamine, and oligoethylenimine 
(polyethylenimine with low molecular weight, Mn = 423) were obtained from Aldrich. 
β-CD was purchased from Tokyo Kasei Inc. DMSO-d6 and D2O used as solvent in the 
NMR measurements were also obtained from Aldrich. 
 
4.2.2 Synthesis 
4.2.2.1 Preparation of PEO-PPO-PEO Tetra(amine) 
PEO-PPO-PEO triblock copolymer 1 (Mn = 2,930, 2.985 g, 1.02 mmol) was heated 
overnight in a flask at 80 °C in vacuum. When the flask cooled, 15 mL of anhydrous 
DMF was injected under nitrogen. After 1 was dissolved, the DMF solution of 1 was 
added dropwise during a period of 6 h under nitrogen to 15 mL of anhydrous DMF 
solution in which 1,1’-carbonyldiimidazole (CDI) (1.65 g, 10.2 mmol) was dissolved, 
and the mixture was stirred overnight under nitrogen at room temperature. Then, the 
resulting solution was slowly added dorpwise during a period of 3 h into 15.54 g (102 
mmol) of tris(2-aminoethyl)amine which was dissolved in 15 mL of anhydrous DMF 
with stirring at room temperature, followed by stirring the mixture overnight. DMF 
was removed by vacuum evaporation, and the resulting mixture was dissolved in 
CHCl3 and washed with H2O for 3 times to remove excess tris(2-aminoethyl)amine. 
After removing CHCl3, the product was further purified on a Sephadex LH-20 column 
using methanol as eluent, to give 2.315 g of 2 as viscous liquid (yielded, 69%). 1H 
NMR (400 MHz, DMSO-d6, 22 °C): δ 3.33-3.54 (m, 107H and 91H, -CH2CH2O- of 
 86
PEO block and -CH2CHO- of PPO block), 3.13 (m, 4H, OCONCH2), 2.87 (m, 4H, 
OCONCCH2), 2.65 (m, 8H, CNCH2), 2.49 (m, 8H, CH2N), 1.05 (d, 91H, –CH3 of 
PPO block). Anal. Calcd for C158H322N8O60•3H2O: C, 56.70; H, 9.88; N, 3.35. Found: 
C, 56.42; H, 9.94; N, 3.40. 
4.2.2.2 Preparation of β-CD-PEO-PPO-PEO Polyrotaxane  
PEO-PPO-PEO tetra(amine) 2 (0.4 g) was added to 266 mL of β-CD aqueous 
solution (0.03 g/mL) together with 0.6 g of NaHCO3 for adjusting the pH of the 
solution. The reaction mixture was ultrasonicated for 20 min and stirred overnight at 
room temperature. The inclusion complex 3 was formed as white precipitate. To block 
the ends of the inclusion complex, 3.36 g of sodium salt of 2,4,6-trinitrobenzene 
sulfonic acid was added into the mixture and stirred overnight. The reaction mixture 
was centrifuged and the precipitate was washed 3 times with water. The resulting wet 
solid was dissolved in 30 mL of DMSO and poured into 450 mL of MeOH to 
precipitate the product. The precipitate was collected and washed 3 times with MeOH. 
The precipitate was dissolved in 30 mL of DMSO again and poured into 500 mL of 
H2O to precipitate the product. The resulting precipitate was centrifuged and washed 
3 times with H2O. Finally, the resulting wet solid was freeze dried to give the pure 
polyrotaxane 4 as yellow solid (yield, 2.033 g, 90%). 1H NMR (400 MHz, DMSO-d6, 
22 °C): δ 9.24 (s, 4H, meta H of phenyl), 8.93 (s, 4H, meta H of phenyl), 5.75 (s, 90H, 
O(2)H of CD), 5.70 (m 90H, O(3)H of CD), 4.83 (s, 90H, H(1)H of CD), 4.43 (d, 
90H, O(6)H of CD), 3.00-4.00 (m, 540H, H(3), H(6), H(5), H(2) and H(4) of CD, 
107H, -CH2CH2O- of PEO block, 91H, -CH2CHO- of PPO block), 1.04 (m, 91H, -
CH3 of PPO block). Anal. Calcd for C721H1222N20O532•53H2O: C, 44.10; H, 6.82; N, 
1.43. Found: C, 43.62; H, 6.86; N, 1.69. 
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4.2.2.3 Preparation of cationic multiple OEI-grafted β-CD-PEO-PPO-PEO 
polyrotaxane 
The procedures for the preparation of 5b from polyrotaxane 4 are given below as a 
typical example. Polyrotaxane 4 (0.261 g, 0.015 mmol) was dried at 40 °C in vacuum 
overnight. When the flask cooled, 40 mL of dry DMSO was injected under nitrogen. 
After 4 was dissolved, the DMSO solution of 4 was added dropwise during a period 
of 6 h under nitrogen to 40 mL of anhydrous DMSO solution in which 1,1’-
carbonyldiimidazole (CDI) (3.60 g, 22.2 mmol) was dissolved, and the mixture was 
stirred overnight under nitrogen at room temperature. A mixture of 300 mL of THF 
and 600 mL of Et2O was poured into the resulting solution to precipitate the product. 
The precipitate was centrifuged and washed 3 times with THF. The resulting wet solid 
was dissolved in 40 mL of DMSO and this solution was slowly added dorpwise 
during a period of 3 h into 8.60 mL (29.6 mmol) of pentaethylenehexamine that was 
dissolved in 40 mL of DMSO with stirring at room temperature, followed by stirring 
the mixture overnight. Next, 900 mL of THF was poured into the reaction mixture to 
precipitate the product. The precipitate was centrifuged and washed 3 times with 
THF, and the resulting crude product was purified on a Sephadex G-50 column using 
deionized water as eluent. Finally, 0.333 g of brown solid 5b was obtained (yield, 
61%).  
The yields and analytical data for all four cationic polyrotaxanes are given below. 
Cationic polyrotaxane 5a. Yield, 39%. 1H NMR (400 MHz, D2O, 22 °C): δ 7.89 (s, 
8H, meta H of phenyl), 5.04 (d, broad, 90H, H(1)H of CD), 2.94-4.63 (m, broad, 
540H, H(3), H(6), H(5), H(2) and H(4) of CD, 101H, -CH2CH2O- of PEO block, 45H, 
-CH2CHO- of PPO block, 170H, CONCH2 of ethylenediamine), 2.74 (m, 170H, 
NCH2 of ethylenediamine), 1.12 (d, 91H, -CH3 of PPO block). Anal. Calcd for 
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C976H1732N190O617•130H2O: C, 41.36; H, 7.09; N, 9.39. Found: C, 40.61; H, 6.58; N, 
11.10. 
Cationic polyrotaxane 5b. Yield, 61%.1H NMR (400 MHz, D2O, 22 °C): δ 7.98 (s, 
8H, meta H of phenyl), 5.02 (d, broad, 90H, H(1)H of CD), 3.00-4.62 (m, broad, 
540H, H(3), H(6), H(5), H(2) and H(4) of CD, 101H, -CH2CH2O- of PEO block, 45H, 
-CH2CHO- of PPO block, 135H, CONCH2 of pentaethylenehexamine), 2.69 (m, 
1214H, NCH2 of pentaethylenehexamine), 1.09 (d, 91H, -CH3 of PPO block). Anal. 
Calcd for C1463H2976N425O599•130H2O: C, 45.70; H, 8.48; N, 15.47. Found: C, 45.19; 
H, 7.99; N, 16.01. 
Cationic polyrotaxane 5c. Yield, 44%. 1H NMR (400 MHz, D2O, 22 °C): δ 7.98 (s, 
8H, meta H of phenyl), 4.98 (d, broad, 90H, H(1)H of CD), 2.96-4.60 (m, broad, 
540H, H(3), H(6), H(5), H(2) and H(4) of CD, 101H, -CH2CH2O- of PEO block, 45H, 
-CH2CHO- of PPO block, 86H, CONCH2 of OEI-9), 2.55 (m, 1532H, NCH2 of OEI-
9), 1.08 (d, 91H, -CH3 of PPO block). Anal. Calcd for C1573H3288N467O575•130H2O: C, 
46.47; H, 8.90; N, 16.10. Found: C, 45.86; H, 8.43; N, 16.80. 
 
4.2.3 Measurements 
Gel permeation chromatography (GPC) Gel permeation chromatography (GPC) 
analysis for PEO-PPO-PEO triblock copolymer was carried out with a Shimadzu 
SCL-10A and LC-10ATVP system equipped with two Phenogel 5 μm, 50 and 1000 Å 
columns (size: 300 × 4.6 mm) in series and a Shimadzu RID-10A refractive index 
detector. THF was used as eluent at a flow rate of 0.30 mL/min at 40 °C. 
Monodispersed poly(ethylene glycol) standards were used to obtain a calibration 
curve.  
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GPC analysis for cationic polyrotaxanes was carried out with a Shimadzu SCL-10A 
and LC-10AT system equipped with a Sephadex G-75 column (size: 2.5 × 32 cm), a 
Shimadzu RID-10A refractive index detector. 1× PBS buffer solution was used as the 
eluent. Fractions were collected per 1 mL and were detected with a HORIBA SEPA-
300 high speed accurate polarimeter at wavelength 589 nm with cell length 10 cm and 
response 2 s. 
1H NMR spectra 1H NMR spectra were recorded on a Bruker AV-400 NMR 
spectrometer at 400 MHz at room temperature. The 1H NMR measurements were 
carried out with an acquisition time of 3.2 s, a pulse repetition time of 2.0 s, a 30° 
pulse width, 5208-Hz spectral width, and 32 K data points. Chemical shifts were 
referred to the solvent peaks (δ = 2.50 ppm for DMSO-d6 and δ = 4.70 ppm for D2O).  
Plasmid The plasmid used was pRL-CMV (Promega, USA), encoding Renilla 
luciferase, which was originally cloned from the marine organism Renilla reniformis. 
All plasmid DNAs were amplified in E. coli and purified according to the supplier’s 
protocol (Qiagen, Hilden, Germany). The purity and concentration of the purified 
plasmid DNA were determined by absorption at 260 and 280 nm and by agarose gel 
electrophoresis. The purified plasmid DNA was resuspended in TE buffer (10 mM 
Tris-Cl, pH 7.5, 1 mM EDTA) and kept in aliquots at a concentration of 0.5 mg/ml.  
Gel retardation experiments All polymer stock solutions were prepared at a 
nitrogen concentration of 1 mM in distilled water and the pH was adjusted to 7.4. 
pRL-CMV (0.2 μg in 2 μl TE buffer) was mixed with the polymer at 
nitrogen/phosphate (N/P) ratios from 0 to 10. Each mixture was vortexed and 
incubated for approximately 30 min at room temperature, and analyzed on 1% 
agarose gel in TAE running buffer (40 mM Tris-acetate, 1 mM EDTA) for 40 min at 
80 V in a Sub-Cell system (Bio-Rad Laboratories, CA). The gel was stained with 
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ethidium-bromide (0.5 μg/ml) and the DNA bands were visualized and photographed 
by a UV transilluminator and BioDoc-It imaging system (UVP Inc, USA). 
Particle size and zeta-potential measurements The particle sizes of the 
polymer/pRL-CMV complexes were determined using a N4 Plus Submicron Particle 
Sizer (COULTER, USA). Complex solutions (100 µl) containing 20 µg of DNA were 
prepared at various weight ratios ranging from 2 to 20. After 30 min incubation, the 
complex solutions were diluted to a final volume of 1 ml prior to measurements. 
Scattering light was detected at 90º, running of 200 s at room temperature. The data 
obtained were analyzed in the Unimodal Analysis mode. Zeta-potential measurements 
were carried out using a Zeta Plus zeta-potential analyzer (BIC, USA) at 25 ºC. Five 
hundred microliter of complex solutions containing 100 µg of pRL-CMV were 
prepared at various N/P ratios ranging from 2 to 30. After 30 minutes incubation, the 
complex solutions were diluted to 1.5 ml of the final volume prior to measurements. 
The sampling time was set to automatic mode. Zeta-potential values were presented 
as the average of 10 runs. 
Cell viability assay The cytotoxicity of the cationic polyrotaxanes in comparison 
with PEI (25 K) was evaluated using MTT assay in L929 and HEK293 cell lines. The 
cells were cultured in the medium supplemented with 10% FBS at 37 °C, 5% CO2, 
and 95% relative humidity. For cell viability assay, the cells were seeded in a 96-well 
plate at a density of 10,000 cells/well. After 24 h, culture media were replaced with 
serum-supplemented culture media containing serial dilutions of polymers and the 
cells were incubated for 24 h. Then, 10 μl of sterile filtered MTT stock solution in 
PBS (5 mg/ml) was added to each well, reaching a final MTT concentration of 0.5 
mg/ml. After 5 h, unreacted dye was removed by aspiration. The formazan crystals 
were dissolved in DMSO (100 μl/well) and the absorbance was measured using a 
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microplate reader (Spectra Plus, TECAN) at the wavelength of 570 nm. The relative 
cell viability (%) was related to control cells cultured in media without polymer. All 
experiments were conducted for six samples and averaged. 
In vitro transfection and luciferase assay Transfection studies were performed 
with HEK293 cells using the plasmid pRL-CMV as reporter gene. In brief, 24-well 
plates were seeded with cells at a density of 5 x 104/well 24 h before transfection. The 
polymer/DNA complexes at various N/P ratios were prepared by adding the polymer 
into DNA solutions dropwise, followed by vortexing and incubation for 30 min at 
room temperature before the transfection. At the time of transfection, the medium in 
each well was replaced with reduced-serum medium or normal medium. The 
complexes were added into the transfection medium and incubated with cells for 4 h 
under standard incubator conditions. After 4 h, the medium was replaced with 500 µl 
of fresh medium supplemented with 10% FBS, and the cells were further incubated 
for an additional 68 h under the same conditions, resulting in a total transfection time 
of 72 h. Cells were washed with PBS twice, lysed in 100 µl of cell culture lysis 
reagent (Promega, Cergy Pontoise, France). Luciferase gene expression was 
quantified using a commercial kit (Promega, Cergy Pontoise, France) and a 
luminometer (Berthold Lumat LB 9507, Germany). Protein concentration in the 
samples were analyzed using a bicinchoninic acid assay (Biorad, CA, USA). 
Absorption was measured on a microplate reader (Spectra Plus, TECAN) at 570 nm 
and compared to a standard curve calibrated with BSA samples of known 
concentration. Results are expressed as relative light units (RLUs) per milligram of 
cell protein lysate (RLU/mg protein).  
 
4.3 Results and discussion 
 92
4.3.1 Synthesis and characterization of cationic polyrotaxanes 
Scheme 4.1 shows the synthesis procedures and the structures of the cationic 
polyrotaxanes (5a, 5b, and 5c). α-, β-, and γ-CD consist of 6, 7, and 8 glucose units, 
respectively.42 Oligoethylenimine-grafted β-CD was selected as the building block, 
because β-CD is larger than α-CD and could therefore accommodate grafting with 
more chains of oligoethylenimine (OEI); the ethylenimine unit has a high cationic 
density because every third atom is an amino nitrogen that can potentially be 
protonated.43 Pluronic triblock copolymer 1, with a number-average molecular weight 
(Mw) of 2900 and a 40 wt% content of poly(ethylene oxide) (PEO) was selected as the 
threading polymer. Copolymer 1 has a central poly(propylene oxide) (PPO) block of 
30 PO units, and two flanking PEO blocks of 13 EO units. β-CD is known to 
selectively thread around PPO segments.44 Therefore, in complex 3 and polyrotaxane 
4, PPO segments were covered with 13 β-CD rings, whereas PEO segments were free 
of complexation. This provided some free space for β-CD rings to move along the 
polymer chain in polyrotaxane 4, allowing more efficient grafting of OEI to β-CD ⎯ 
a dense coverage of β-CD on the polymer might be spatially unfavorable to the 
grafting reaction. For blocking the ends of the copolymer to prevent the dethreading 
of β-CD, whose cavity is relatively large, we designed a bifunctional end group as 
shown in 2 and 3, that could react with two molecules of 2,4,6-trinitrobenzene 
sulfonate (TNBS) to form a bulky stopper that is big enough to trap the threaded β-
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OCO  ( NHCH2CH2 )  NH2k
=
1 (m = 30, n = 13)
2
3 (x = 13)
4 (x = 13)
5a (k = 1, y = 6.7)
5b (k = 5, y = 5.3)
5c (k = 9, y = 3.4)
 
Scheme 4.1 Synthesis procedures and structures of 
cationic supramolecules with multiple OEI-grafted β-CD rings. 
 
As shown in Scheme 4.1, OEIs with different chain lengths, ethylenediamine (k = 
1), pentaethylenehexamine (k = 5), and linear oligoethylenimine with average 
molecular weight of 423 (OEI-9, k = 9), were grafted to the polyrotaxane 4 to give 
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OEI-grafted polyrotaxanes 5a, 5b, and 5c, respectively. To ensure that there was no 
intra- or inter-molecular crosslinking, a large excess of OEI (100 times of β-CD) was 
used in the grafting reactions. Of the three types of hydroxyl groups in β-CD, those at 
the 6-position (primary hydroxyl groups) are the most nucleophilic, and are thought to 
be modified under these weak basic conditions.45 This is also in accordance with the 
fact that the maximum number of grafted OEI per β-CD did not exceed 7, the number 
of the glucose units of β-CD. 
Figure 4.1 shows the GPC diagram of the PEO-PPO-PEO triblock copolymer 1. 
The elution curve showed a single unimodal peak. The number-average molecular 
weight was found to be 2930, which is in accordance with the value given by the 




Figure 4.1 GPC diagram of PEO-PPO-PEO triblock copolymer 1. The following 
molecular weight data were obtained: Mn = 2930, Mw/Mn = 1.04. 
 
Figure 4.2 shows the 1H NMR spectra of polyrotaxane 4 in comparison with β-CD 
and PEO-PPO-PEO tetra(amine) 2 in DMSO-d6. In Figure 4.2c, the peaks for β-CD, 
EO and PO segments of the triblock copolymer, and the 2,4,6-trinitrophenyl end 
group were all observed, while they were broadened as compared with the respective 
free counterparts in Figure 4.2a and b. This is due to the restricted molecular 
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movement of the components in the polyrotaxane. Quantitative comparisons between 
the integral intensities of the peaks of β-CD and those of threading copolymer 
segments gave the compositions of the polyrotaxanes. In other words, the numbers of 
β-CD rings threaded in a single polyrotaxane chain could be determined. It was found 
that 13 molecules of β-CD, on average, were threaded and blocked on the PEO-PPO-

























































Figure 4.2 1H NMR spectra of β-CD (a), PEO-PPO-PEO tetra(amine) 2 (b), and 
polyrotaxane 4 in DMSO-d6. 
 
Figure 4.3 shows the size exclusion chromatography (SEC) diagrams of 5a, 5b, and 
5c in comparison with free β-CD. β-CD has a relatively small molecular size, which 
was eluted out at the low molecular weight region of the column, and was detected by 
RI and OR. There was no detection by UV (419 nm) because β-CD has no UV 
absorption. In contrast, all three cationic polyrotaxanes 5a, 5b, and 5c were eluted out 
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at the high molecular weight region of the column, and were detected by RI, UV (419 
nm), and OR at the same time. The results indicate that the cationic polyrotaxanes 5a, 
5b, and 5c had large molecular size because there were 13 molecules of OEI-grafted 
β-CD threaded and blocked on the polymer chain forming an integrated 
supramolecular entity. The OEI-grafted β-CD rings were capped by the 2,4,6-





































Figure 4.3 Size exclusion chromatograms of β-CD (a), cationic polyrotaxanes 5a (b), 
5b (c), and 5c (d) detected with refractive index (RI), UV at 419 nm, and optical 
rotation (OR), respectively. 
 
Figure 4.4 shows the 1H NMR spectra of 5a, 5b, and 5c in comparison with β-CD. 
In the spectra of 5a, 5b, and 5c, the signals for β-CD, the grafting OEI, the threading 
PEO-PPO-PEO triblock copolymer, and the end capping groups were all observed, 
while the peaks were much broadened because of the restriction of the molecular 
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motion by the chain interlocking. The average number of OEI chains grafted onto 
each β-CD (y) was estimated from the 1H NMR spectra. About 6.7 molecules of 
ethylenediamine were grafted onto each β-CD in 5a, nearly every glucose unit of β-
CD being grafted with one ethylenediamine. Approximately 5.3 molecules of 
pentaethylenehexamine were grafted onto each β-CD in 5b, and about 3.4 molecules 
of OEI-9 were grafted on each β-CD in 5c. It is clear that the longer the OEI chain, 




























































Figure 4.4 1H NMR spectra of β-CD (a), cationic polyrotaxanes 5a (b), 5b (c), and 5c 
(d) in D2O. 
 
4.3.2 Formation of cationic polyrotaxane/DNA complexes 
The ability of the cationic polyrotaxanes to condense plasmid DNA (pDNA) into 
particulate structures was confirmed by agarose gel electrophorsis, particle size 
analysis, and zeta potential measurements. Figure 4.5a shows the gel retardation 
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results of cationic polyrotaxane/DNA complexes with increasing N/P ratios, in 
comparison with PEI (25 K). Cationic polyrotaxane 5a could inhibit the migration of 
the pDNA at N/P ratios of 1.5 and above, while 5b and 5c could completely complex 
the pDNA at N/P ratios of 2 and above. Therefore, the cationic polyrotaxanes 
developed in this work have similar or slightly better DNA condensation ability 
compared to PEI (25 K). 
 
Figure 4.5 Binding ability of cationic polyrotaxanes to DNA and the particle size and 
zeta-potential of their complexes with DNA in comparison with PEI (25 K). (a) 
Electrophoretic mobility of plasmid DNA in the complexes; (b) Particle size of the 
complexes; and (c) Zeta-potential of the complexes. 
 
All three cationic polyrotaxanes could efficiently compact pDNA into small 
nanoparticles, as shown in Figure 4.5b. Generally, the particle size decreased with an 
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increase in N/P ratio until the N/P ratio was 4 to 6. The particle size remained in the 
150 to 250 nm range after the N/P ratio reached 6. At low N/P ratios, the pDNA 
complexes with PEI (25 K) had larger particle sizes than those with cationic 
polyrotaxanes, but decreased between 100 and 150 nm after the N/P ratio reached 10 
(Figure 4.5b). The surface net charge of complexes of pDNA with cationic 
polyrotaxanes increased from negative to positive as the N/P ratio increased from 0 to 
4, and reached a plateau at the N/P ratio of 4 and above (Figure 4.5c).  
 
4.3.3 Transfection efficiency of cationic polyrotaxanes 
The transfection efficiency of cationic polyrotaxane/DNA complexes was assessed 
using luciferase as a marker gene in HEK293 cells. Figure 4.6 shows the gene 
transfection efficiency of cationic polyrotaxanes for DNA delivery in the absence and 
presence of serum, in comparison with those of PEI (25 K) and naked pDNA (ND). 
We found that the cationic supramolecules showed high gene transfection efficacy in 
the absence as well as in the presence of serum, comparable to that of PEI (25 K), one 
of the most effective gene delivery polymers studied to date.33 Luciferase expression 
by transfection with cationic polyrotaxanes was several orders higher than that 
mediated by ND. 
The transfection efficiency mediated by cationic polyrotaxanes was dependant 
upon the chain length of OEI grafted onto β-CD, and follow the order of 5c > 5b > 5a 
in most cases. Therefore, it is preferable to graft longer OEI onto polyrotaxanes for 
more efficient gene transfection. In the absence of serum, the optimal N/P ratio for 
most efficient transfection for 5b and 5c was 5 : 1, which is a very low N/P ratio. In 
contrast, in the presence of serum, the transfection efficiency increased with the N/P 
ratio, reaching an optimal transfection efficiency at N/P ratio of 25 to 35. It is 
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interesting that the gene transfection efficiency of 5b and 5c in the presence of serum 
was significantly higher than that in the absence of serum. This indicates that the 
cationic polyrotaxane/DNA complexes are stable enough in the complete medium, 
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Figure 4.6 In vitro gene transfection efficiency of the complexes of cationic 
polyrotaxane/DNA in HEK293 cells in comparison with that of PEI (25 K) or naked 
DNA, in the absence (a) and presence (b) of serum. The transfection efficiency of PEI 
(25 K) was obtained with the optimal N/P ratio of 10. Data represent mean ± standard 
deviation (n = 3). 
 
4.3.4 Cytotoxicity of cationic polyrotaxanes 
Cytotoxicity of polymeric gene vectors may be an important factor that affects the 
transfection efficiency. Our studies showed that the cationic polyrotaxanes were much 
less toxic than PEI in cell cultures. Figure 4.7 shows the cytotoxicity of cationic 
polyrotaxanes 5a, 5b, and 5c in L929 cells and HEK293 cells in comparison with PEI 
(25 K). Generally, all three cationic polyrotaxanes showed significantly lower 
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cytotoxicity than PEI (25 K) in both cell lines. The high amino density and the high 
molecular weight may be the reasons of the toxicity of PEI. Although cationic 
polyrotaxanes 5a, 5b, and 5c were grafted with OEI, the very different chain 
architectures from that of PEI may result in lower cytotoxicity. Generally, the amino 
density of cationic polyrotaxanes 5a, 5b, and 5c is lower than PEI. Despite the lower 

















































































Figure 4.7 Cytotoxicity of cationic polyrotaxanes 5a, 5b, and 5c in L929 cells (a) and 
HEK293 cells (b) in comparison with PEI (25 K). Data represent the mean ± standard 
deviation (n = 6). 
 
It was reported that polyiminocarbonate-containing β-CD,46 β-CD-modified PEI,47 
and polyamidoamine dendrimer conjugates with CDs48,49 have been synthesized for 
enhanced gene transfection. These conjugates or derivatives are basically composed 
of amino-bearing polymers covalently bonded with CDs. Our cationic polyrotaxanes 
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are different, where many small OEI-grafted β-CD units are threaded and blocked 
upon a polymer chain to form an integrated macromolecular entity.  
Ooya et al. also reported the use of dimethylaminoethyl-modified α-CDs threaded 
onto a PEO chain and capped by cleavable end groups.50 In their cases, α-CD only 
contains tertiary amines, which may not be as efficient in DNA complexation and 
gene delivery. Our design using oligoethylenimine-grafted β-CDs threaded on a PEO-
PPO-PEO triblock copolymer may have the following advantages. First, the low 
spatial hindrance presented by the spare PEO segment permits efficient grafting of 
OEI chains onto β-CDs. Second, the OEI-grafted β-CD rings can freely move along 
both PPO and PEO segments in solution, giving flexibility for efficient complexation 
with DNA. Finally, our system has a lot of “flapping” OEI chains with many primary 
and secondary amines, which may also be beneficial for interaction with DNA and/or 
cell membranes. These factors may contribute to the transfection efficiency that is 
equal to PEI (25K) at the optimized N/P ratio and molecular weight, and is 2 ⎯ 4 
orders higher than the dimethylaminoethyl-modified α-CDs polyrotaxane system.50 
However, the work of Ooya et al. was more focused on release of the DNA in cells by 
dethreading through cleavage of the end groups, which addressed a different but very 
important aspect of gene-delivery design. 
 
4.4 Conclusion 
In this study, we have successfully demonstrated a smart materials design of 
cationic supramolecular polyrotaxane entities for efficient gene delivery. When 
properly designed, the structures and conformations of the cationic polyrotaxanes can 
be further controlled in terms of the density of amino groups and the flexibility of the 
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Over the last few decades, supramolecular architectures have intrigued researchers 
because of their unique structures and remarkable properties such as molecular 
recognition, self-assembly, self-organisation and kinetic and thermo- dynamic 
complementarity.1-3 Polyrotaxane, formed by multiple macrocycles threading over a 
polymeric chain, is such an example. Since the first polyrotaxane was synthesized in 
1992,4-5 growing interests have been shown in the study of the supramolecular 
structure of the polyrotaxanes and their potentials for electronical and biomedical 
applications.4-18 
Currently, cationic polymers have gained much attention for their potential use as 
nonviral gene carriers. Compared with other gene delivery systems (viral vectors and 
cationic lipids), cationic polymers for gene delivery are generally economical and 
stable, and they can be produced in a large scale and show low host immunogenicity. 
By now a great number of polycations have been reported to be able to deliver gene, 
including homopolymers or derivatives of polyethylenimine (PEI),19 poly(L-lysine),20 
polyamidoamine,21 poly(L-glutamic acid),22 polyphosphoester,23,24 and chitosan.25,26  
For conventional polycations containing long sequences of covalently bonded 
repeating units, the mobility of their molecular chains will decrease with an increase 
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of their repeating units and molecular weight in the solution state. In contrast, under 
the same condition the macrocycles in polyrotaxanes will rotate and/or slide along the 
polymeric chain freely, which can improve the mobility of cationic ligands linked to 
the macrocycles and enhance the interaction of the cationic ligands and receptor 
DNA.27,28 In 2004, Ooya et al. introduced aminoethylcarbamoyl (ACE) groups to 
polyrotaxanes consisting of α-CD and poly(ethylene glycol), and found that the 
introduction of ACE groups enhanced the opportunity of complexion with DNA.29 
They also reported the use of dimethylaminoethyl-modified α-CDs threaded onto a 
PEO chain and capped by cleavable end groups. The cleavage of the end groups cause 
the dethreading of α-CDs and rapid release of DNA in cells, but the tertiary amines 
conjugated to the α-CDs may not be efficient in DNA complexation and gene 
delivery.30 Our group also designed and synthesized cationic supramolecules 
composed of multiple oligoethylenimine-grafted β-CDs threaded on a polymeric 
chain, these supramolecules showed good DNA binding ability, low cytotoxicity and 
high gene-transfection efficiency in HEK293 cells.31 
In this study, we synthesized a variety of novel cationic polyrotaxanes containing 
PPO-PEO-PPO triblock copolymer, α-CD and various linear or nonlinear 
oligoethylenimine (OEI) chains for gene delivery. In both HEK293 and COS7 cells, 
these polyrotaxanes showed low cytotoxicity and high transfection efficiency which is 
similar to that of branched PEI (25 K), one of the most effective gene-delivery 
polymers studied to date. Especially, they displayed sustained gene delivery capability 
in HEK293 cells in both serum and serum free condition, while the transfection 
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efficiency of PEI (25 K) decreased dramatically with the increasing expression 
duration.  
 
5.2 Experimental section 
5.2.1 Materials 
Pluronic-R PPO-PEO-PPO triblock copolymer (Mn =1,990, Mw/Mn =1.04) was 
obtained by Aldrich. This polymer has chain composition of PO8EO23PO8. The 
molecular characteristics were determined by combination of GPC and 1H NMR 
results, which were found to be within the specification of the supplier. 2,4,6-Tri- 
nitrobenzene sulfonic acid solution and pentaethylenehexamine was obtained from 
Fluka. 1,1’-Carbonyldiimidazole (CDI) and α-cyclodextrin were purchased from 
Tokyo Kasei incorporation. Ethylenediamine, linear PEI with molecular weight of 
423 (OEI-9), branched PEI with molecular weight of 600 (OEI-14) and branched PEI 
(25 K) were also supplied by Aldrich. DMSO-d6 and D2O used as solvent in the NMR 
measurements were also obtained from Aldrich. Qiagen kit and Luciferase kit were 
purchase from Qiagen and Promega, respectively. 3-(4,5-Dimethylthiazol-2-yl)-2,5- 




The procedures for preparation of 5b from PPO-PEO-PPO triblock copolymer 1 are 
given below as a typical example. 
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5.2.2.1 Synthesis Preparation of PPO-PEO-PPO bis(amine) 
Pluroic-R PPO-PEO-PPO triblock copolymer 1 (Mn = 1990, 2.0 g, 1 mmol) was 
heated in a flask at 80 °C in vacuum overnight. When the flask cooled, 15 mL of 
anhydrous DMF was injected under nitrogen. After all of 1 was dissolved, the DMF 
solution of 1 was added dropwise over a period of 6 h under nitrogen to 15 mL of 
anhydrous DMF solution in which CDI (1.622 g, 10 mmol) was dissolved, and the 
mixture was stirred overnight under nitrogen at room temperature. The resulting 
solution was slowly added dropwise during a period of 3 h into 24.0 g (400 mmol) of 
ethylenediamine which was dissolved in 15 mL of anhydrous DMF with stirring at 
room temperature and stirred overnight. Excess ethylenediamine and DMF was 
removed by vacuum evaporation. The resulting viscous solution was purified by size 
exclusion chromatography (SEC) on a Sephadex LH-20 column using methanol as 
eluent. Finally, 1.80 g viscous liquid 2 was yielded (83%). 1H NMR (400 MHz, 
DMSO-d6, 22 ºC): δ 3.25-3.71 (m, 92H and 48H, -CH2CH2O- of PEO block and 
-CH2CHO- of PPO block), 3.22 (s, 4H, CONCH2 of ethylenediamine), 2.04 (s, 4H, 
NCH2 of ethylenediamine), 1.04 (s, 48H, –CH3 of PPO block). 
5.2.2.2 Preparation of α-CD-PPO-PEO-PPO polyrotaxane 
0.5 g of the resulting PPO-PEO-PPO bis(amine) 2 was added to 59 mL α-CD 
saturated solution (0.145 g α-CD/mL H2O), and 0.75 g NaHCO3 was added to adjust 
the pH value of the solution. The reaction mixture was ultrasonicated for 20 min and 
stirred at room temperature overnight. Then, 3.15 g of sodium salt of picrylsulfonic 
acid was added to the mixture and stirred overnight. Subsequently, 200 mL H2O was 
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poured into the reaction mixture to precipitate the product. The precipitate was 
centrifuged and washed 3 times with water. The resulting wet solid was dissolved in 
30 mL DMSO and poured into 500 mL CH3COOCH2CH3 to precipitate the product. 
The precipitate was centrifuged and washed 3 times with CH3COOCH2CH3. The 
resulting wet solid was dissolved in 30 mL DMSO again and poured into 500 mL H2O 
to precipitate the product. The resulting precipitate was centrifuged and washed with 
H2O for 3 times. Finally, the resulting wet solid was dried by freeze (liquid nitrogen) 
in vacuo and 1.76 g pure polyrotaxane 4 was yielded (89 %). 1H NMR (400 MHz, 
DMSO-d6, 22 ºC): δ 8.89 (s, 2H, meta H of phenyl), 8.77 (s, 2H, meta H of phenyl), 
5.62 (s, 47H, O(2)H of CD), 5.47 (m, 47H, O(3)H of CD), 4.75 (s, 47H, H(1)H of 
CD), 4.38 (s, 47H, O(6)H of CD), 2.80-4.00 (m, 282H, H(3), H(6), H(5), H(2) and 
H(4) of CD, 92H, -CH2CH2O- of PEO block, 48H, -CH2CHO- of PPO block), 1.04 (s, 
48H, -CH3 of PPO block). 
5.2.2.3 Preparation of cationic multiple OEI-grafted α-CD-PPO-PEO-PPO 
polyrotaxane 
The resulting polyrotaxane 4 (0.2028 g, 0.02 mmol) was dried at 40 °C in vacuum 
overnight. When the flask cooled, 40 mL dry DMSO was injected under nitrogen. 
After all 4 was dissolved, the DMSO solution of 4 was added dropwise over a period 
of 6 h under nitrogen to 40 mL of anhydrous DMSO solution in which CDI (2.27 g, 
14 mmol) was dissolved, and the mixture was stirred overnight under nitrogen at 
room temperature. A mixture of 300 mL THF and 600 mL Et2O was poured into the 
resulting solution to precipitate the product. The precipitate was centrifuged and 
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washed 3 times with THF. The resulting wet solid was dissolved in 40 mL DMSO and 
this solution was slowly added dropwise over a period of 3 h into 4.90 mL (16.8 
mmol) of pentaethylenehexamine which had been dissolved in 40 mL of DMSO with 
stirring at room temperature and stirred overnight. 900 mL THF was poured in the 
reaction mixture to precipitate the product. The precipitate was centrifuged and 
washed 3 times with THF, and the resulting crude product was purified by size 
exclusion chromatography (SEC) on a Sephadex G-50 column using DI water as 
eluent. Finally, 0.186 g brown solid 5b was yielded (46%).  
The yields and analytical data for all four cationic polyrotaxanes are given below. 
Cationic polyrotaxane 5a. Yield, 77%. 1H NMR (400 MHz, D2O, 22 °C): δ 8.38 (s, 
2H, meta H of phenyl), 8.01 (s, 2H, meta H of phenyl), 5.03 (d, broad, 47H, H(1) of 
CD), 2.92-4.59 (m, broad, 282H, H(3), H(6), H(5), H(2) and H(4) of CD, 92H, 
-CH2CH2O- of PEO block, 48H, -CH2CHO- of PPO block, 124H, CONCH2 of 
ethylenediamine), 2.74 (s, 124H, NCH2 of ethylenediamine), 1.12 (s, 48H, -CH3 of 
PPO block).  
Cationic polyrotaxane 5b. Yield, 46%. 1H NMR (400 MHz, D2O, 22 °C): δ 8.43 (s, 
2H, meta H of phenyl), 8.04 (s, 2H, meta H of phenyl), 5.07 (d, broad, 47H, H(1)H of 
CD), 3.00-4.57 (m, broad, 282H, H(3), H(6), H(5), H(2) and H(4) of CD, 92H, 
-CH2CH2O- of PEO block, 48H, -CH2CHO- of PPO block, 78H, CONCH2 of 
pentaethylenehexamine), 2.74 (m, 937H, NCH2 of pentaethylenehexamine), 1.11 (s, 
48H, -CH3 of PPO block). 
Cationic polyrotaxane 5c. Yield, 54%. 1H NMR (400 MHz, D2O, 22 °C): δ 8.39 (s, 
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2H, meta H of phenyl), 8.02 (s, 2H, meta H of phenyl), 5.00 (d, broad, 47H, H(1)H of 
CD), 2.96-4.61 (m, broad, 282H, H(3), H(6), H(5), H(2) and H(4) of CD, 92H, 
-CH2CH2O- of PEO block, 48H, -CH2CHO- of PPO block, 36H, CONCH2 of OEI-9), 
2.72 (m, 823H, NCH2 of OEI-9), 1.11 (s, 48H, -CH3 of PPO block).  
Cationic polyrotaxane 5d. Yield, 66%. 1H NMR (400 MHz, D2O, 22 °C): δ 8.34 (s, 
2H, meta H of phenyl), 7.96 (s, 2H, meta H of phenyl), 4.96 (d, broad, 47H, H(1)H of 
CD), 2.94-4.62 (m, broad, 282H, H(3), H(6), H(5), H(2) and H(4) of CD, 92H, 
-CH2CH2O- of PEO block, 48H, -CH2CHO- of PPO block, 55H, CONCH2 of 
OEI-14), 2.57 (m, 1827H, NCH2 of OEI-14), 1.08 (s, 48H, -CH3 of PPO block).  
 
5.2.3 Measurements 
Gel permeation chromatography (GPC) Gel permeation chromatography (GPC) 
analysis for PPO-PEO-PPO triblock copolymer was carried out with a Shimadzu 
SCL-10A and LC-10ATVP system equipped with two Phenogel 5 μm, 50 and 1000 Å 
columns (size: 300 × 4.6 mm) in series and a Shimadzu RID-10A refractive index 
detector. THF was used as eluent at a flow rate of 0.30 mL/min at 40 °C. 
Monodispersed poly(ethylene glycol) standards were used to obtain a calibration 
curve.  
GPC analysis for cationic polyrotaxanes was carried out with a Shimadzu SCL-10A 
and LC-10AT system equipped with a Sephadex G-75 column (size: 2.5 × 32 cm), a 
Shimadzu RID-10A refractive index detector. 1× PBS buffer solution was used as the 
eluent. Fractions were collected per 1 mL and were detected with a HORIBA 
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SEPA-300 high speed accurate polarimeter at wavelength 589 nm with cell length 10 
cm and response 2 s. 
1H NMR spectra The 1H NMR spectra were recorded on a Bruker AV-400 NMR 
spectrometer at 400 MHz at room temperature. The 1H NMR measurements were 
carried out with an acquisition time of 3.2 s, a pulse repetition time of 2.0 s, a 30° 
pulse width, 5208-Hz spectral width, and 32 K data points. Chemical shifts were 
referred to the solvent peaks (δ = 4.70 ppm for D2O and 2.50 ppm for DMSO-d6).  
13C NMR spectra The 13C NMR spectra were recorded on a Bruker AV-400 NMR 
spectrometer at 100 MHz at room temperature. The 13C NMR measurements were 
carried out using composite pulse decoupling with an acquisition time of 0.82 s, a 
pulse repetition time of 5.0 s, a 30° pulse width, 20,080-Hz spectral width, and 32 K 
data points. 
Basic hydrolysis of cationic polyrotaxane 5c The basic hydrolysis was conducted 
at room temperature by adding 50.6 mg of cationic polyrotaxane 5c to a 5 wt% of 
content of NaOH solution (2.5 mL, 1.25 mol/L). The resulting hydrolyzed product 
was sampled and detected by GPC at 24 h, 48 h and 96 h, respectively. Prior to 
measurements, all the samples were neutralized to pH 7.3. 
Plasmid The plasmid used was pRL-CMV (Promega, USA), encoding Renilla 
luciferase, which was originally cloned from the marine organism Renilla reniformis. 
All plasmid DNAs were amplified in Escherichia coli and purified according to the 
supplier’s protocol (Qiagen, Hilden, Germany). The purity and concentration of the 
purified plasmid DNA were determined by absorption at 260 and 280 nm and by 
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agarose gel electrophoresis. The purified plasmid DNA was resuspended in TE buffer 
(10 mM Tris-Cl, pH 7.5, 1 mM EDTA) and kept in aliquots at a concentration of 0.5 
mg/mL.  
Cells and Media All cell lines were purchased from ATCC (Rockville, MD). 
COS7 and HEK293 cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mg 
penicillin, 100 μg/mL streptomycin at 37 °C and 5% CO2. Opti-MEM reduced serum 
medium, and DMEM medium were purchased from Gibco BRL (Gaithersburg, MD).  
Gel Retardation Experiments All polymer stock solutions were prepared at a 
nitrogen concentration of 1 mM in distilled water and the pH was adjusted to 7.4. 
pRL-CMV (0.2 μg in 2 μL TE buffer) was mixed with polymer at N/P ratios from 0 to 
10. Each mixture was vortexed and incubated for approximately 30 min at room 
temperature, and then analyzed on 1% agarose gel in TAE running buffer (40 mM 
Tris-acetate, 1 mM EDTA) for 40 min at 80V in a Sub-Cell system (Bio-Rad 
Laboratories, CA). The gel was stained with ethidium bromide (0.5 µg/mL) and the 
DNA bands were visualized and photographed by a UV transilluminator and 
BioDoc-It imaging system (UVP Inc., USA). 
Cell viability assay Two cell lines (COS7 and HEK293) were cultured in the 
DMEM medium supplemented with 10% FBS at 37 °C, 5% CO2, and 95% relative 
humidity. For cell viability assay, the cells were seeded in a 96-well microtiter plate 
(Nunc, Wiesbaden, Germany) at a density of 10,000 cells/well for COS7 cells and 
15,000 cells/well for HEK293 cells. After 24 h, culture media were replaced with 
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serum-supplemented culture media containing serial dilutions of the polymers and the 
cells were incubated for 24 h. Then, 10 μL of sterile filtered MTT stock solution in 
PBS (5 mg/mL) was added to each well, reaching a final concentration of 0.5 mg/mL. 
After 5 h, unreacted dye was removed by aspiration. The formazan crystals were 
dissolved in DMSO (100 μL/well) and the absorbance was measured using a 
microplate reader (Spectra Plus, TECAN) at the wavelength of 570 nm. The relative 
cell viability (%) was related to control cells cultured in media without polymer. All 
experiments were conducted for six samples and averaged. 
In vitro transfection and luciferase assay Transfection studies were performed 
with COS7 and HEK293 cells using the plasmid pRL-CMV as reporter gene. In brief, 
24 h before transfection, 24-well plates were seeded with cells at a density of 
5×104/well. The polymer/DNA complexes at various N/P ratios were prepared by 
adding the polymer into DNA solutions dropwise, followed by vortexing and 
incubation for 30 min at room temperature before the transfection. At the time of 
transfection, the medium in each well was replaced with reduced-serum medium or 
normal medium. The complexes were added into the transfection medium and 
incubated with cells for 4 h under standard incubator conditions. After 4 h, the 
medium was replaced with 500 µL of fresh medium supplemented with 10% fetal 
bovine serum (FBS), and the cells were further incubated for an additional 20 h 
(longer incubation time of 44 h and 68 h for sustained gene delivery study) under the 
same conditions, resulting in a total transfection time of 24 h (longer total transfection 
time of 48 h and 72 h for sustained gene delivery study). Cells were washed twice 
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with PBS and lysed in 100 µL of cell culture lysis reagent (Promega, Cergy Pontoise, 
France). Luciferase gene expression was quantified using a commercial kit (Promega, 
Cergy Pontoise, France) and a luminometer (Berthold Lumat LB 9507, Germany). 
Protein concentration in the samples was analyzed using a bicinchoninic acid assay 
(Biorad, CA, USA). Absorption was measured on a microplate reader (Spectra Plus, 
TECAN) at 570 nm and compared to a standard curve calibrated with bovine serum 
albumin (BSA) samples of known concentration. Results are expressed as relative 
light units per milligram of cell protein lysate (RLU/mg protein).  
Dynamic light scattering and zeta-potential Measurements of particle size and 
zeta potential of the complexes were performed using a Zetasizer Nano ZS (Malvern 
Instruments, Southborough, MA, USA) with a laser light wavelength of 633 nm at a 
173° scattering angle. Complex solutions (100 µl) containing 3 µg of pDNA 
(pRL-CMV) were prepared at various N/P ratios ranging from 2-30. The mixture was 
vortexed for 20 s, incubated for 30 min at room temperature and diluted in 1 mL of 
distilled water before being analyzed on the Zetasizer. The size measurement was 
performed at 25 °C in triplicate. The deconvolution of the measured correlation curve 
to an intensity size distribution was accomplished using a non-negative least squares 
algorithm. The Z-average hydrodynamic diameters of the particles were given by the 
instrument. The Z-average size is the intensity weighted mean diameter derived from 
a Cumulants or single exponential fit of the intensity autocorrelation function. The 
zeta potential measurements were performed using a capillary zeta potential cell in 
automatic mode using the same samples for the particle size measurements. 
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Confocal microscopy For confocal microscopy imaging of the gene transfection, 
the plasmid pEGFP-N1 (Clontech Laboratories Inc., USA), encoding a red-shifted 
variant of wild-type green fluorescence protein (GFP), was used to examine the GFP 
expression in HEK293 cells. HEK293 cells were seeded onto lab-Tek 4-chambered 
coverglass (Nalge-Nane international, USA) at density of 5×104 cells/well in 500 µL 
of complete DMEM medium. After 24 hours, transfection was undertaken with 2 µg 
EGFP plasmid in 0.3 mL of reduced-serum Opti-MEM medium in each well. At the 
time of transfection, 20 μL of cationic polyrotaxane 5b-DNA complex solution was 
added in each well. After 4 h, the transfection media was removed and the cells were 
washed with fresh complete DMEM medium. After 20 h of further incubation in 
serum-containing complete DMEM medium, the cells were washed with phosphate- 
buffered saline (PBS) and imaged under a laser scanning confocal microscope (LSM 
410, Carl Zeiss, USA). GFP fluorescence was excited at 488 nm and emission was 
collected using a 515 nm filter. 
AFM A Digital Instruments MultiMode-AFM with Nanoscope IV controller in a 
tapping mode was employed to image the nanoparticle samples. Briefly, silicon disks 
were soaked in 50% acetone for a minimum of 2 h and rinsed with distilled water. 
When the silicon disks were completely dried, 20 µL of cationic polyrotaxane 
5b-DNA complexes containing 1.0 µg of pRL-CMV at N/P ratios 0, 2, and 10 were 
placed on the silicon surface for 2 min, followed by removing the complex solutions 
carefully with a piece of tissue paper. All the AFM images were obtained with a scan 
rate of 0.5 or 1 Hz over a selected area of 2×2 µm. Image analysis was performed 
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using Nanoscope software after removing the background slope by flatting images. 
 
5.3 Results and discussion 
5.3.1 Synthesis and characterization of cationic polyrotaxanes 
1 (m = 23, n = 8)
2
3 (x = 8)
4 (x = 8)
5a (k =  1, y = 5.3) 
5b (k =  5, y = 5.0) 
5c (k =  9, y = 2.3) 
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Scheme 5.1 synthesis procedures and the structures of multiple 
OEI-modified cationic α-CD-PPO-PEO-PPO polyrotaxanes 5a, 5b, 5c and 5d. 
Scheme 5.1 shows the synthesis procedures and the structures of the cationic 
polyrotaxanes (5a, 5b, 5c and 5d). Firstly, for conversion of both of the terminal 
hydroxyl groups of the PPO-PEO-PPO triblock copolymer 1 to amino groups, the 
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hydroxyl groups were activated with CDI, followed by reaction with a large excess of 
ethylenediamine to give PPO-PEO-PPO bis(amine) 2. These copolymers were 
allowed to react with saturated solution of α-CD and a large excess 2,4,6-trinitro- 
benzene sulfonate (TNBS) in sequence to form polyrotaxanes 4. Finally, various 
linear or nonlinear OEIs with different molecular weights were grafted to 
polyrotaxane 4 to give the corresponding cationic polyrotaxanes (5a, 5b, 5c and 5d).  
Figure 5.1 shows the 1H NMR spectra of polyrotaxane 4 with reference to α-CD 
and PPO-PEO-PPO bis(amine) 2 in DMSO-d6. In Figure 5.1c, the peaks for α-CD, 
EO and PO segments of the triblock copolymer, and the 2,4,6-trinitrophenyl end 
groups were all observed, while they were broadened as compared with the respective 
free counterparts in Figure 5.1a and b. This is due to the restricted molecular 
movement of the components in the polyrotaxane. Quantitative comparisons between 
the integral intensities of the peaks of α-CD and those of threading copolymer 
segments gave the compositions of the polyrotaxanes. It was found that 8 α-CD rings, 
on average, were covered and blocked on the PPO-PEO-PPO triblock copolymer in 
one polyrotaxane 4. 
Figure 5.2 shows the size exclusion chromatograms of the cationic polyrotaxanes in 
contrast to free α-CD. α-CD has relative small molecular size, which was eluted out 
at the low molecular weight region of the column, and was detected by RI and OR. 
There was no detection by UV (419 nm) because α-CD has no UV absorption. In 
contrast, all four cationic polyrotaxanes were detected by RI, UV (419 nm), and OR at 
the same time. It is found that they eluted out at higher molecular weight region of the 
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column due to their large molecular size. Comparing to the other synthetic 
polyrotaxanes, 5a eluted out late, which is in agreement with its smaller molecular 
size. Each cationic polyrotaxane showed a unimodal peak and this peak eluted out at 
the same position in all three spectra. This result indicates that these polyrotaxanes are 
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Figure 5.1 1H NMR spectra of α-CD (a), PPO-PEO-PPO bis(amine) (b), 













































Figure 5.2 GPC trace of α-CD and cationic polyrotaxane 5a, 5b, 5c and 5d with their 
respective refractive index (RI), UV at 419 nm and Optical rotation (OR) curve. 
Figure 5.3 shows the 13C NMR spectra of the cationic polyrotaxane 5b with 
reference to free α-CD and pentaethylenehexamine. In Figure 5.3c, all peaks 
attributed to α-CD and grafting OEI were observed clearly. The peak at δ 158.2 ppm 
corresponds to the carbon of carbonyl groups conjugated OEI chains to α-CD rings. 
Additionally, compared to free α-CD, the peak of C-6 on the α-CD rings of 5b shifted 
from 60.7 ppm to 64.3 ppm. It may be attributed mainly to the grafting of OEI. In fact, 
of the three types of hydroxyl groups of α-CD, those at the 6-position (primary 
hydroxyl groups) are the most nucleophilic and are thought to be modified under the 





































Figure 5.3 13C NMR spectra of α-CD (a), pentaethylenehexamine (b), 
and cationic polyrotaxanes 5b (c) in D2O. 
Figure 5.4 shows the 1H NMR spectra of the cationic polyrotaxanes with reference 
to α-CD. In the spectra of 4b-e, the signals for both α-CD and grafting OEI were 
observed. The peaks were much broadened due to the restriction of molecular motion 
by the grafting OEI units. From the 1H NMR spectra, the average number of OEI 
chains conjugated to each α-CD (y) was estimated. About 5.3 molecules of 
ethylenediamine were grafted onto each α-CD in 5a and about 5.0 molecules of 
pentaethylenehexamine were grafted onto each α-CD in 5b, near to one OEI chain per 
glucose unit of α-CD. About 2.3 molecules of OEI-9 were grafted on each α-CD in 5c 
and about 3.5 molecules of OEI-14 were grafted on each α-CD in 5d. From 5a, 5b to 
5c, it is clear that the longer the OEI chain, the less number of OEI chains could be 
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conjugated to each α-CD. It can be attributed to the influence of the steric hindrance 
of OEI chains on the conjugating reaction. But, for 5d, more primary amino groups 
from branched structure of OEI-14 participated in the conjugation reaction, leading to 








































































Figure 5.4 1H NMR spectra of α-CD (a), and cationic polyrotaxanes 5a (b), 5b (c), 5c 
(d) and 5d (e) in D2O. 
 
5.3.2. Degradation of cationic polyrotaxane 5c under basic condition 
Figure 5.5 shows the GPC trace of cationic polyrotaxane 5c and its basic 
degradation products at 24 h, 48 h, and 96 h, with reference to α-CD, with their 
respective RI, UV at 419 nm and OR curve. From Figure 5.5b to d, it is evident that 
on the OR curves the elution time of the degradation products were much longer than 
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those of cationic polyrotaxane 5c, increasing with an increase of degradation period, 
indicating the declining trend of molecular size. The degradation product at 96 h 
eluted out at the same position of α-CD, suggests that not only the bulky stoppers, 
TNBS moieties, of the cationic polyrotaxane 5c have been cut off and the 
OEI-9-grafted α-CD rings had slid out of the polymeric chain, but the carbamic bonds 
were cleaved and OEI-9 moieties removed under the strong basic condition. On the 
UV curves of Figure 5.5b-d, the peaks eluting out at about 440 min represents the 
TNBS residues. 









































Figure 5.5 GPC trace of cationic polyrotaxane 5c (a) and its basic hydrolysis products 
at 24 h (b), 48 h (c), and 96 h (d), in comparison with α-CD (e), with their respective 
refractive index (RI), UV at 419 nm and optical rotation (OR) curve.  
 
5.3.3 Formation of cationic polyrotaxane/DNA complexes 
The ability of the cationic polyrotaxanes to condense plasmid DNA (pDNA) into 
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particulate structures was confirmed by agarose gel electrophoresis, particle size and 
zeta potential measurements, as well as AFM images. It is known that the DNA 
condensation capability of cationic polymers is one of the prerequisites to be a gene 
carrier. To confirm the formation of the synthesized cationic polyrotaxane/DNA 
complexes, agarose gel electrophoresis was performed and retardation of DNA 
mobility examined. Figure 5.6a shows the gel retardation results of cationic 
polyrotaxane/DNA complexes with increasing N/P ratios compared to branched PEI 
(25 K). Cationic polyrotaxane 5a could compact pDNA entirely at the low N/P ratio 
of 1, while 5b and 5c could inhibit the migration of pDNA at N/P ratio of 2 and above. 
This indicates that cationic polyrotaxanes with linear OEI units have similar or 
slightly better DNA condensation ability compared to PEI (25 K). For 5d, complexes 
with pDNA complete only at N/P ratio of 3 and above, probably because of the 
branched OEI units in this cationic polyrotaxane. 
Figure 5.6b and c shows the particle size and zeta potential of cationic 
polyrotaxane/DNA complexes with reference to PEI (25 K)/DNA complex at various 
N/P ratios. In Figure 5.6b, all four cationic polyrotaxanes efficiently compacted 
pDNA into small nanoparticles. Generally, their mean particle size decreased sharply 
with increasing N/P ratio from 2 to 6. After a N/P ratio of 6 was reached, the particle 
size varied within 85-165 nm. In the case of the complex formed by PEI (25 K), its 
hydrodynamic size reached a plain around 120-160 nm at N/P ratio of 4 and above. 
Within the range of N/P ratio 10-30, the particle size of PEI (25 K)/DNA complex was 
higher than that of the cationic polyrotaxanes at the same N/P ratio.  
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Zeta potential measurements are indicative of the surface charge of polymer /DNA 
particles, and a positive surface charge of untargeted polymer is necessary for binding 
to anionic cell surface, which consequently facilitates cell uptake.33 As shown in 
Figure 5.6c, the surface net charge of the complexes of pDNA with PEI and 5d 
increased abruptly from negative to positive as the N/P ratio increased from 0 to 4 and 
stabilized at N/P ratio of 10 and above. Also, though the surface net charge of the 
complex of 5a, 5b and 5c with pDNA was positive and beyond 8 mV at N/P ratio 2, 
they stabilized within 20~28 mV and were lower than that of PEI (25 K)/DNA 
complex, which reached an almost constant value around 33 mV, from N/P ratio of 8 
to 30. 
N/P ratio































































































Figure 5.6 Binding ability of cationic polyrotaxanes to DNA and the particle size and 
zeta potential of their complexes with DNA in comparison with PEI (25K). (a). 
Electrophoretic mobility of plasmid DNA in the complexes; (b). particle size of the 
complexes; and (c). zeta potential of the complexes.  
Figure 5.7 showed representative tapping mode AFM images of naked DNA and 
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cationic polyrotaxane 5b/DNA complexes at N/P ratio of 2 and 10. Results from the 
AFM study showed that the complexation of DNA by 5b led to the formation of 
compact nanoparticle. In Figure 5.7a, loose, supercoiled structure of pDNA could be 
found when the pDNA was not condensed by polymer. At N/P ratio of 2, supercoiled 
plasmid DNA could still be identified under AFM while some of the pDNA was 
condensed to nanoparticles by 5b. Compared to this partial condensation at N/P ratio 
of 2, the same amount of pDNA could be tightly packed and formed pDNA 
complexes at N/P ratio of 10 completely. Moreover, it was found that the diameter of 
the nanoparticles in Figure 5.7c ranged within 110-160 nm, which is in agreement 
with the dynamic light scattering results. 
500 nm 500 nm 500 nm
a b c
 
Figure 5.7 Atomic force microscopy (AFM) images of the supercoiled plasmid DNA 
(a), and cationic polyrotaxane 5b/DNA complex at N/P = 2 (b) and N/P = 10 (c). 
 
5.3.4 Cytotoxicity of cationic polyrotaxanes 
Cytotoxicity of polymeric gene vector may be an important factor that affects the 
transfection efficiency. Figure 5.8 showed the results of in vitro cytotoxicity of the 
cationic polyrotaxanes analyzed by MTT method in two cell lines (COS7 and 
HEK293). As shown in Figure 5.8a, all the synthesized cationic polymers and PEI (25 
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K) showed a strong dose-dependent effect on cytotoxicity and the cytotoxicity of the 
polymers was much lower than that of PEI (25K). For example, at concentration of 
62.5 μg/ml, COS7 cells only showed approximately 7% cell viability when incubated 
with PEI (25 K). In the meanwhile, in the case of 5a, 5b and 5c, which were grafted 
with linear OEI chains, their relative growth rate in COS7 cells showed more than 
70% viability under the same condition. 5d, which was grafted with branched OEI-14, 
exhibited nearly 50% cell viability at this concentration. LD50 value was also 
calculated to further compare the cytotoxicity of the cationic polymers with PEI (25 
K). The LD50 value of PEI (25 K) in COS7 was 25 µg/ml, while those of cationic 
polyrotaxanes 5a, 5b, 5c and 5d were 155, 135, 140 and 55 µg/ml, respectively, 
which were much lower than that of the PEI (25 K). These results may be attributed to 
the reduction of amino density resulted from the supramolecular structure of the 
polyrotaxanes since high amino density and the high molecular weight may be the 
reasons of the toxicity of PEI (25 K). A similar trend was also observed in HEK293 

























































































Figure 5.8 Cell viability of cationic polyrotaxanes in (a) COS7 and (b) HEK293 cells 
in comparison with PEI (25 K).  
 
5.3.5 Transfection efficiency of cationic polyrotaxanes 
In vitro transfection efficiency of complexes formed between pDNA and cationic 
polyrotaxanes was assessed utilizing a transient expression of luciferase reporter in 
both HEK293 and COS7 cells. Figure 5.9 shows the gene transfection efficiency of 
cationic polyrotaxanes for DNA delivery compared with those of branched PEI (25 K) 
and naked pDNA in the absence and presence of serum (ND), in both COS7 and 
HEK293 cells. The structure of polymers play an important role in the transfection 
efficiency. In COS7 cells the transfection efficiency mediated by cationic 
polyrotaxanes was dependent upon the chain length of the OEI conjugated to α-CD. 
Among the polymers examined, increased OEI length produced greater transfection 
efficiency following the order 5c>5b>5a, but the transfection capability of 5d did not 
follow this rule probably because of  its branched OEI chains. 
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The relationship of transfection efficiency with the chain length of OEI was not 
strong in HEK 293 cells. The transfection efficiency mediated by 5b was quite similar 
to PEI at various N/P ratios in the absence of serum. Compared with PEI (25 K), 5b 
and 5c showed a similar or higher gene delivery capability in the presence of serum. 
Especially, when the transfection was conducted at N/P ratio of 30, the transfection 
efficiency of 5b and 5c in the presence of serum was 10-fold and 7-fold more than 









































































































































































































Figure 5.9 In vitro gene transfection efficiency of the complexes of cationic 
polyrotaxanes in comparison with that of PEI (25 K) and naked DNA (ND), in COS7 
cell in the absence and presence of serum (a) and (b); in HEK293 cell in the absence 
and presence of serum (c) and (d). Data represent mean ± standard deviation (n=3). 
Kinetics of expression is also important for gene delivery. Figure 5.10 shows the 
time-dependent changes of gene expression of the cationic polyrotaxane 5b and 5c in 
comparison with that of PEI (25 K) at N/P ratio of 10 in HEK293 cells, and the 
transfection efficiency was monitored for 3 days. While the transfection efficiency 
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mediated by PEI (25 K) decreased with the increasing expression duration no matter 
in the absence or in the presence of serum, 5b and 5c showed a sustained gene 
delivery capability. In both serum and serum free condition, increases in transfection 
efficiency could be found in HEK293 cells transfected with 5b and 5c/pRL-CMV 
when the expression duration increased from 24 h to 48 h, and then to 72 h. These 
results may be mainly attributed to the supramolecular structure of these polymers: in 
these cationic polyrotaxanes, the OEI-grafted α-CD rings can rotate and/or move 
along the polymeric chain freely, and this flexibility may enhance the interaction of 






































































































Figure 5.10 In vitro gene transfection efficiency of the complexes of cationic 
polyrotaxane 5b and 5c in comparison with that of PEI (25 K) at N/P ratio of 10 in the 
absence (a) and presence (b) of serum at different expression duration (24 h, 48 h and 
72 h) in HEK293 cells. Data represent mean ± standard deviation (n=3). 
Confirmation of the gene delivery capability of cationic polyrotaxane 5b was also 
obtained by fluorescence microscopy in contrast with that of PEI (25 K) (Figure 5.11). 
Plasmid pEGFP-N1 encoding green fluorescence protein (GFP) was used to examine 
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the GFP expression in HEK293 cells. Strong fluorescence signal could be observed 
when transfections were mediated by either 5b or PEI at N/P ratio of 10. Also, when 
the transfection was mediated by PEI, the GFP expression in HEK293 cells was 
stronger than that of mediated by 5b. GFP expression could not be detected when the 






Figure 5.11 The confocal microscope images of transfected HEK293 cells. The 
transfections were mediated by (a) 5b and (b) PEI (25 K) at N/P ratio of 10 in the 
absence of serum using green fluorescence protein gene as a reporter gene. The same 
field of cells was observed by Nomarski optics (right panel) or by fluorescence 
microscope (left panel) to visualize GFP expression. 
 
5.4 Conclusion 
In this study, a series of water soluble cationic polyrotaxanes containing 
PPO-PEO-PPO triblock copolymer, α-CD and various OEI chains were synthesized 
and investigated for gene delivery. Cytotoxicity studies showed that these cationic 
polyrotaxanes displayed significantly low cytotoxicity in comparison with branched 
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PEI (25 K), owing to the low positive charge density resulted from the supramolecular 
structure of the polyrotaxanes. For the cationic polyrotaxanes with linear OEI chains, 
an increased OEI length produced greater transfection efficiency in COS7 cells. In 
HEK293 cells, 5b and 5c showed a similar or higher gene delivery capability in the 
presence of serum, and even 10-fold and 7-fold more than that of branched PEI (25 K) 
at N/P ratio of 30, respectively. More interestingly, in both serum and serum free 
condition, the cationic polyrotaxane 5b and 5c displayed the sustained gene delivery 
capability in HEK293 cells, while the transfection efficiency of PEI (25 K) decreased 
dramatically with the increasing expression duration. These transfection results can be 
attributed to the structure of the above cationic polyrotaxanes. Such a supramolecular 
structure enables the OEI-grafted α-CD rings to rotate and/or move along the 
polymeric chain freely, and this flexibility may enhance the interaction of the 
polyrotaxanes with DNA and/or cellular membrane. 
Therefore, these cationic polyrotaxanes have a high potential as novel nonviral 
gene carriers, especially for continuous, large dose of in vivo administration, due to 
their low cytotoxicity, high and sustained gene delivery capability, which are crucial 
factors in clinical uses. 
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Over the last few decades, the development of non-viral gene carriers with low 
cytotoxicity and high transfection efficiency has been the hardest task for gene 
delivery systems, and hundreds of cationic polymers were developed as gene carriers 
in numerous laboratories around the world.1,2 Compared with viral vectors and 
cationic lipids, cationic polymers for gene delivery are generally economical and 
stable. They can be produced in a large scale and show low host immunogenicity. So 
far, a great number of cationic polymers have been reported to be able to deliver 
genes, including homopolymers or derivatives of polyethylenimine (PEI),3 poly(L- 
lysine),4 polyamidoamine,5 poly(L-glutamic acid),6 polyphosphoester,7 chitosan,8 and 
cyclodextrins (CDs).9-13  
Cyclodextrins (CDs) are a series of cyclic oligosaccharides composed of 6, 7, or 8 
D(+)-glucose units linked by α-1,4-linkages and named α-, β-, or γ-CD, respectively. 
Recently, increasing attention has been focused on studies of supramolecular 
structures of polyrotaxanes formed by CDs threaded on a polymer chain 14-22 and their 
applications in biomaterials.23-25 In contrast to conventional polymers containing long 
sequences of covalently bonded repeating units, the macrocycles in polyrotaxanes can 
rotate and/or slide along the polymeric chain freely.26,27 We recently reported the 
synthesis of a novel cationic supramolecule composed of multiple oligoethylen- 
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imine-grafted β-CD that are threaded and blocked on a polymer chain as a new class 
of polymeric gene delivery vectors.28 The novel supramolecular gene carriers contain 
many cationic cyclic units that are threaded upon a polymer chain to form an 
integrated supramolecular entity to function as a macromolecular gene vector, which 
showed excellent DNA binding ability, low cytotoxicity, and high gene transfection 
efficiency HEK293 cells. Yui and co-workers also reported the use of dimethyl- 
aminoethyl-modified α-CDs threaded onto a poly(ethylene oxide) (PEO) chain and 
capped by cleavable end groups for gene delivery.29 The cleavage of the end groups 
caused the dethreading of α-CDs and rapid release of DNA in cells, but the tertiary 
amine conjugated to the α-CD rings might not be efficient in DNA complexation and 
gene delivery.  
We previously found that a random copolymer, poly[(ethylene oxide)-ran- 
(propylene oxide)] (P(EO-r-PO)) can form inclusion complexes with α-CD.30 
Although there are propylene oxide (PO) units randomly placed in the polymer 
backbone, the copolymer still can penetrate the smallest cavity of α-CD to form 
inclusion complexes. It was concluded that α-CD can overcome the energy barrier in 
passing over a PO unit or a short PO segment, and then form a stable inclusion 
complex with ethylene oxides (EO) units of the copolymer. In this chapter, we report 
the synthesis and characterization of a series of polyrotaxanes consisting of multiple 
cationic α-CD rings threaded on P(EO-r-PO) copolymer as a new gene carriers. The 
design of the gene carriers was based on the inclusion complex formation between 
α-CD and P(EO-r-PO) copolymer. In the polyrotaxane gene carriers, the cationic 
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α-CD rings only resided selectively on the EO segments of the P(EO-r-PO) chain, 
which may increase the mobility of α-CD rings through rotating and/or sliding along 
the copolymer as well as the flexibility of the polyrotaxane, enhancing the interaction 
of the cations of α-CD rings with DNA and/or cellular membranes. The polyrotaxane 
gene carriers showed high transfection efficiencies in a variety of cell lines, while 
exhibiting much lower cytotoxicity than branched high molecular weight PEI.  
 
6.2 Experimental section 
6.2.1 Materials  
The P(EO-r-PO) copolymer (Mn = 2,370, Mw/Mn =1.06) was supplied by Aldrich. 
This copolymer had a chain composition of EO41PO10. The molecular characteristics 
were confirmed using GPC and 1H NMR spectroscopy, which were found to be within 
the specification of the supplier. 2,4,6-Trinitrobenzene sulfonic acid (TNBS) solution 
and pentaethylenehexamine (OEI-5) was obtained from Fluka. 1,1’-Carbonyl- 
diimidazole (CDI) and α-cyclodextrin were purchased from Tokyo Kasei 
incorporation. Ethylenediamine (OEI-1), linear PEI with molecular weight of 423 
(OEI-9), branched PEI with molecular weight of 600 (OEI-14) and branched PEI 
(molecular weight 25 K) were supplied by Aldrich. DMSO-d6 and D2O used as 
solvent in the NMR measurements were obtained from Aldrich. Qiagen kit and 
Luciferase kit were purchase from Qiagen and Promega, respectively. 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazodium bromide (MTT), penicillin, and 
streptomycin were obtained from Sigma. 
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 6.2.2 Synthesis  
The procedure for synthesis of polyrotaxanes consisting of multiple cationic α-CD 
rings threaded on P(EO-r-PO) copolymer is shown in Scheme 6.1. The following 
describes the details of the synthesis of 5b from P(EO-r-PO) copolymer 1 as a typical 
example. 
6.2.2.1 Preparation of P(EO-r-PO) bis(amine) 
P(EO-r-PO) copolymer 1 (Mn = 2,370, 1.90 g, 0.80 mmol) was heated in a flask at 
80 °C in vacuum overnight. When the flask cooled, 15 mL of anhydrous DMF was 
injected under nitrogen. After all of 1 was dissolved, the DMF solution of 1 was 
added dropwise during a period of 6 hours under nitrogen to 15 mL of anhydrous 
DMF solution in which CDI (1.30 g, 8.0 mmol) was dissolved, and the mixture was 
stirred overnight under nitrogen at room temperature. The resulting solution was 
slowly added dropwise during a period of 3 hours into 4.8 g (80 mmol) of 
ethylenediamine which was separately dissolved in 15 mL of anhydrous DMF with 
stirring at room temperature, followed by stirring the mixture overnight. Excess 
ethylenediamine and DMF was removed by vacuum evaporation. The resulting 
viscous solution was purified by size exclusion chromatography (SEC) on a Sephadex 
LH-20 column using methanol as eluent. Finally, 1.42 g of viscous liquid 2 was 
obtained (yield, 70%). 1H NMR (400 MHz, DMSO-d6, 22 °C): δ 3.25-3.71 (m, 168H 
and 33H, methylene of EO segments, and methylene and methine of PO segments), 
3.23 (s, 4H, -CH2- of -CONHCH2-), 2.01 (s, 4H, -CH2- of -CH2NH2), 1.06 (d, 33H, 
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–CH3 of PO segments). 
6.2.2.2 Preparation of α-CD-P(EO-r-PO) polyrotaxane  
P(EO-r-PO)-bis(amine) 2 (0.20 g) was added to 27.6 mL of α-CD saturated 
aqueous solution (0.145 g/mL) that contained 0.30 g of NaHCO3 for adjustment of the 
pH value of the solution. The reaction mixture was ultrasonicated for 20 min and 
stirred at room temperature overnight. Then, 0.55 g of sodium salt of 2,4,6- 
trinitrobenzene sulfonic acid solution was added and stirred overnight, followed by 
pouring 100 mL of water into the reaction mixture. The precipitate was centrifuged 
and washed 3 times with water. The resulting wet solid was dissolved in 20 mL of 
DMSO and poured into 300 mL of MeOH to precipitate the product. The precipitate 
was centrifuged and washed 3 times with MeOH. The resulting wet solid was 
dissolved in 20 mL of DMSO again and poured into 300 mL water to precipitate the 
product. The resulting precipitate was centrifuged and washed 3 times with water. 
Finally, the resulting wet solid was freeze dried and 0.59 g of pure polyrotaxane 4 was 
obtained (yield, 52%). 1H NMR (400 MHz, DMSO-d6, 22 °C): δ 8.93 (broad, s, 4H, 
meta H of phenyl), 5.63 (s, 66H, O(2)H of CD), 5.47 (m, 66H, O(3)H of CD), 4.75 (s, 
66H, H(1) of CD), 4.41 (s, 66H, O(6)H of CD), 3.17-3.840 (m, 396H, H(3), H(6), 
H(5), H(2), and H(4) of CD; 168H, methylene of EO segments; 33H, methylene and 
methine of PO segments), 1.07 (broad, s, 33H, -CH3 of PO segments). 
6.2.2.3 Preparation of cationic multiple OEI-grafted α-CD-P(EO-r-PO) polyrotaxane 
The resulting polyrotaxane 4 (0.206 g, 0.015 mmol) was dried in a flask at 40 °C in 
vacuum overnight. When the flask cooled, 40 mL of anhydrous DMSO was injected 
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under nitrogen. After all 4 was dissolved, the DMSO solution of 4 was added 
dropwise during a period of 6 hours under nitrogen to 40 mL of anhydrous DMSO 
solution in which CDI (2.56 g, 16.35 mmol) was dissolved, and the mixture was 
stirred overnight under nitrogen at room temperature. A mixture of THF (300 mL) and 
Et2O (600 mL) was poured into the resulting solution to precipitate the product. The 
precipitate was centrifuged and washed 3 times with THF. Then, the resulting wet 
solid was dissolved in 40 mL of anhydrous DMSO and this solution was slowly added 
dropwise during a period of 3 hours into 5.70 mL (19.62 mmol) of penta- 
ethylenehexamine which was dissolved in 40 mL of anhydrous DMSO while stirring 
at room temperature, followed by stirring the mixture overnight. THF (900 mL) was 
poured into the reaction mixture to precipitate the product. The precipitate was 
centrifuged and washed 3 times with THF, and the resulting crude product was 
purified by size exclusion chromatography (SEC) on a Sephadex G-50 column using 
deionized water as eluent. Finally, 0.169 g of brown solid 5b was obtained (yield, 
41%).  
The yields and analytical data for all four cationic polyrotaxanes synthesized in this 
work are given below. 
Cationic Polyrotaxane 5a. Yield, 35%. 1H NMR (400 MHz, D2O, 22 °C): δ 8.38 
(s, 2H, meta H of phenyl), 7.99 (s, 2H, meta H of phenyl), 5.03 (s, broad, 66H, H(1) 
of CD), 2.95-4.61 (m, broad, 396H, H(3), H(6), H(5), H(2), and H(4) of CD; 168H, 
methylene of EO segments; 33H, methylene and methine of PO segments; 138H, 
methylene of -CONHCH2-), 2.78 (s, 138H, methylene of -CH2NH2), 1.08 (d, 33H, 
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-CH3 of PPO block).  
Cationic Polyrotaxane 5b. Yield, 41%. 1H NMR (400 MHz, D2O, 22 °C): δ 8.36 
(s, 2H, meta H of phenyl), 7.97 (s, 2H, meta H of phenyl), 4.95 (s, broad, 66H, H(1)H 
of CD), 2.94-4.58 (m, broad, 396H, H(3), H(6), H(5), H(2), and H(4) of CD; 168H, 
methylene of EO segments; 33H, methylene and methine of PO segments; 106H, 
methylene of -CONHCH2-), 2.67 (m, 1268H, methylene of pentaethylenehexamine), 
1.07 (s, 33H, -CH3 of PO segments). 
Cationic Polyrotaxane 5c. Yield, 30%. 1H NMR (400 MHz, D2O, 22 °C): δ 8.37 (s, 
2H, meta H of phenyl), 7.98 (s, 2H, meta H of phenyl), 4.98 (d, broad, 66H, H(1)H of 
CD), 2.97-4.62 (m, broad, 396H, H(3), H(6), H(5), H(2), and H(4) of CD; 168H, 
methylene of EO segments; 33H, methylene and methine of PO segments; 57H, 
methylene of -CONHCH2-), 2.67 (m, 1305H, methylene of OEI-9), 1.08 (d, 33H, 
-CH3 of PO segments).  
Cationic Polyrotaxane 5d. Yield, 48%. 1H NMR (400 MHz, D2O, 22 °C): δ 8.36 (s, 
2H, meta H of phenyl), 7.98 (s, 2H, meta H of phenyl), 4.98 (d, broad, 66H, H(1)H of 
CD), 2.97-4.61 (m, broad, 396H, H(3), H(6), H(5), H(2), and H(4) of CD; 168H, 
methylene of EO segments; 33H, methylene and methine of PO segments; 69H, 
methylene of -CONHCH2-), 2.56 (m, 1293H, methylene of OEI-14), 1.09 (d, 33H, 
-CH3 of PO segments).  
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6.2.3 Measurements  
Gel permeation chromatography (GPC) GPC analysis for P(EO-r-PO) copolymer 
was carried out with a Shimadzu SCL-10AVP and LC-10ATVP system equipped 
with two Phenogel 5 μm, 50 and 1000 Å columns (size: 300 × 4.6 mm) in series and a 
Shimadzu RID-10A refractive index detector. THF was used as eluent at a flow rate 
of 0.30 mL/min at 40 °C. Monodispersed poly(ethylene glycol) standards were used 
to obtain a calibration curve.  
Size exclusion chromatography (SEC) analysis for cationic polyrotaxanes was 
carried out with a Shimadzu SCL-10AVP and LC-10ATVP system equipped with a 
Sephadex G-75 column (size: 2.5 × 32 cm), a Shimadzu RID-10A refractive index 
detector and a Shimadzu SPD-10Avp UV-Vis detector. PBS buffer solution (1×) was 
used as the eluent. Fractions were collected per 1 mL and their optical rotation (OR) 
were further measured using a HORIBA SEPA-300 high speed accurate polarimeter at 
wavelength 589 nm with cell length of 10 cm and response time of 2 s. 
1H NMR spectra The 1H NMR spectra were recorded on a Bruker AV-400 NMR 
spectrometer at 400 MHz at room temperature. The 1H NMR measurements were 
carried out with an acquisition time of 3.2 s, a pulse repetition time of 2.0 s, a 30° 
pulse width, 5208-Hz spectral width, and 32 K data points. Chemical shifts were 
referred to the solvent peaks (δ = 4.70 ppm for D2O and 2.50 ppm for DMSO-d6).  
The 13C NMR spectra were recorded on a Bruker AV-400 NMR spectrometer at 100 
MHz at room temperature. The 13C NMR measurements were carried out using 
composite pulse decoupling with an acquisition time of 0.82 s, a pulse repetition time 
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of 5.0 s, a 30° pulse width, 20,080-Hz spectral width, and 32 K data points. The 
chemical shifts were referred to an external standard. 
Plasmid The plasmid used was pRL-CMV (Promega, USA), encoding Renilla 
luciferase, which was originally cloned from the marine organism Renilla reniformis. 
The plasmid DNA was amplified in Escherichia coli and purified according to the 
supplier’s protocol (Qiagen, Hilden, Germany). The purity and concentration of the 
purified plasmid DNA were determined by absorption at 260 and 280 nm and by 
agarose gel electrophoresis. The purified plasmid DNA was resuspended in TE buffer 
(10 mM Tris-Cl, pH 7.5, 1 mM EDTA) and kept in aliquots at a concentration of 0.5 
mg mL-1.  
Cells and Media All cell lines were purchased from ATCC (Rockville, MD, USA). 
COS7, HEK293, and BHK-21 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 
100 units/mg penicillin, and 100 μg/mL streptomycin at 37 °C and 5% CO2. MES-SA 
and SK-OV-3 cells were grown in McCoy’s 5a medium with 1.5 mM L-glutamine 
supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mg penicillin, 
and 100 μg/mL streptomycin at 37 °C and 5% CO2. Reduced-serum Opti-MEM 
medium, DMEM medium, and McCoy’s 5a medium were purchased from Gibco 
BRL (Gaithersburg, MD, USA). 
Gel Retardation Experiments Each polymer was examined for its ability to bind 
pRL-CMV plasmid DNA through agarose gel electrophoresis experiments. All 
polymer stock solutions were prepared at a nitrogen concentration of 1 mM in 
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distilled water and the pH was adjusted to 7.4. pRL-CMV (0.2 μg in 2 μL TE buffer) 
was mixed with polymer at nitrogen/phosphate (N/P) ratios from 0 to 10. Each 
mixture was vortexed and incubated for approximately 30 min at room temperature, 
and analyzed on 1% agarose gel containing 0.5 µg/mL ethidium bromide (EtBr). The 
gel electrophoresis was carried out in TAE running buffer (40 mM Tris-acetate, 1 mM 
EDTA) for 40 min at 80V in a Sub-Cell system (Bio-Rad Laboratories, CA, USA). 
The DNA bands were visualized and photographed by a UV transilluminator and 
BioDoc-It imaging system (UVP Inc., USA). 
Cell viability assay The cytotoxicity of the cationic polyrotaxanes in comparison 
with PEI (25 K) was evaluated using MTT assay in COS7 and HEK293 cell lines. The 
cells were cultured in complete DMED medium supplemented with 10% FBS at 37 
°C, 5% CO2, and 95% relative humidity. The cells were seeded in a 96-well microtiter 
plate (Nunc, Wiesbaden, Germany) at a density of 10,000 and 15,000 cells/well for 
COS7 and HEK293, respectively. After 24 h, culture media were replaced with 
serum-supplemented culture media containing serial dilutions of polymers, and the 
cells were incubated for 24 h. Then, 10 μL of sterile filtered MTT stock solution in 
PBS (5 mg/mL) was added to each well, reaching a final MTT concentration of 0.5 
mg/mL. After 5 h, unreacted dye was removed by aspiration. The formazan crystals 
were dissolved in DMSO (100 μl/well), and the absorbance was measured using a 
microplate reader (Spectra Plus, TECAN) at the wavelength of 570 nm. The relative 
cell viability (%) related to control cells cultured in media without polymers was 
calculated with [A]test/[A]control × 100%, where [A]test is the absorbance of the wells 
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with polymers and [A]control is the absorbance of the control wells. All experiments 
were conducted for six samples and averaged. 
In vitro transfection and luciferase assay Transfection studies were performed in 
five cell lines (HEK293, COS7, BHK-21, MES-SA and SK-OV-3 cells) using the 
plasmid pRL-CMV as the reporter gene. In brief, 24 h before transfection, 24-well 
plates were seeded with cells at a density of 5×104/well. The polymer-DNA 
complexes (2.0 μg DNA/well for HEK293 and COS7 cells and 1.0 μg DNA/well for 
the other cell lines) at various N/P ratios were prepared by adding the polymer into 
DNA solutions dropwise, followed by vortexing and incubation for 30 min at room 
temperature before the transfection. At the time of transfection, the medium in each 
well was replaced with reduced-serum Opti-MEM medium or normal complete 
DMEM medium. The complexes were added into the transfection medium and 
incubated with cells for 4 h under standard incubator conditions. After 4 h, the 
medium was replaced with 500 µL of fresh medium supplemented with 10% fetal 
bovine serum (FBS), and the cells were further incubated for an additional 20 h under 
the same conditions, resulting in a total transfection time of 24 h. Cells were washed 
with PBS twice, lysed in 100 µL of cell culture lysis reagent (Promega, Cergy 
Pontoise, France). Luciferase gene expression was quantified using a commercial kit 
(Promega, Cergy Pontoise, France) and a luminometer (Berthold Lumat LB 9507, 
Germany). Protein concentration in the samples was analyzed using a bicinchoninic 
acid assay (Biorad, CA, USA). Absorption was measured on a microplate reader 
(Spectra Plus, TECAN) at 570 nm and compared to a standard curve calibrated with 
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BSA samples of known concentration. Results are expressed as relative light units per 
milligram of cell protein lysate (RLU mg-1 protein).  
Dynamic light scattering and zeta-potential Measurements of particle size and 
zeta potential of the complexes were performed using a Zetasizer Nano ZS (Malvern 
Instruments, Southborough, MA, USA) with a laser light wavelength of 633 nm at a 
173° scattering angle. Complex solutions (100 µl) containing 3 µg of pDNA 
(pRL-CMV) were prepared at various N/P ratios ranging from 2-30. The mixture was 
vortexed for 20 s, incubated for 30 min at room temperature and diluted in 1 mL of 
distilled water before being analyzed on the Zetasizer. The size measurement was 
performed at 25 °C in triplicate. The deconvolution of the measured correlation curve 
to an intensity size distribution was accomplished using a non-negative least squares 
algorithm. The Z-average hydrodynamic diameters of the particles were given by the 
instrument. The Z-average size is the intensity weighted mean diameter derived from 
a Cumulants or single exponential fit of the intensity autocorrelation function. The 
zeta potential measurements were performed using a capillary zeta potential cell in 
automatic mode using the same samples for the particle size measurements. 
Confocal microscopy For confocal microscopy imaging of the gene transfection, 
the plasmid pEGFP-N1 (Clontech Laboratories Inc., USA), encoding a red-shifted 
variant of wild-type green fluorescence protein (GFP), was used to examine the GFP 
expression in HEK293 cells. HEK293 cells were seeded onto lab-Tek 4-chambered 
coverglass (Nalge-Nane international, USA) at density of 5×104 cells/well in 500 µL 
of complete DMEM medium. After 24 hours, transfection was undertaken with 2 µg 
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EGFP plasmid in 0.3 mL of reduced-serum Opti-MEM medium in each well. At the 
time of transfection, 20 μL of cationic polyrotaxane 5c-DNA complex solution was 
added in each well. After 4 h, the transfection media was removed and the cells were 
washed with fresh complete DMEM medium. After 20 h of further incubation in 
serum-containing complete DMEM medium, the cells were washed with phosphate- 
buffered saline (PBS) and imaged under a laser scanning confocal microscope (LSM 
410, Carl Zeiss, USA). GFP fluorescence was excited at 488 nm and emission was 
collected using a 515 nm filter. 
Atomic Force Microscopy A Digital Instruments MultiMode-AFM with Nanoscope 
IV controller in a tapping mode was employed to image the nanoparticle samples. 
Briefly, silicon disks were soaked in 50% acetone for a minimum of 2 h and rinsed 
with distilled water. When the silicon disks were completely dried, 20 µL of cationic 
polyrotaxane 5c-DNA complexes containing 1.0 µg of pRL-CMV at N/P ratios 0, 2, 
and 10 were placed on the silicon surface for 2 min, followed by removing the 
complex solutions carefully with a piece of tissue paper. All the AFM images were 
obtained with a scan rate of 0.5 or 1 Hz over a selected area of 2×2 µm. Image 
analysis was performed using Nanoscope software after removing the background 
slope by flatting images. 
 
6.3 Results and discussion 
6.3.1 Synthesis and characterization of cationic polyrotaxanes  
Scheme 6.1 shows the synthesis procedures and the structures of the cationic 
polyrotaxanes (5a, 5b, 5c and 5d). First, P(EO-r-PO)-bis(amine) 2 was prepared from 
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P(EO-r-PO) random copolymer 1, which has a number-average molecular weight 
(MW) of 2370 and an 80 mol % content of ethylene oxide (EO) segments. The two 
hydroxy end groups were activated with 1,1’-carbonyldiimidazole (CDI), followed by 
reaction with excessive ethylenediamine to give 2. It is known that P(EO-r-PO) can 
form inclusion complexes with α-CD, although there were PO segments randomly 
placed in the copolymer backbone, and a PPO homopolymer can not form a complex 
with α-CD because the PPO chain is too large to penetrate the small inner cavity of 
α-CD.30 We interestingly found that α-CD molecules are able to overcome the energy 
barrier in passing over a PO unit or a short PO segment and then form a stable 
inclusion complex with EO segments of the P(EO-r-PO) random copolymer. 
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Scheme 6.1 Synthesis procedures and the structures of multiple 
OEI-grafted cationic polyrotaxanes (5a, 5b, 5c and 5d). 
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Polypseudorotaxane 3 was formed between P(EO-r-PO)-bis(amine) 2 and α-CD, 
and polyrotaxanes 4 was synthesized by adding 2,4,6-trinitrobenzene sulfonate 
(TNBS) to 3, forming two bulky stoppers to block the two ends of the inclusion 
complex, in which about 12 α-CD rings are trapped on the copolymer chain. Finally, 
linear or nonlinear oligoethyleneimines (OEIs) with different MW, ethylenediamine (k 
= 1), pentaethylenehexamine (k = 5), linear OEI with MW of 423 (OEI-9, k = 9), and 
branched OEI with MW of 600 (OEI-14, k = 14), were grafted to the α-CD molecules 
of polyrotaxanes 4 to give cationic polyrotaxanes 5a, 5b, 5c and 5d, respectively. 
 
6.3.2. Molecular Characterization of Cationic Polyrotaxanes.  
Figure 6.1 shows the size exclusion chromatography (SEC) profiles of the cationic 
polyrotaxanes with reference to pristine α-CD. The elution curves for all four cationic 
polyrotaxanes were recorded against refractive index (RI), UV-vis absorption (Abs) at 
419 nm, and optical rotation (OR), while that for pristine α-CD was recorded against 
RI and OR since it has no UV-vis absorption. As shown in Figure 6.1, α-CD has 
relative small molecular size, which was eluted out at the low MW region of the 
column. In contrast, all four cationic polyrotaxanes were eluted out at higher MW 
region of the column due to their larger molecular sizes, and were detected by RI, Abs, 
and OR at the same time, indicating the cationic polyrotaxanes comprise the 
2,4,6-trinitrophenyl (TNP) ends and cationic α-CD units. Compared to the other 
synthetic polyrotaxanes, 5a was eluted out a bit later, which corresponds to its smaller 
molecular size than the other cationic polyrotaxanes, since 5a is grafted with the 
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shortest ethylenediamine chains. Each cationic polyrotaxane showed a single peak in 
the SEC profiles, indicating that the cationic polyrotaxanes are pure and there was no 










































Elution time (min)  
Figure 6.1 Size exclusion chromatograms of pristine α-CD and cationic polyrotaxane 
5a, 5b, 5c, and 5d detected using refractive index (RI), UV-vis absorption (Abs) at 
419 nm, and optical rotation (OR). 
Figure 6.2 shows the 13C NMR spectra of cationic polyrotaxane 5b in comparison 
with pristine α-CD and pentaethylenehexamine. In Figure 6.2c, all peaks attributed to 
α-CD, the grafting OEI, and the threading copolymer were observed clearly; and the 
peaks were broadened because all components of the cationic polyrotaxane formed an 
integrated macromolecular system which restricts their molecular motion. The peak at 
δ 158.1 ppm corresponds to the carbon of carbonyl groups, which links the OEI 
chains to α-CD rings. Compared to pristine α-CD, the peak of C-6 of α-CD in 5b 
shifted from 60.8 to 64.4 ppm. This is evidence that the grafting of OEI chains 
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happened mainly at the 6-position hydroxyl groups. In fact, of the three types of 
hydroxyl groups of α-CD, those at the 6-position (primary hydroxyl groups) are the 






































Figure 6.2 13C NMR spectra of pristine α-CD (a), pentaethylenehexamine (b), 
 and cationic polyrotaxanes 5b (c) in D2O. 
 
Figure 6.3 shows the 1H NMR spectra of polyrotaxane 4 with reference to pristine 
α-CD and P(EO-r-PO) bis(amine) 2 in DMSO-d6. In Figure 6.3c, the peaks for α-CD, 
EO and PO segments of the triblock copolymer, and the 2,4,6-trinitro- phenyl end 
groups were all observed, while they were broadened as compared with the respective 
free counterparts in Figure 6.3a and b. This is due to the restricted molecular 
movement of the components in the polyrotaxane. Quantitative comparisons between 
the integral intensities of the peaks of α-CD and those of threading copolymer 
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segments gave the compositions of the polyrotaxanes. It was found that 12 α-CD 





















































Figure 6.3 1H NMR spectra of α-CD (a), P(EO-r-PO) bis(amine) (b), 
and α-CD-P(EO-r-PO) polyrotaxane (c) in DMSO-d6. 
Figure 6.4 shows the 1H NMR spectra of the cationic polyrotaxanes with reference 
to pristine α-CD. In the spectra of (b) – (e) in Figure 6.4, the signals for α-CD, the 
grafting OEI chains, the threading copolymer, and the TNP ends were observed, while 
the peaks were much broadened due to the restriction of the molecular motion by 
molecular interlocking and the grafting of the OEI units. From this 1H NMR spectra, 
the average number of OEI chains grafted to each α-CD (y) was estimated. 
Corresponding to cationic polyrotaxane 5a, 5b, 5c, and 5d, the number of the OEI 
chains grafted to one α-CD molecule in these cationic polyrotaxanes is about 4.2, 4.8, 
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2.6, and 3.1, respectively. Generally, the longer the OEI chain, the less number of OEI 
chains could be grafted to each α-CD ring due to the influence of the steric hindrance 
of OEI chains on the grafting reaction. However, for 5d, more primary amino groups 
from branched structure of OEI-14 could participate in the grafting reaction, resulting 







































































Figure 6.4 1H NMR spectra of prisine α-CD (a), and cationic polyrotaxanes 5a (b), 
5b (c), 5c (d) and 5d (e) in D2O. 
 
6.3.3 Formation of cationic polyrotaxane/DNA complexes  
The ability of the cationic polyrotaxanes to condense plasmid DNA (pDNA) into 
particulate structures was confirmed by agarose gel electrophoresis, particle size and 
zeta potential measurements, as well as AFM images.  
DNA condensation capability is a prerequisite for polymeric gene vectors. In this 
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study, the complexation of cationic polyrotaxanes with DNA was analyzed using 
agarose gel electrophoresis. Figure 6.5 shows the gel retardation results of cationic 
polyrotaxane/DNA complexes with increasing N/P ratios in comparison with 
branched PEI (25 K)/DNA complex. Cationic polyrotaxanes 5a, 5c, and 5d could 
compact pDNA entirely at the low N/P ratio of 1.5 to 2.0, while PEI (25 K) could 
inhibit the migration of pDNA at N/P ratio of 2 and above, indicating that these 
polyrotaxanes have slightly better DNA condensation ability than PEI (25 K). 
Different from the other cationic polyrotxanes, 5b showed lower ability to condense 
DNA since the migration of DNA was only retarded at N/P ratio of 3 and above. 
N/P ratio










Figure 6.5 Electrophoretic mobility of plasmid DNA in the complexes between 
cationic polyrotaxanes and DNA in comparison with PEI/DNA complex at various 
N/P ratios. 
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Figure 6.6 shows the particle size and zeta potential of cationic polyrotaxane/DNA 
complexes in comparison with PEI (25 K)/DNA complex at various N/P ratios. In 
Figure 6.6a, all four cationic polyrotaxanes could efficiently compact pDNA into 
small nanoparticles. The diameters of the complexes formed by 5a, 5b, and 5c with 
DNA decreased sharply from more than 500 nm to around 200 nm with the increase 
of N/P ratio from 2 to 4, similar to the case of PEI (25 K)/DNA complex. The 
hydrodynamic size of 5d/DNA complex only varied within the range of 100 to 200 
nm with the increase of N/P ratio from 2 to 30. After N/P ratio reached 6, all four 
cationic polyrotaxanes and PEI (25 K) could condense DNA into nanoparticles with 
diameters ranged within 100 to 200 nm. 
Zeta potential is an indicator of the surface charge of polymer/DNA naoparticles, 
and a positive surface charge allows an electrostatic interaction between negatively 
charged cellular membranes and the positively charged complexes.32 As shown in 
Figure 6.6b, the surface net charge of the complexes of pDNA with PEI (25 K) and 
cationic polyrotaxanes 5a, 5b or 5c increased dramatically as the N/P ratio increased 
from 2 to 4 and stabilized at N/P ratio of 10 and above. The zeta potential of 5d/DNA 
complex only varied within the range of 13 to 27 mV with the increase of N/P ratio 
from 2 to 30. After N/P ratio reached 10, the zeta potential of the complexes of pDNA 
with all four cationic polyrotaxanes and PEI (25 K) was strongly positive and varies 





































































Figure 6.6 Particle size (a) and zeta potential (b) of cationic polyrotaxanes/DNA 
complexes in comparison with PEI (25 K)/DNA complex at various N/P ratios.  
Figure 6.7 shows representative taping mode AFM images of naked pDNA and 
cationic polyrotaxane 5c/DNA complexe at N/P ratio of 2 and 10. The images 
obtained clearly demonstrate significant morphological differences when different 
N/P ratios were applied, as well as the formation of compact nanoparticles. In Figure 
6.7a, loose, supercoiled structure of pDNA could be observed when pDNA was not 
condensed by a cationic polymer. At N/P ratio of 2, supercoiled plasmid pDNA could 
still be identified under AFM while small and compact nanoparticles were formed at 
the same time. Compared to this partial condensation at N/P ratio of 2, the same 
amount of pDNA could be tightly packed and completely formed pDNA complexes in 
the form of spherical nanoparticles at N/P ratio of 10. 
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Figure 6.7 Atomic force microscopy (AFM) images of the supercoiled plasmid DNA 
(a), and cationic polyrotaxane 5c/DNA complex at N/P = 2 (b) and N/P = 10 (c). 
 
6.3.4 Cytotoxicity of cationic polyrotaxanes  
Cytotoxicity is one of the most important factors to be considered in selecting 
polymeric materials as gene carriers. Figure 6.8 shows the results of in vitro 
cytotoxicity studies of cationic polyrotaxanes in two cell lines (HEK293 and COS7) 
using MTT assay. As shown in Figure 6.8, all the cationic polyrotaxanes showed a 
dose-dependent effect on cytotoxicity. It is worth noting that the cationic 
polyrotaxanes with linear OEI chains exhibited less toxicity in both cultured HEK293 
and COS7 cells than the PEI control. The slopes of the dose-response cytotoxicity 
curves were much steeper for PEI (25 K) than those for 5a, 5b and 5c. One possible 
reason is that the introduction of cyclodextrin and copolymer results in the lower 
density of amino groups and the high density of amino groups is always considered as 
an important factor leading to high cytotoxicity of PEI.34 Likewise, the cytotoxicity of 
5d was similar to that of PEI (25 K), which can also be attributed to its higher density 
of amino groups because 5d was grafted with higher MW branched OEI-14. These 
results also appeared to be supported by the calculated LD50 values: in COS7 cell 
lines, the LD50 value of PEI (25 K) was less than 25 µg/mL, while those of cationic 
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polyrotaxanes 5a, 5b, 5c, and 5d were 97, 308, 170, and 36 µg/mL, respectively. The 


























































Figure 6.8 Cell viability of cationic polyrotaxanes in (a) HEK293 and (b) COS7 cells 
in comparison with PEI (25 K).  
 
6.3.5 Transfection efficiency of cationic polyrotaxanes.  
In vitro gene transfection efficiency of cationic polyrotaxane/DNA complexes was 
assessed using luciferase as a marker gene in HEK293 and COS7 cells. Figure 6.9 
shows the gene transfection efficiency of cationic polyrotaxanes compared with those 
of branched PEI (25 K) and naked pDNA (ND) at various N/P ratios in the absence 
and presence of serum in HEK293 and COS7 cells.  
In HEK293 cells (Figure 6.9, a and b), the transfection efficiencies mediated by 
cationic polyrotaxanes were comparable to or even higher than those of branched PEI 
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(25 K). When the transfection was conducted in the absence of serum, 5c constantly 
exhibited the highest transfection efficiencies among the four cationic polyrotaxanes, 
which were also higher than the PEI control at low and high N/P ratios. From 5a to 5c, 
the transfection efficiency increased with an increase in the length of the OEI grafted 
to α-CD. However, 5d, the one with longest OEI grafted, showed the lowest 
transfection efficiency. This is much different from PEI, where higher MW always 
results in higher transfection efficiency. When the transfection medium was 
supplemented with 10% FBS, 5b exhibited the highest transfection efficiencies 
among the four cationic polyrotaxanes. The transfection efficiencies mediated by 5a, 
5b, and 5c increased with increasing N/P ratio, and finally became much higher than 
those of PEI at high N/P ratio, while the transfection efficiency of PEI dropped at 
higher N/P ratios. Particularly, 5b displayed approximately 10 times higher 
transfection efficiency than that of the PEI control at N/P of 20 to 30. Again, 5d 
showed the lowest transfection efficiency among the four cationic polyrotaxanes 
except at N/P ratio of 10. 
In COS7 cells (Figure 6.9, c and d), however, 5d showed the highest transfection 
efficiency among the four cationic polyrotaxanes at low N/P ratio (10 to 20), while 5b 
was the best for gene transfection at higher N/P ration (25 and 30). Generally, the 
transfection efficiencies mediated by cationic polyrotaxanes were comparable to or 
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Figure 6.9 In vitro gene transfection efficiency of the complexes of cationic 
polyrotaxanes in comparison with that of PEI (25 K) and naked DNA (ND), in 
HEK293 cell in the absence and presence of serum (a) and (b); in COS7 cell in the 
absence and presence of serum (c) and (d). Data represent mean ± standard deviation 
(n=3). 
The in vitro transfection efficiencies of cationic polyrotaxane 5b were also 
evaluated in three other cell lines including BHK-21, SK-OV-3, and MES-SA cells at 
various N/P ratios, in comparison with those of branched PEI (25 K) at N/P of 10, at 
which branched PEI (25 K) usually exhibits the highest transfection efficiency. Like 
other transfection hosts such as HEK293 and COS7, the Syrian golden hamster 
kidney fibroblast cell line BHK-21 has been also widely used to evaluate in vitro gene 
transfection efficiency mediated by cationic polymers.9 The human cell lines 
SK-OV-3 (ovarian carcinoma) and MES-SA (uterus sarcoma) are derived from human 
tumor cells, which could serve as excellent candidates for tumor cell transfection 
investigations.35,36 As shown in Figure 6.10, the gene transfection efficiencies of 5b 
were dependant on serum condition of the culture medium in different cell lines. In 
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BHK-21 cells, the transfection efficiencies of 5b improved with the increase in N/P 
ratio in serum condition, while its transfection efficiencies in serum-free condition 
were lower at high N/P ratio. In SK-OV-3 cells, the transfection efficiencies of 5b at 
N/P ratio of 15 to 40 were similar to that of the PEI control in both serum-free and 
serum conditions. In MES-SA cells, the transfection efficiencies of 5b were higher 
than that of the PEI control in serum-free condition, while those of 5b were much 
lower than that of the PEI control. Hence, when the cationic polyrotaxanes are 
properly designed with different compositions, density of the amino groups, lengths 
of OEI grafted, and flexibility of the main chains, the properties of the gene carriers 
may be altered to suit gene delivery in a wide range of different cells with high gene 
transfection efficiencies. 
Finally, confirmation of the gene delivery capability of the cationic polyrotaxane 5c 
was also obtained by fluorescence microscopy in contrast with that of PEI (25 K). 
Plasmid pEGFP-N1 encoding green fluorescence protein (GFP) was used to examine 
the GFP expression in HEK293 cells. As shown in Figure 6.11, strong fluorescence 
signal could be observed when transfection was mediated by either 5c or PEI at N/P 
ratio of 10. However, when the transfection was mediated by PEI, the GFP expression 
in HEK293 cells was stronger than that mediated by 5c. In contrast, GFP expression 
could not be detected when the transfection was mediated by naked DNA, which was 
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Figure 6.10 In vitro gene transfection efficiency of the complexes of cationic 
polyrotaxane 5b in comparison with that of PEI (25 K) in BHK-21 cell (a), SK-OV-3 
cell (b), and MES-SA cell (c), in the absence and presence of serum. Data represent 




Figure 6.11 The confocal microscope images of transfected HEK293 cells. The 
transfections were mediated by (a) 5c and (b) PEI (25 K) at N/P ratio of 10 in the 
absence of serum using green fluorescence protein gene as a reporter gene. The same 
field of cells was observed by Nomarski optics (right panel) or by fluorescence 
microscope (left panel) to visualize GFP expression. 
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 6.4 Conclusion 
In the present study, four supramolecular cationic polyrotaxanes (5a, 5b, 5c, and 5d) 
with multiple OEI-grafted cationic α-CD rings threaded and blocked on a P(EO-r-PO) 
copolymer chain have been successfully synthesized and characterized. In the cationic 
polyrotaxanes, approximately 12 cationic α-CD rings were threaded on the 
P(EO-r-PO) copolymer with a MW of 2370 and an EO/PO molar ratio of 4:1, while 
the cationic α-CD rings were grafted with liner OEI of MW up to 423 for 5a, 5b, 5c, 
and with branched OEI of MW of 600 for 5d. All four cationic polyrotaxanes could 
efficiently bind pDNA and for nanoparticles with sizes of 100 to 200 nm, which were 
suitable for cell uptake. In vitro cytotoxicity studies showed that cationic 
polyrotaxanes 5a, 5b, and 5c exhibited much lower cytotoxicity than high MW 
branched PEI (25 K), while cationic polyrotaxane 5d with branched OEI chains of 
higher MW (MW 600) exhibited similar cytotoxicity to high MW branched PEI in 
both HEK293 and COS7 cells. The cationic polyrotaxanes displayed high gene 
transfection efficiencies in a number of cell lines such as HEK293, COS7, BHK-21, 
SK-OV-3, and MES-SA., and showed strong cell type and serum condition 
dependency. In serum condition, cationic polyrotaxane 5b displayed approximately 10 
times higher transfection efficiency than that of the PEI control at N/P of 20 to 30. It 
is thought that the OEI-grafted α-CD rings were only located selectively on EO 
segments of the P(EO-r-PO) chain in the polyrotaxanes, while PO segments were free 
of complexation. Such structure increased the mobility of the cationic α-CD rings and 
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the flexibility of the polyrotaxanes, which enhanced the interaction of the cationic 
α-CD rings with DNA and/or cellular membrane. 
Our studies have demonstrated that the new cationic polyrotaxanes have high gene 
delivery capability a variety of cell lines. When properly designed, the structure, 
conformation and composition of the cationic polyrotaxanes may be controlled to give 
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In this study, novel cationic star polymers consisting of α-CD core and 
oligoethylenimine (OEI) arms and a series of soluble, cationic supramolecular 
polyrotaxanes composed of multiple OEI-grafted CDs threaded on various copolymer 
chains were prepared and characterized, and these new polymer systems were used as 
DNA carriers in the gene delivery systems. 
To prepare the above novel cationic star polymers, multiple OEI arms of different 
chain length and structure (ethylenediamine, pentaethylenehexamine, linear PEI with 
an average molecular weight of 423, and branched PEI with an average molecular 
weight of 600) were conjugated onto an α-CD ring core. These star polymers were 
isolated and purified using size exclusion chromatography (SEC), and characterized 
using Gel Permeation Chromatography (GPC), 13C and 1H NMR, and elemental 
analysis.  
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It was found that all the α-CD-OEI star polymers could inhibit the migration of 
pDNA on agarose gel through formation of complexes with pDNA, and the 
complexes formed nanoparticles with sizes ranging from 100 – 200 nm at N/P ratios 
of 8 or higher. The complexation was supposed to rely predominantly on electrostatic 
interactions between positively charged amino groups of OEI arms of the star 
polymers with the negatively charged phosphate groups of DNA. The α-CD-OEI star 
polymers displayed much lower in vitro cytotoxicity than that of branched 
polyethylenimine (PEI) of molecular weight 25 K due to the introduction of α-CD in 
the star polymers. They also showed excellent gene transfection efficiency in 
HEK293 and COS7 cells since the amino groups on the OEI arms of the star polymers 
increased the binding ability and complex stability, thus leading to much higher 
transfection efficiency. 
To synthesize cationic, soluble CD-containing supramolecular polyrotaxanes, firstly, 
a series of new polyrotaxanes were synthesized in high yield with copolymers 
(PPG-PEG-PPG triblock copolymers, PEG-PPG-PEG triblock copolymers or 
PPG-ran-PEG copolymers) and CDs (α-CDs or β-CDs) based on the block-selected 
inclusion complexation between the copolymers and CDs, followed by conjugation of 
2,4,6-trinitrobenzene sulfonate (TNBS) to both ends of copolymer chains as blocking 
stoppers. These polyrotaxanes were purified by SEC and their compositions were 
characterized by 1H and 13C NMR; secondly, multiple OEI chains with different chain 
length and structure (ethylenediamine, pentaethylene- hexamine, linear PEI with an 
average molecular weight of 423, and branched PEI with an average molecular weight 
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of 600) were grafted onto the CD rings of the above polyrotaxanes. These resulting 
soluble supramolecular polyrotaxanes were purified by SEC and their compositions 
were characterized by using GPC, 13C and 1H NMR, and elemental analysis. 
All the cationic, soluble supramolecular polyrotaxanes could efficiently condense 
plasmid DNA (pDNA) into small nanoparticles due to the electrostatic interactions 
between supramolecular polyrotaxanes with pDNA. They also showed excellent gene 
transfection efficiency that was comparable to or even higher than that of branched 
PEI (25 K), one of the most effective polymeric gene-delivery carriers studied to date. 
In addition, they displayed much lower in vitro cytotoxicity than that of branched PEI 
(25 K) in a variety of cell lines.  
Overall, in this study, the compositions of the cationic, soluble supramolecular 
polyrotaxanes could be varied by changing different cyclodextrins (α-CD or β-CD) 
and various copolymers (PPG-PEG-PPG triblock copolymers, PEG-PPG-PEG 
triblock copolymers or PPG-ran-PEG copolymers). Thus, the density and distribution 
of the cationic charges were changed. These changes were proved to have a great 
influence on the gene tranfection efficacy and cytotoxicity in the study. Generally, the 
supramolecular polyrotaxanes with longer grafting linear OEI chains showed good 
gene transfection efficiency and higher cytotoxicity. Nevertheless, the cationic 
polyrotaxanes with various copolymer chains showed distinctly different 
performances in various cell lines. 
Besides the above cationic supramolecular polyrotaxanes, single cationic 
OEI-grafted α-CD ring (i.e. star polymer consisting of α-CD core and OEI arms) was 
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also prepared and investigated as gene carrier in the study. With an increase of 
grafting arm length, the transfection efficiency and cytotoxicity of the synthesized 
cationic star polymers also increased. Especially, the cationic star polymer grafting 
with branched OEI with MW of 600 has the largest density of cationic charge. 
Although the transfection efficiency of the cationic star polymer was comparable to 
that of branched PEI (25 K), its cytotoxicity is almost the same with the PEI control.  
 
7.2 Future work 
It is well known that each gene-delivery carrier has strengths and limitations, e.g. 
immune responsiveness may limit the usefulness of one carrier, inability to be 
concentrated to be adequately tittered to another, etc. Hence, while one vector may be 
best suited to a particular situation, none of these vectors is clearly superior to the 
others for general use.1 In this study, I not only synthesized a variety of cationic 
polymers for efficient gene delivery, but also demonstrated a “smart design” of 
supramolecular polyrotaxanes. This “smart design” means that the structure, 
conformation and composition of the synthetic cationic supramolecular polyrotaxanes 
can be further modified and controlled in terms of the density of the amino groups and 
the flexibility of the polyrotaxanes. Thus, novel gene-delivery carriers with different 
properties will be developed for various applications. Also, for the cationic 
supramolecular polyrotaxanes I have obtained, determination of transfection 
efficiency and in vitro cytotoxicity will be carried out in more cell lines, to find out 
the specific situation in which the supramolecular polyrotaxanes perform well.  
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PEGylation is the most extensive modification method for many cationic polymers 
since it will increase the solubility of the complexes formed by cationic polymers with 
DNA and reduce the cytotoxicity of the polymers.2-4 Moreover, during the 
PEGylation process, targeting ligands such as galatose, transferring and insulin are 
always used for cell-specific uptake.5-7 Davis and co-workers have demonstrated 
post-PEGylation of the complexes by modification with adamantane-PEG 
conjugates.8 For the star polymers I have synthesized, PEGylation, including 
pre-PEGylation and post-PEGylation, can also be carried out, and targeting ligands 
will be introduced to the cationic polymer-DNA complexes at the same time. 
In addition, in the future, the biodegradable blocking groups will be used, thus the 
cationic supramolecular polyrotaxanes can be degraded in the cell and the cytotoxicity 
is expect to be reduced. The determination of toxicities and gene transfection 
efficiency in vivo of the cationic supramolecular polyrotaxanes as DNA vectors will 
be carried out.  
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